drug1,drug2,text,interacts,type
DDI-DrugBank.d758.s0.e0,DDI-DrugBank.d758.s0.e1,The CNS depressant effects of drug1 may be additive with that of other drug2,True,effect
DDI-DrugBank.d598.s0.e0,DDI-DrugBank.d598.s0.e1,drug1 may inhibit the hepatic metabolism of drug2,True,mechanism
DDI-DrugBank.d598.s1.e0,DDI-DrugBank.d598.s1.e1,"drug1, given at a common clinical dosage, increased the drug2 half-life by 51% and decreased the drug0",True,mechanism
DDI-DrugBank.d598.s1.e0,DDI-DrugBank.d598.s1.e2,"drug1, given at a common clinical dosage, increased the drug0 half-life by 51% and decreased the drug2",True,mechanism
DDI-DrugBank.d598.s1.e1,DDI-DrugBank.d598.s1.e2,"drug0, given at a common clinical dosage, increased the drug1 half-life by 51% and decreased the drug2",False, 
DDI-DrugBank.d739.s0.e0,DDI-DrugBank.d739.s0.e1,drug1 at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of drug2,False, 
DDI-DrugBank.d739.s1.e0,DDI-DrugBank.d739.s1.e1,- did not change the pharmacokinetic profile of drug1 (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of drug2,False, 
DDI-DrugBank.d739.s3.e0,DDI-DrugBank.d739.s3.e1,"- did not change the plasma concentration profile of drug1 (a substrate of cytochrome P450 3A4) or drug2, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with drug0",False, 
DDI-DrugBank.d739.s3.e0,DDI-DrugBank.d739.s3.e2,"- did not change the plasma concentration profile of drug1 (a substrate of cytochrome P450 3A4) or drug0, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with drug2",False, 
DDI-DrugBank.d739.s4.e0,DDI-DrugBank.d739.s4.e1,drug1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral drug2 containing drug0 1 mg/ethinyl drug0,False, 
DDI-DrugBank.d739.s4.e0,DDI-DrugBank.d739.s4.e2,drug1 at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral drug0 containing drug2 1 mg/ethinyl drug0,False, 
DDI-DrugBank.d739.s5.e0,DDI-DrugBank.d739.s5.e1,- did not cause any clinically significant change in plasma profiles of drug1 or drug2 following administration of either oral drug0 or intravenous drug0,False, 
DDI-DrugBank.d739.s5.e0,DDI-DrugBank.d739.s5.e2,- did not cause any clinically significant change in plasma profiles of drug1 or drug0 following administration of either oral drug2 or intravenous drug0,False, 
DDI-DrugBank.d739.s6.e0,DDI-DrugBank.d739.s6.e1,"drug1, which induces hepatic metabolism, decreased the AUC of drug2 approximately 40% following a single 10-mg dose of drug0",False, 
DDI-DrugBank.d739.s6.e0,DDI-DrugBank.d739.s6.e2,"drug1, which induces hepatic metabolism, decreased the AUC of drug0 approximately 40% following a single 10-mg dose of drug2",False, 
DDI-DrugBank.d739.s8.e0,DDI-DrugBank.d739.s8.e1,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as drug1 or drug2, are co-administered with drug0",False, 
DDI-DrugBank.d739.s8.e0,DDI-DrugBank.d739.s8.e2,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as drug1 or drug0, are co-administered with drug2",True,advise
DDI-DrugBank.d739.s8.e1,DDI-DrugBank.d739.s8.e2,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as drug0 or drug1, are co-administered with drug2",True,advise
DDI-DrugBank.d739.s10.e0,DDI-DrugBank.d739.s10.e1,"In drug-interaction studies, the recommended clinical dose of drug1 did not have clinically important effects on the pharmacokinetics of the following drugs: drug2, drug0, drug0, oral drug0 (drug0 1 mg/drug0 35 mcg), drug0, drug0, and drug0",False, 
DDI-DrugBank.d739.s10.e0,DDI-DrugBank.d739.s10.e2,"In drug-interaction studies, the recommended clinical dose of drug1 did not have clinically important effects on the pharmacokinetics of the following drugs: drug0, drug2, drug0, oral drug0 (drug0 1 mg/drug0 35 mcg), drug0, drug0, and drug0",False, 
DDI-DrugBank.d739.s12.e0,DDI-DrugBank.d739.s12.e1,"These medications included drug1, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d739.s12.e0,DDI-DrugBank.d739.s12.e2,"These medications included drug1, drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d739.s13.e0,DDI-DrugBank.d739.s13.e1,"drug1, which induces hepatic metabolism, decreased the AUC of drug2 approximately 40% following a single 10-mg dose of drug0",False, 
DDI-DrugBank.d739.s13.e0,DDI-DrugBank.d739.s13.e2,"drug1, which induces hepatic metabolism, decreased the AUC of drug0 approximately 40% following a single 10-mg dose of drug2",False, 
DDI-DrugBank.d739.s15.e0,DDI-DrugBank.d739.s15.e1,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as drug1 or drug2, are co-administered with drug0",False, 
DDI-DrugBank.d739.s15.e0,DDI-DrugBank.d739.s15.e2,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as drug1 or drug0, are co-administered with drug2",True,advise
DDI-DrugBank.d739.s15.e1,DDI-DrugBank.d739.s15.e2,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as drug0 or drug1, are co-administered with drug2",True,advise
DDI-DrugBank.d698.s0.e0,DDI-DrugBank.d698.s0.e1,Interactions for drug1 (drug2):  drug0 - impairs the intestinal absorption of drug0,False, 
DDI-DrugBank.d698.s0.e0,DDI-DrugBank.d698.s0.e2,Interactions for drug1 (drug0):  drug2 - impairs the intestinal absorption of drug0,False, 
DDI-DrugBank.d698.s0.e2,DDI-DrugBank.d698.s0.e3,Interactions for drug0 (drug0):  drug1 - impairs the intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d698.s1.e0,DDI-DrugBank.d698.s1.e1,drug1 - concurrent use decreases gastrointestinal absorption of drug2,True,mechanism
DDI-DrugBank.d698.s2.e0,DDI-DrugBank.d698.s2.e1,requirements for drug1 may be increased in patients receiving drug2,True,effect
DDI-DrugBank.d756.s0.e0,DDI-DrugBank.d756.s0.e1,"Dosages of concomitantly administered drug1 should be reduced by approximately half, because drug2 amplifies the therapeutic actions and side-effects of drug0",True,effect
DDI-DrugBank.d756.s0.e0,DDI-DrugBank.d756.s0.e2,"Dosages of concomitantly administered drug1 should be reduced by approximately half, because drug0 amplifies the therapeutic actions and side-effects of drug2",False, 
DDI-DrugBank.d756.s0.e1,DDI-DrugBank.d756.s0.e2,"Dosages of concomitantly administered drug0 should be reduced by approximately half, because drug1 amplifies the therapeutic actions and side-effects of drug2",True,effect
DDI-DrugBank.d756.s1.e0,DDI-DrugBank.d756.s1.e1,Combination with drug1 (drug2,False, 
DDI-DrugBank.d756.s2.e0,DDI-DrugBank.d756.s2.e1,Additive sedative effects and confusional states may emerge if drug1 is given with drug2 or drug0,True,effect
DDI-DrugBank.d756.s2.e0,DDI-DrugBank.d756.s2.e2,Additive sedative effects and confusional states may emerge if drug1 is given with drug0 or drug2,True,effect
DDI-DrugBank.d756.s2.e1,DDI-DrugBank.d756.s2.e2,Additive sedative effects and confusional states may emerge if drug0 is given with drug1 or drug2,False, 
DDI-DrugBank.d756.s4.e0,DDI-DrugBank.d756.s4.e1,Exert particular caution in combining drug1 with other drug2 (drug0 and drug0,True,advise
DDI-DrugBank.d756.s4.e0,DDI-DrugBank.d756.s4.e2,Exert particular caution in combining drug1 with other drug0 (drug2 and drug0,True,advise
DDI-DrugBank.d756.s4.e0,DDI-DrugBank.d756.s4.e3,Exert particular caution in combining drug1 with other drug0 (drug0 and drug2,True,advise
DDI-DrugBank.d756.s4.e1,DDI-DrugBank.d756.s4.e2,Exert particular caution in combining drug0 with other drug1 (drug2 and drug0,False, 
DDI-DrugBank.d756.s4.e1,DDI-DrugBank.d756.s4.e3,Exert particular caution in combining drug0 with other drug1 (drug0 and drug2,False, 
DDI-DrugBank.d756.s7.e0,DDI-DrugBank.d756.s7.e1,drug1 and/or stimulantes of the drug2/drug0 type may counteract the specific actions of drug0,False, 
DDI-DrugBank.d756.s7.e0,DDI-DrugBank.d756.s7.e2,drug1 and/or stimulantes of the drug0/drug2 type may counteract the specific actions of drug0,False, 
DDI-DrugBank.d756.s7.e0,DDI-DrugBank.d756.s7.e3,drug1 and/or stimulantes of the drug0/drug0 type may counteract the specific actions of drug2,True,effect
DDI-DrugBank.d756.s7.e1,DDI-DrugBank.d756.s7.e3,drug0 and/or stimulantes of the drug1/drug0 type may counteract the specific actions of drug2,True,effect
DDI-DrugBank.d756.s7.e2,DDI-DrugBank.d756.s7.e3,drug0 and/or stimulantes of the drug0/drug1 type may counteract the specific actions of drug2,True,effect
DDI-DrugBank.d624.s0.e0,DDI-DrugBank.d624.s0.e1,"In clinical studies of drug1, patients taking drug2 concomitantly with drug0 (drug0   , Genentech), drug0, inhaled drug0, other drug0, or parenteral drug0",False, 
DDI-DrugBank.d624.s0.e0,DDI-DrugBank.d624.s0.e2,"In clinical studies of drug1, patients taking drug0 concomitantly with drug2 (drug0   , Genentech), drug0, inhaled drug0, other drug0, or parenteral drug0",False, 
DDI-DrugBank.d624.s0.e1,DDI-DrugBank.d624.s0.e2,"In clinical studies of drug0, patients taking drug1 concomitantly with drug2 (drug0   , Genentech), drug0, inhaled drug0, other drug0, or parenteral drug0",True,effect
DDI-DrugBank.d624.s0.e1,DDI-DrugBank.d624.s0.e3,"In clinical studies of drug0, patients taking drug1 concomitantly with drug0 (drug2   , Genentech), drug0, inhaled drug0, other drug0, or parenteral drug0",True,effect
DDI-DrugBank.d624.s0.e1,DDI-DrugBank.d624.s0.e4,"In clinical studies of drug0, patients taking drug1 concomitantly with drug0 (drug0   , Genentech), drug2, inhaled drug0, other drug0, or parenteral drug0",True,effect
DDI-DrugBank.d624.s0.e1,DDI-DrugBank.d624.s0.e5,"In clinical studies of drug0, patients taking drug1 concomitantly with drug0 (drug0   , Genentech), drug0, inhaled drug2, other drug0, or parenteral drug0",True,effect
DDI-DrugBank.d624.s0.e1,DDI-DrugBank.d624.s0.e6,"In clinical studies of drug0, patients taking drug1 concomitantly with drug0 (drug0   , Genentech), drug0, inhaled drug0, other drug2, or parenteral drug0",True,effect
DDI-DrugBank.d624.s0.e1,DDI-DrugBank.d624.s0.e7,"In clinical studies of drug0, patients taking drug1 concomitantly with drug0 (drug0   , Genentech), drug0, inhaled drug0, other drug0, or parenteral drug2",True,effect
DDI-DrugBank.d624.s2.e0,DDI-DrugBank.d624.s2.e1,Some drug1 can enhance drug2 toxicity by altering drug0,True,effect
DDI-DrugBank.d624.s2.e0,DDI-DrugBank.d624.s2.e2,Some drug1 can enhance drug0 toxicity by altering drug2,False, 
DDI-DrugBank.d624.s2.e1,DDI-DrugBank.d624.s2.e2,Some drug0 can enhance drug1 toxicity by altering drug2,False, 
DDI-DrugBank.d624.s3.e0,DDI-DrugBank.d624.s3.e1,"drug1 should not be administered concomitantly with drug2, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d624.s3.e0,DDI-DrugBank.d624.s3.e2,"drug1 should not be administered concomitantly with drug0, drug2, drug0, or drug0",True,advise
DDI-DrugBank.d624.s3.e0,DDI-DrugBank.d624.s3.e3,"drug1 should not be administered concomitantly with drug0, drug0, drug2, or drug0",True,advise
DDI-DrugBank.d624.s3.e0,DDI-DrugBank.d624.s3.e4,"drug1 should not be administered concomitantly with drug0, drug0, drug0, or drug2",True,advise
DDI-DrugBank.d624.s3.e1,DDI-DrugBank.d624.s3.e2,"drug0 should not be administered concomitantly with drug1, drug2, drug0, or drug0",False, 
DDI-DrugBank.d624.s3.e1,DDI-DrugBank.d624.s3.e3,"drug0 should not be administered concomitantly with drug1, drug0, drug2, or drug0",False, 
DDI-DrugBank.d605.s0.e0,DDI-DrugBank.d605.s0.e1,"drug1 may enhance the effects of drug2, drug0 and other drug0",True,effect
DDI-DrugBank.d605.s0.e0,DDI-DrugBank.d605.s0.e2,"drug1 may enhance the effects of drug0, drug2 and other drug0",True,effect
DDI-DrugBank.d605.s0.e0,DDI-DrugBank.d605.s0.e3,"drug1 may enhance the effects of drug0, drug0 and other drug2",True,effect
DDI-DrugBank.d605.s0.e1,DDI-DrugBank.d605.s0.e2,"drug0 may enhance the effects of drug1, drug2 and other drug0",False, 
DDI-DrugBank.d605.s0.e1,DDI-DrugBank.d605.s0.e3,"drug0 may enhance the effects of drug1, drug0 and other drug2",False, 
DDI-DrugBank.d573.s0.e0,DDI-DrugBank.d573.s0.e1,"Interaction with drug1: Although drug2 does not itself cause orthostatic hypotension, its administration to patients already receiving drug0",False, 
DDI-DrugBank.d573.s0.e0,DDI-DrugBank.d573.s0.e2,"Interaction with drug1: Although drug0 does not itself cause orthostatic hypotension, its administration to patients already receiving drug2",False, 
DDI-DrugBank.d573.s0.e1,DDI-DrugBank.d573.s0.e2,"Interaction with drug0: Although drug1 does not itself cause orthostatic hypotension, its administration to patients already receiving drug2",True,effect
DDI-DrugBank.d573.s1.e0,DDI-DrugBank.d573.s1.e1,If at all possible drug1 should be discontinued well before drug2,True,advise
DDI-DrugBank.d736.s1.e0,DDI-DrugBank.d736.s1.e1,Hypokalemia may develop during concomitant use of drug1 or drug2,False, 
DDI-DrugBank.d736.s3.e0,DDI-DrugBank.d736.s3.e1,drug1 may decrease arterial responsiveness to drug2,True,effect
DDI-DrugBank.d736.s5.e0,DDI-DrugBank.d736.s5.e1,drug1 may increase the responsiveness of drug2,True,effect
DDI-DrugBank.d736.s6.e0,DDI-DrugBank.d736.s6.e1,"drug1 renal clearance is reduced by drug2, increasing the risk of drug0",True,mechanism
DDI-DrugBank.d736.s6.e0,DDI-DrugBank.d736.s6.e2,"drug1 renal clearance is reduced by drug0, increasing the risk of drug2",False, 
DDI-DrugBank.d736.s6.e1,DDI-DrugBank.d736.s6.e2,"drug0 renal clearance is reduced by drug1, increasing the risk of drug2",False, 
DDI-DrugBank.d736.s7.e0,DDI-DrugBank.d736.s7.e1,drug1 may add to or potentiate the action of other drug2,True,effect
DDI-DrugBank.d736.s8.e0,DDI-DrugBank.d736.s8.e1,Potentiation occurs with drug1 or drug2,False, 
DDI-DrugBank.d652.s0.e0,DDI-DrugBank.d652.s0.e1,The effects of drug1 on gastrointestinal motility are antagonized by drug2 and drug0,True,effect
DDI-DrugBank.d652.s0.e0,DDI-DrugBank.d652.s0.e2,The effects of drug1 on gastrointestinal motility are antagonized by drug0 and drug2,True,effect
DDI-DrugBank.d652.s0.e1,DDI-DrugBank.d652.s0.e2,The effects of drug0 on gastrointestinal motility are antagonized by drug1 and drug2,False, 
DDI-DrugBank.d652.s1.e0,DDI-DrugBank.d652.s1.e1,"Additive sedative effects can occur when drug1 is given with drug2, drug0, drug0, drug0, or drug0",True,effect
DDI-DrugBank.d652.s1.e0,DDI-DrugBank.d652.s1.e2,"Additive sedative effects can occur when drug1 is given with drug0, drug2, drug0, drug0, or drug0",True,effect
DDI-DrugBank.d652.s1.e0,DDI-DrugBank.d652.s1.e3,"Additive sedative effects can occur when drug1 is given with drug0, drug0, drug2, drug0, or drug0",True,effect
DDI-DrugBank.d652.s1.e0,DDI-DrugBank.d652.s1.e4,"Additive sedative effects can occur when drug1 is given with drug0, drug0, drug0, drug2, or drug0",True,effect
DDI-DrugBank.d652.s1.e0,DDI-DrugBank.d652.s1.e5,"Additive sedative effects can occur when drug1 is given with drug0, drug0, drug0, drug0, or drug2",True,effect
DDI-DrugBank.d652.s1.e1,DDI-DrugBank.d652.s1.e2,"Additive sedative effects can occur when drug0 is given with drug1, drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d652.s1.e1,DDI-DrugBank.d652.s1.e3,"Additive sedative effects can occur when drug0 is given with drug1, drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d652.s2.e0,DDI-DrugBank.d652.s2.e1,"The finding that drug1 releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving drug2",True,advise
DDI-DrugBank.d652.s3.e0,DDI-DrugBank.d652.s3.e1,"Absorption of drugs from the stomach may be diminished (e.g., drug1) by drug2, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., drug0, drug0, drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d652.s3.e0,DDI-DrugBank.d652.s3.e2,"Absorption of drugs from the stomach may be diminished (e.g., drug1) by drug0, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d652.s3.e0,DDI-DrugBank.d652.s3.e3,"Absorption of drugs from the stomach may be diminished (e.g., drug1) by drug0, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., drug0, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d652.s3.e1,DDI-DrugBank.d652.s3.e2,"Absorption of drugs from the stomach may be diminished (e.g., drug0) by drug1, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., drug2, drug0, drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d652.s6.e0,DDI-DrugBank.d652.s6.e1,"Because the action of drug1 will influence the delivery of food to the intestines and thus the rate of absorption, drug2",True,advise
DDI-DrugBank.d680.s1.e0,DDI-DrugBank.d680.s1.e1,"Based on studies evaluating possible interactions of drug1 with other drugs, no dosage adjustment is needed with concomitant use of the following: drug2, drug0, drug0, drug0, drug0, drug0 (and its active metabolite, drug0), drug0, drug0, drug0, drug0, drug0, drug0, an oral drug0 (drug0/drug0), drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d680.s1.e0,DDI-DrugBank.d680.s1.e2,"Based on studies evaluating possible interactions of drug1 with other drugs, no dosage adjustment is needed with concomitant use of the following: drug0, drug2, drug0, drug0, drug0, drug0 (and its active metabolite, drug0), drug0, drug0, drug0, drug0, drug0, drug0, an oral drug0 (drug0/drug0), drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d680.s3.e0,DDI-DrugBank.d680.s3.e1,"Therefore, when coadministered with drug1, adjustment of the dosage of drug2",False, 
DDI-DrugBank.d680.s5.e0,DDI-DrugBank.d680.s5.e1,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving drug1, including drug2, and drug0",False, 
DDI-DrugBank.d680.s5.e0,DDI-DrugBank.d680.s5.e2,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving drug1, including drug0, and drug2",True,effect
DDI-DrugBank.d680.s5.e1,DDI-DrugBank.d680.s5.e2,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving drug0, including drug1, and drug2",True,effect
DDI-DrugBank.d680.s7.e0,DDI-DrugBank.d680.s7.e1,Patients treated with drug1 and drug2,True,advise
DDI-DrugBank.d680.s8.e0,DDI-DrugBank.d680.s8.e1,"Because of profound and long lasting inhibition of gastric acid secretion, drug1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, drug2, drug0 esters, and drug0",True,mechanism
DDI-DrugBank.d680.s8.e0,DDI-DrugBank.d680.s8.e2,"Because of profound and long lasting inhibition of gastric acid secretion, drug1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, drug0, drug2 esters, and drug0",True,mechanism
DDI-DrugBank.d680.s8.e0,DDI-DrugBank.d680.s8.e3,"Because of profound and long lasting inhibition of gastric acid secretion, drug1 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, drug0, drug0 esters, and drug2",True,mechanism
DDI-DrugBank.d680.s8.e1,DDI-DrugBank.d680.s8.e2,"Because of profound and long lasting inhibition of gastric acid secretion, drug0 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, drug1, drug2 esters, and drug0",False, 
DDI-DrugBank.d680.s8.e1,DDI-DrugBank.d680.s8.e3,"Because of profound and long lasting inhibition of gastric acid secretion, drug0 may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, drug1, drug0 esters, and drug2",False, 
DDI-DrugBank.d680.s9.e0,DDI-DrugBank.d680.s9.e1,"Laboratory Tests There have been reports of false-positive urine screening tests for drug1 (drug2) in patients receiving most drug0, including drug0",False, 
DDI-DrugBank.d680.s9.e0,DDI-DrugBank.d680.s9.e2,"Laboratory Tests There have been reports of false-positive urine screening tests for drug1 (drug0) in patients receiving most drug2, including drug0",False, 
DDI-DrugBank.d616.s1.e0,DDI-DrugBank.d616.s1.e1,Caution should be exercised when administering drug1 therapy in combination with other drug2,True,advise
DDI-DrugBank.d610.s0.e0,DDI-DrugBank.d610.s0.e1,Pharmacokinetic properties of drug1 were not altered by the addition of either drug2 or drug0 or the combination of drug0 and drug0,False, 
DDI-DrugBank.d610.s0.e0,DDI-DrugBank.d610.s0.e2,Pharmacokinetic properties of drug1 were not altered by the addition of either drug0 or drug2 or the combination of drug0 and drug0,False, 
DDI-DrugBank.d610.s1.e0,DDI-DrugBank.d610.s1.e1,No clinically significant changes to drug1 or drug2 pharmacokinetics were observed following concomitant administration of drug0,False, 
DDI-DrugBank.d610.s1.e0,DDI-DrugBank.d610.s1.e2,No clinically significant changes to drug1 or drug0 pharmacokinetics were observed following concomitant administration of drug2,False, 
DDI-DrugBank.d610.s2.e0,DDI-DrugBank.d610.s2.e1,drug1 has no effect on the pharmacokinetic properties of drug2,False, 
DDI-DrugBank.d610.s3.e0,DDI-DrugBank.d610.s3.e1,drug1 decreases the elimination of drug2 causing an increase in overall exposure . The addition of drug0 has no clinically significant effect on the pharmacokinetic properties of drug0,True,mechanism
DDI-DrugBank.d610.s3.e0,DDI-DrugBank.d610.s3.e2,drug1 decreases the elimination of drug0 causing an increase in overall exposure . The addition of drug2 has no clinically significant effect on the pharmacokinetic properties of drug0,False, 
DDI-DrugBank.d610.s3.e0,DDI-DrugBank.d610.s3.e3,drug1 decreases the elimination of drug0 causing an increase in overall exposure . The addition of drug0 has no clinically significant effect on the pharmacokinetic properties of drug2,False, 
DDI-DrugBank.d610.s4.e0,DDI-DrugBank.d610.s4.e1,"In a study of 11 HIV-infected patients receiving drug1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of drug2 twice daily (twice the currently recommended dose), oral drug0",True,mechanism
DDI-DrugBank.d610.s4.e0,DDI-DrugBank.d610.s4.e2,"In a study of 11 HIV-infected patients receiving drug1-maintenance therapy (40 mg and 90 mg daily) with 600 mg of drug0 twice daily (twice the currently recommended dose), oral drug2",False, 
DDI-DrugBank.d610.s4.e1,DDI-DrugBank.d610.s4.e2,"In a study of 11 HIV-infected patients receiving drug0-maintenance therapy (40 mg and 90 mg daily) with 600 mg of drug1 twice daily (twice the currently recommended dose), oral drug2",False, 
DDI-DrugBank.d782.s0.e0,DDI-DrugBank.d782.s0.e1,"drug1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - drug2: can increase seizure activity - drug0: may potentiate the replication of the drug0 virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - drug0: may cause shortness of breath and bronchospasm - drug0: may decrease patient's response to the drug0",True,int
DDI-DrugBank.d782.s0.e0,DDI-DrugBank.d782.s0.e2,"drug1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - drug0: can increase seizure activity - drug2: may potentiate the replication of the drug0 virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - drug0: may cause shortness of breath and bronchospasm - drug0: may decrease patient's response to the drug0",True,int
DDI-DrugBank.d782.s0.e0,DDI-DrugBank.d782.s0.e3,"drug1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - drug0: can increase seizure activity - drug0: may potentiate the replication of the drug2 virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - drug0: may cause shortness of breath and bronchospasm - drug0: may decrease patient's response to the drug0",False, 
DDI-DrugBank.d782.s0.e0,DDI-DrugBank.d782.s0.e4,"drug1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - drug0: can increase seizure activity - drug0: may potentiate the replication of the drug0 virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - drug2: may cause shortness of breath and bronchospasm - drug0: may decrease patient's response to the drug0",True,int
DDI-DrugBank.d782.s0.e0,DDI-DrugBank.d782.s0.e5,"drug1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - drug0: can increase seizure activity - drug0: may potentiate the replication of the drug0 virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - drug0: may cause shortness of breath and bronchospasm - drug2: may decrease patient's response to the drug0",True,int
DDI-DrugBank.d782.s0.e0,DDI-DrugBank.d782.s0.e6,"drug1 can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - drug0: can increase seizure activity - drug0: may potentiate the replication of the drug0 virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - drug0: may cause shortness of breath and bronchospasm - drug0: may decrease patient's response to the drug2",False, 
DDI-DrugBank.d591.s0.e0,DDI-DrugBank.d591.s0.e1,drug1 should be used with caution in patients receiving other local drug2 or agents structurally related to drug0,True,advise
DDI-DrugBank.d591.s0.e0,DDI-DrugBank.d591.s0.e2,drug1 should be used with caution in patients receiving other local drug0 or agents structurally related to drug2,False, 
DDI-DrugBank.d591.s0.e1,DDI-DrugBank.d591.s0.e2,drug0 should be used with caution in patients receiving other local drug1 or agents structurally related to drug2,False, 
DDI-DrugBank.d591.s2.e0,DDI-DrugBank.d591.s2.e1,"In vivo, the plasma clearance of drug1 was reduced by 70% during coadministration of drug2",True,mechanism
DDI-DrugBank.d591.s3.e0,DDI-DrugBank.d591.s3.e1,"Thus strong inhibitors of cytochrome P4501A2, such as drug1, given concomitantly during administration of drug2, can interact with drug0 leading to increased drug0",True,int
DDI-DrugBank.d591.s3.e0,DDI-DrugBank.d591.s3.e2,"Thus strong inhibitors of cytochrome P4501A2, such as drug1, given concomitantly during administration of drug0, can interact with drug2 leading to increased drug0",False, 
DDI-DrugBank.d591.s3.e0,DDI-DrugBank.d591.s3.e3,"Thus strong inhibitors of cytochrome P4501A2, such as drug1, given concomitantly during administration of drug0, can interact with drug0 leading to increased drug2",False, 
DDI-DrugBank.d591.s5.e0,DDI-DrugBank.d591.s5.e1,Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as drug1 and drug2,False, 
DDI-DrugBank.d591.s6.e0,DDI-DrugBank.d591.s6.e1,"Coadministration of a selective and potent inhibitor of CYP3A4, drug1 (100 mg bid for 2 days with drug2 infusion administered 1 hour after drug0) caused a 15% reduction in in-vivo plasma clearance of drug0",False, 
DDI-DrugBank.d591.s6.e0,DDI-DrugBank.d591.s6.e2,"Coadministration of a selective and potent inhibitor of CYP3A4, drug1 (100 mg bid for 2 days with drug0 infusion administered 1 hour after drug2) caused a 15% reduction in in-vivo plasma clearance of drug0",False, 
DDI-DrugBank.d591.s6.e0,DDI-DrugBank.d591.s6.e3,"Coadministration of a selective and potent inhibitor of CYP3A4, drug1 (100 mg bid for 2 days with drug0 infusion administered 1 hour after drug0) caused a 15% reduction in in-vivo plasma clearance of drug2",True,mechanism
DDI-DrugBank.d634.s0.e0,DDI-DrugBank.d634.s0.e1,drug1 (oral): The activity of oral drug2 may be potentiated by anti-vitamin-K activity attributed to drug0,False, 
DDI-DrugBank.d634.s0.e0,DDI-DrugBank.d634.s0.e2,drug1 (oral): The activity of oral drug0 may be potentiated by anti-vitamin-K activity attributed to drug2,False, 
DDI-DrugBank.d634.s0.e1,DDI-DrugBank.d634.s0.e2,drug0 (oral): The activity of oral drug1 may be potentiated by anti-vitamin-K activity attributed to drug2,True,effect
DDI-DrugBank.d634.s3.e0,DDI-DrugBank.d634.s3.e1,drug1: Serum digitalis levels may be increased when hyperthyroid patients on a stable drug2,False, 
DDI-DrugBank.d634.s5.e0,DDI-DrugBank.d634.s5.e1,drug1: drug2 clearance may decrease when hyperthyroid patients on a stable drug0,False, 
DDI-DrugBank.d634.s5.e0,DDI-DrugBank.d634.s5.e2,drug1: drug0 clearance may decrease when hyperthyroid patients on a stable drug2,False, 
DDI-DrugBank.d750.s0.e0,DDI-DrugBank.d750.s0.e1,Concomitant use of drug1 with drug2,True,int
DDI-DrugBank.d577.s0.e0,DDI-DrugBank.d577.s0.e1,"In elderly patients concurrently receiving certain drug1, primarily drug2",False, 
DDI-DrugBank.d577.s1.e0,DDI-DrugBank.d577.s1.e1,It has been reported that drug1 may prolong the prothrombin time in patients who are receiving the drug2 drug0,False, 
DDI-DrugBank.d577.s1.e0,DDI-DrugBank.d577.s1.e2,It has been reported that drug1 may prolong the prothrombin time in patients who are receiving the drug0 drug2,True,effect
DDI-DrugBank.d577.s1.e1,DDI-DrugBank.d577.s1.e2,It has been reported that drug0 may prolong the prothrombin time in patients who are receiving the drug1 drug2,False, 
DDI-DrugBank.d577.s3.e0,DDI-DrugBank.d577.s3.e1,drug1 may inhibit the hepatic metabolism of drug2,True,mechanism
DDI-DrugBank.d577.s4.e0,DDI-DrugBank.d577.s4.e1,"At a 1.6-g dose, drug1 produced a slight but significant increase in the half-life of drug2",True,mechanism
DDI-DrugBank.d577.s6.e0,DDI-DrugBank.d577.s6.e1,"drug1 can also displace drug2 from plasma protein-binding sites, thus increasing free drug0",True,mechanism
DDI-DrugBank.d577.s6.e0,DDI-DrugBank.d577.s6.e2,"drug1 can also displace drug0 from plasma protein-binding sites, thus increasing free drug2",False, 
DDI-DrugBank.d577.s6.e1,DDI-DrugBank.d577.s6.e2,"drug0 can also displace drug1 from plasma protein-binding sites, thus increasing free drug2",False, 
DDI-DrugBank.d689.s0.e0,DDI-DrugBank.d689.s0.e1,"drug1, particularly drug2, may cause serious cardiac arrhythmias during drug0",False, 
DDI-DrugBank.d689.s0.e0,DDI-DrugBank.d689.s0.e2,"drug1, particularly drug0, may cause serious cardiac arrhythmias during drug2",True,effect
DDI-DrugBank.d689.s0.e1,DDI-DrugBank.d689.s0.e2,"drug0, particularly drug1, may cause serious cardiac arrhythmias during drug2",True,effect
DDI-DrugBank.d689.s1.e0,DDI-DrugBank.d689.s1.e1,drug1 - The pressor effect of drug2 is markedly potentiated in patients receiving drug0 (drug0,False, 
DDI-DrugBank.d689.s1.e0,DDI-DrugBank.d689.s1.e2,drug1 - The pressor effect of drug0 is markedly potentiated in patients receiving drug2 (drug0,False, 
DDI-DrugBank.d689.s1.e1,DDI-DrugBank.d689.s1.e2,drug0 - The pressor effect of drug1 is markedly potentiated in patients receiving drug2 (drug0,True,effect
DDI-DrugBank.d689.s1.e1,DDI-DrugBank.d689.s1.e3,drug0 - The pressor effect of drug1 is markedly potentiated in patients receiving drug0 (drug2,True,effect
DDI-DrugBank.d689.s3.e0,DDI-DrugBank.d689.s3.e1,The pressor response of drug1 may also be potentiated by drug2,True,effect
DDI-DrugBank.d623.s1.e0,DDI-DrugBank.d623.s1.e1,drug1 administered concomitantly with drug2 may significantly decrease the serum concentrations of drug0,True,mechanism
DDI-DrugBank.d623.s1.e0,DDI-DrugBank.d623.s1.e2,drug1 administered concomitantly with drug0 may significantly decrease the serum concentrations of drug2,False, 
DDI-DrugBank.d623.s1.e1,DDI-DrugBank.d623.s1.e2,drug0 administered concomitantly with drug1 may significantly decrease the serum concentrations of drug2,False, 
DDI-DrugBank.d633.s0.e0,DDI-DrugBank.d633.s0.e1,"Since drug1 is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter drug2",False, 
DDI-DrugBank.d633.s1.e0,DDI-DrugBank.d633.s1.e1,"In a formal, single-dose interaction study (n = 6 males) the clearance of drug1 was decreased by 38% following the coadministration of drug2",True,mechanism
DDI-DrugBank.d633.s2.e0,DDI-DrugBank.d633.s2.e1,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of drug1 did not alter the kinetics of drug2",False, 
DDI-DrugBank.d633.s4.e0,DDI-DrugBank.d633.s4.e1,"In this crossover steady state study, the pharmacokinetics of drug1 were unaffected in either phenotype by the coadministration of drug2",False, 
DDI-DrugBank.d633.s5.e0,DDI-DrugBank.d633.s5.e1,"Addition of drug1 to drug2 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than drug0",False, 
DDI-DrugBank.d633.s5.e0,DDI-DrugBank.d633.s5.e2,"Addition of drug1 to drug0 did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than drug2",False, 
DDI-DrugBank.d633.s6.e0,DDI-DrugBank.d633.s6.e1,"When concomitant administration of either of these two drugs with drug1 is initiated, the dose of drug2",False, 
DDI-DrugBank.d633.s7.e0,DDI-DrugBank.d633.s7.e1,"In a large compassionate use program drug1    has been used concurrently with commonly employed antianginal, drug2, and drug0",False, 
DDI-DrugBank.d633.s7.e0,DDI-DrugBank.d633.s7.e2,"In a large compassionate use program drug1    has been used concurrently with commonly employed antianginal, drug0, and drug2",False, 
DDI-DrugBank.d633.s8.e0,DDI-DrugBank.d633.s8.e1,A variety of drug1 such as drug2 or drug0,False, 
DDI-DrugBank.d633.s8.e0,DDI-DrugBank.d633.s8.e2,A variety of drug1 such as drug0 or drug2,False, 
DDI-DrugBank.d633.s9.e0,DDI-DrugBank.d633.s9.e1,"When drug1 or other hepatic enzyme inducers such as drug2 and drug0 have been taken concurrently with drug0   , lowered drug0",False, 
DDI-DrugBank.d633.s9.e0,DDI-DrugBank.d633.s9.e2,"When drug1 or other hepatic enzyme inducers such as drug0 and drug2 have been taken concurrently with drug0   , lowered drug0",False, 
DDI-DrugBank.d633.s9.e0,DDI-DrugBank.d633.s9.e3,"When drug1 or other hepatic enzyme inducers such as drug0 and drug0 have been taken concurrently with drug2   , lowered drug0",True,mechanism
DDI-DrugBank.d633.s9.e1,DDI-DrugBank.d633.s9.e3,"When drug0 or other hepatic enzyme inducers such as drug1 and drug0 have been taken concurrently with drug2   , lowered drug0",True,mechanism
DDI-DrugBank.d633.s9.e2,DDI-DrugBank.d633.s9.e3,"When drug0 or other hepatic enzyme inducers such as drug0 and drug1 have been taken concurrently with drug2   , lowered drug0",True,mechanism
DDI-DrugBank.d633.s11.e0,DDI-DrugBank.d633.s11.e1,"In a formal study, drug1 were shown not to affect drug2",False, 
DDI-DrugBank.d633.s12.e0,DDI-DrugBank.d633.s12.e1,"ECG intervals (PR, QRS, and QT) were not affected by concurrent drug1    and drug2, drug0, or drug0",False, 
DDI-DrugBank.d633.s12.e0,DDI-DrugBank.d633.s12.e2,"ECG intervals (PR, QRS, and QT) were not affected by concurrent drug1    and drug0, drug2, or drug0",False, 
DDI-DrugBank.d633.s13.e0,DDI-DrugBank.d633.s13.e1,"Concurrent administration of drug1 and drug2    has been reported to increase, decrease, or leave unchanged drug0",True,mechanism
DDI-DrugBank.d633.s13.e0,DDI-DrugBank.d633.s13.e2,"Concurrent administration of drug1 and drug0    has been reported to increase, decrease, or leave unchanged drug2",False, 
DDI-DrugBank.d633.s13.e1,DDI-DrugBank.d633.s13.e2,"Concurrent administration of drug0 and drug1    has been reported to increase, decrease, or leave unchanged drug2",False, 
DDI-DrugBank.d633.s15.e0,DDI-DrugBank.d633.s15.e1,"drug1    does not alter serum drug2 levels but drug0, when used to treat gastrointestinal symptoms due to drug0   , has been reported to lower serum drug0",False, 
DDI-DrugBank.d633.s15.e0,DDI-DrugBank.d633.s15.e2,"drug1    does not alter serum drug0 levels but drug2, when used to treat gastrointestinal symptoms due to drug0   , has been reported to lower serum drug0",False, 
DDI-DrugBank.d633.s15.e2,DDI-DrugBank.d633.s15.e4,"drug0    does not alter serum drug0 levels but drug1, when used to treat gastrointestinal symptoms due to drug0   , has been reported to lower serum drug2",True,mechanism
DDI-DrugBank.d633.s16.e0,DDI-DrugBank.d633.s16.e1,Concurrent use of drug1    and drug2 may lead to increased plasma drug0,True,mechanism
DDI-DrugBank.d633.s16.e0,DDI-DrugBank.d633.s16.e2,Concurrent use of drug1    and drug0 may lead to increased plasma drug2,False, 
DDI-DrugBank.d633.s16.e1,DDI-DrugBank.d633.s16.e2,Concurrent use of drug0    and drug1 may lead to increased plasma drug2,False, 
DDI-DrugBank.d633.s18.e0,DDI-DrugBank.d633.s18.e1,"This increase was observed at the first test point which was the second day after starting drug1   . drug2 plasma levels returned to pre-drug0    values within 48 hours after discontinuing drug0   . If drug0 and drug0 are to be used concurrently, drug0 blood levels should be monitored, particularly when the drug0",False, 
DDI-DrugBank.d633.s18.e0,DDI-DrugBank.d633.s18.e2,"This increase was observed at the first test point which was the second day after starting drug1   . drug0 plasma levels returned to pre-drug2    values within 48 hours after discontinuing drug0   . If drug0 and drug0 are to be used concurrently, drug0 blood levels should be monitored, particularly when the drug0",False, 
DDI-DrugBank.d633.s18.e1,DDI-DrugBank.d633.s18.e3,"This increase was observed at the first test point which was the second day after starting drug0   . drug1 plasma levels returned to pre-drug0    values within 48 hours after discontinuing drug2   . If drug0 and drug0 are to be used concurrently, drug0 blood levels should be monitored, particularly when the drug0",True,mechanism
DDI-DrugBank.d633.s18.e4,DDI-DrugBank.d633.s18.e5,"This increase was observed at the first test point which was the second day after starting drug0   . drug0 plasma levels returned to pre-drug0    values within 48 hours after discontinuing drug0   . If drug1 and drug2 are to be used concurrently, drug0 blood levels should be monitored, particularly when the drug0",True,advise
DDI-DrugBank.d633.s20.e0,DDI-DrugBank.d633.s20.e1,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of drug1 was decreased 50% following the administration of drug2",True,mechanism
DDI-DrugBank.d732.s0.e0,DDI-DrugBank.d732.s0.e1,drug1 is not known to interact with other drugs including drug2,False, 
DDI-DrugBank.d732.s2.e0,DDI-DrugBank.d732.s2.e1,"Concomitant administration of drug1 with other chelation therapy, such as drug2",True,advise
DDI-DrugBank.d688.s0.e0,DDI-DrugBank.d688.s0.e1,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of drug1 or drug2 to warrant dosage adjustment when drug0,False, 
DDI-DrugBank.d688.s0.e0,DDI-DrugBank.d688.s0.e2,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of drug1 or drug0 to warrant dosage adjustment when drug2,False, 
DDI-DrugBank.d688.s1.e0,DDI-DrugBank.d688.s1.e1,A pharmacokinetic study demonstrated that coadministration of drug1 and drug2 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of drug0,True,mechanism
DDI-DrugBank.d688.s1.e0,DDI-DrugBank.d688.s1.e2,A pharmacokinetic study demonstrated that coadministration of drug1 and drug0 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of drug2,False, 
DDI-DrugBank.d688.s1.e1,DDI-DrugBank.d688.s1.e2,A pharmacokinetic study demonstrated that coadministration of drug0 and drug1 results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of drug2,False, 
DDI-DrugBank.d688.s2.e0,DDI-DrugBank.d688.s2.e1,Administration of a higher dose of drug1 should be considered when coadministering with drug2,True,advise
DDI-DrugBank.d688.s3.e0,DDI-DrugBank.d688.s3.e1,"The effects of drug1, drug2 or drug0 on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d688.s3.e0,DDI-DrugBank.d688.s3.e2,"The effects of drug1, drug0 or drug2 on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d638.s0.e0,DDI-DrugBank.d638.s0.e1,drug1 may decrease the hypotensive effect of drug2,True,effect
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e1,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug2, drug0 (drug0, drug0, drug0), drug0, and drug0 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e2,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug2 (drug0, drug0, drug0), drug0, and drug0 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e3,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug2, drug0, drug0), drug0, and drug0 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e4,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug2, drug0), drug0, and drug0 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e5,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug0, drug2), drug0, and drug0 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e6,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug0, drug0), drug2, and drug0 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e7,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug0, drug0), drug0, and drug2 (drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e8,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug0, drug0), drug0, and drug0 (drug2, drug0, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e9,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug0, drug0), drug0, and drug0 (drug0, drug2, drug0",True,mechanism
DDI-DrugBank.d638.s2.e0,DDI-DrugBank.d638.s2.e10,"Human pharmacologic studies have shown that drug1 may inhibit the metabolism of drug0, drug0 (drug0, drug0, drug0), drug0, and drug0 (drug0, drug0, drug2",True,mechanism
DDI-DrugBank.d638.s2.e1,DDI-DrugBank.d638.s2.e2,"Human pharmacologic studies have shown that drug0 may inhibit the metabolism of drug1, drug2 (drug0, drug0, drug0), drug0, and drug0 (drug0, drug0, drug0",False, 
DDI-DrugBank.d638.s2.e1,DDI-DrugBank.d638.s2.e3,"Human pharmacologic studies have shown that drug0 may inhibit the metabolism of drug1, drug0 (drug2, drug0, drug0), drug0, and drug0 (drug0, drug0, drug0",False, 
DDI-DrugBank.d638.s5.e0,DDI-DrugBank.d638.s5.e1,The safety of using drug1 in combination with drug2 or other centrally acting drug0,False, 
DDI-DrugBank.d638.s5.e0,DDI-DrugBank.d638.s5.e2,The safety of using drug1 in combination with drug0 or other centrally acting drug2,False, 
DDI-DrugBank.d690.s0.e0,DDI-DrugBank.d690.s0.e1,"The CNS-depressant effect of drug1 is additive with that of other drug2, including drug0",True,effect
DDI-DrugBank.d690.s0.e0,DDI-DrugBank.d690.s0.e2,"The CNS-depressant effect of drug1 is additive with that of other drug0, including drug2",True,effect
DDI-DrugBank.d690.s0.e1,DDI-DrugBank.d690.s0.e2,"The CNS-depressant effect of drug0 is additive with that of other drug1, including drug2",False, 
DDI-DrugBank.d690.s3.e0,DDI-DrugBank.d690.s3.e1,"Such occurrences have been reported when drug1 was administered to patients on drug2, drug0, or drug0",False, 
DDI-DrugBank.d690.s3.e0,DDI-DrugBank.d690.s3.e2,"Such occurrences have been reported when drug1 was administered to patients on drug0, drug2, or drug0",False, 
DDI-DrugBank.d642.s0.e0,DDI-DrugBank.d642.s0.e1,Prothrombin time or other suitable anticoagulation test should be monitored if drug1 is administered with drug2,True,advise
DDI-DrugBank.d642.s1.e0,DDI-DrugBank.d642.s1.e1,Concurrent use of drug1 with oral drug2 may render oral drug0,True,effect
DDI-DrugBank.d642.s1.e0,DDI-DrugBank.d642.s1.e2,Concurrent use of drug1 with oral drug0 may render oral drug2,False, 
DDI-DrugBank.d642.s1.e1,DDI-DrugBank.d642.s1.e2,Concurrent use of drug0 with oral drug1 may render oral drug2,False, 
DDI-DrugBank.d600.s1.e0,DDI-DrugBank.d600.s1.e1,Concurrent use of drug1 and other drug2 may increase the CNS depressant effects of drug0,False, 
DDI-DrugBank.d600.s1.e0,DDI-DrugBank.d600.s1.e2,Concurrent use of drug1 and other drug0 may increase the CNS depressant effects of drug2,True,effect
DDI-DrugBank.d600.s1.e1,DDI-DrugBank.d600.s1.e2,Concurrent use of drug0 and other drug1 may increase the CNS depressant effects of drug2,True,effect
DDI-DrugBank.d687.s0.e0,DDI-DrugBank.d687.s0.e1,Administration of drug1 decreases oral clearance of drug2,True,mechanism
DDI-DrugBank.d659.s0.e0,DDI-DrugBank.d659.s0.e1,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with drug1 with and without drug2 or drug0",True,effect
DDI-DrugBank.d659.s0.e0,DDI-DrugBank.d659.s0.e2,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with drug1 with and without drug0 or drug2",True,effect
DDI-DrugBank.d659.s0.e1,DDI-DrugBank.d659.s0.e2,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with drug0 with and without drug1 or drug2",False, 
DDI-DrugBank.d659.s2.e0,DDI-DrugBank.d659.s2.e1,Concomitant administration of drug1 and drug2-containing drugs leads to increased drug0 levels and drug0,True,mechanism
DDI-DrugBank.d659.s2.e0,DDI-DrugBank.d659.s2.e2,Concomitant administration of drug1 and drug0-containing drugs leads to increased drug2 levels and drug0,False, 
DDI-DrugBank.d659.s2.e0,DDI-DrugBank.d659.s2.e3,Concomitant administration of drug1 and drug0-containing drugs leads to increased drug0 levels and drug2,False, 
DDI-DrugBank.d659.s4.e0,DDI-DrugBank.d659.s4.e1,"drug1 has been used concurrently with drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d659.s4.e0,DDI-DrugBank.d659.s4.e2,"drug1 has been used concurrently with drug0, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d700.s0.e0,DDI-DrugBank.d700.s0.e1,"drug1: Absorption of a single dose of drug2 was decreased when administered to 12 stable renal transplant patients also taking drug0-drug0 containing drug0 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when drug0",False, 
DDI-DrugBank.d700.s0.e0,DDI-DrugBank.d700.s0.e2,"drug1: Absorption of a single dose of drug0 was decreased when administered to 12 stable renal transplant patients also taking drug2-drug0 containing drug0 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when drug0",False, 
DDI-DrugBank.d700.s0.e1,DDI-DrugBank.d700.s0.e2,"drug0: Absorption of a single dose of drug1 was decreased when administered to 12 stable renal transplant patients also taking drug2-drug0 containing drug0 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when drug0",True,mechanism
DDI-DrugBank.d700.s0.e1,DDI-DrugBank.d700.s0.e3,"drug0: Absorption of a single dose of drug1 was decreased when administered to 12 stable renal transplant patients also taking drug0-drug2 containing drug0 (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when drug0",True,mechanism
DDI-DrugBank.d700.s1.e0,DDI-DrugBank.d700.s1.e1,It is recommended that drug1 and drug2,True,advise
DDI-DrugBank.d700.s2.e0,DDI-DrugBank.d700.s2.e1,"drug1: When studied in stable renal transplant patients, drug2, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of drug0",False, 
DDI-DrugBank.d700.s2.e0,DDI-DrugBank.d700.s2.e2,"drug1: When studied in stable renal transplant patients, drug0, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of drug2",False, 
DDI-DrugBank.d700.s3.e0,DDI-DrugBank.d700.s3.e1,drug1/drug2: may be taken with drug0,False, 
DDI-DrugBank.d700.s3.e0,DDI-DrugBank.d700.s3.e2,drug1/drug0: may be taken with drug2,False, 
DDI-DrugBank.d700.s5.e0,DDI-DrugBank.d700.s5.e1,Both drug1/drug2 and drug0,False, 
DDI-DrugBank.d700.s5.e0,DDI-DrugBank.d700.s5.e2,Both drug1/drug0 and drug2,False, 
DDI-DrugBank.d700.s6.e0,DDI-DrugBank.d700.s6.e1,"drug1/drug2: Given that drug0 and drug0 inhibit purine metabolism, it is recommended that drug0 not be administered concomitantly with drug0 or drug0",False, 
DDI-DrugBank.d700.s6.e0,DDI-DrugBank.d700.s6.e2,"drug1/drug0: Given that drug2 and drug0 inhibit purine metabolism, it is recommended that drug0 not be administered concomitantly with drug0 or drug0",False, 
DDI-DrugBank.d700.s6.e4,DDI-DrugBank.d700.s6.e5,"drug0/drug0: Given that drug0 and drug0 inhibit purine metabolism, it is recommended that drug1 not be administered concomitantly with drug2 or drug0",True,advise
DDI-DrugBank.d700.s6.e4,DDI-DrugBank.d700.s6.e6,"drug0/drug0: Given that drug0 and drug0 inhibit purine metabolism, it is recommended that drug1 not be administered concomitantly with drug0 or drug2",True,advise
DDI-DrugBank.d700.s7.e0,DDI-DrugBank.d700.s7.e1,drug1 and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce drug2 exposure when coadministered with drug0,False, 
DDI-DrugBank.d700.s7.e0,DDI-DrugBank.d700.s7.e2,drug1 and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce drug0 exposure when coadministered with drug2,False, 
DDI-DrugBank.d700.s8.e0,DDI-DrugBank.d700.s8.e1,"Therefore, do not administer drug1 with drug2 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral drug0, because of the potential to reduce the efficacy of drug0",True,advise
DDI-DrugBank.d700.s8.e0,DDI-DrugBank.d700.s8.e2,"Therefore, do not administer drug1 with drug0 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral drug2, because of the potential to reduce the efficacy of drug0",True,advise
DDI-DrugBank.d700.s8.e0,DDI-DrugBank.d700.s8.e3,"Therefore, do not administer drug1 with drug0 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral drug0, because of the potential to reduce the efficacy of drug2",False, 
DDI-DrugBank.d700.s8.e1,DDI-DrugBank.d700.s8.e2,"Therefore, do not administer drug0 with drug1 or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral drug2, because of the potential to reduce the efficacy of drug0",False, 
DDI-DrugBank.d700.s9.e0,DDI-DrugBank.d700.s9.e1,Oral drug1: Given the different metabolism of drug2 and oral drug0,False, 
DDI-DrugBank.d700.s9.e0,DDI-DrugBank.d700.s9.e2,Oral drug1: Given the different metabolism of drug0 and oral drug2,False, 
DDI-DrugBank.d700.s10.e0,DDI-DrugBank.d700.s10.e1,"However, in a drug-drug interaction study, mean drug1 AUC was decreased by 15% when coadministered with drug2",True,mechanism
DDI-DrugBank.d700.s11.e0,DDI-DrugBank.d700.s11.e1,"Therefore, it is recommended that oral drug1 are co- administered with drug2",True,advise
DDI-DrugBank.d700.s12.e0,DDI-DrugBank.d700.s12.e1,"drug1: During treatment with drug2, the use of drug0",False, 
DDI-DrugBank.d700.s12.e0,DDI-DrugBank.d700.s12.e2,"drug1: During treatment with drug0, the use of drug2",False, 
DDI-DrugBank.d700.s12.e1,DDI-DrugBank.d700.s12.e2,"drug0: During treatment with drug1, the use of drug2",True,advise
DDI-DrugBank.d700.s16.e0,DDI-DrugBank.d700.s16.e1,Interference of drug1 hydrolysis may lead to less drug2,False, 
DDI-DrugBank.d635.s0.e0,DDI-DrugBank.d635.s0.e1,Other drug1 should not be used concomitantly with drug2,True,advise
DDI-DrugBank.d579.s0.e0,DDI-DrugBank.d579.s0.e1,Patients receiving drug1 and drug2 generally should not be treated with drug0,False, 
DDI-DrugBank.d579.s0.e0,DDI-DrugBank.d579.s0.e2,Patients receiving drug1 and drug0 generally should not be treated with drug2,True,advise
DDI-DrugBank.d579.s0.e1,DDI-DrugBank.d579.s0.e2,Patients receiving drug0 and drug1 generally should not be treated with drug2,True,advise
DDI-DrugBank.d579.s1.e0,DDI-DrugBank.d579.s1.e1,"The action of drug1 may be potentiated by anesthesia, other drug2 and drug0",True,effect
DDI-DrugBank.d579.s1.e0,DDI-DrugBank.d579.s1.e2,"The action of drug1 may be potentiated by anesthesia, other drug0 and drug2",True,effect
DDI-DrugBank.d579.s1.e1,DDI-DrugBank.d579.s1.e2,"The action of drug0 may be potentiated by anesthesia, other drug1 and drug2",False, 
DDI-DrugBank.d721.s0.e0,DDI-DrugBank.d721.s0.e1,"The bioavailability of drug1 is decreased 80% by drug2, when drug0 and drug0 are administered at the same time, and 60% by some drug0- or drug0-containing drug0, when administered 1 hour before drug0",True,mechanism
DDI-DrugBank.d721.s0.e0,DDI-DrugBank.d721.s0.e2,"The bioavailability of drug1 is decreased 80% by drug0, when drug2 and drug0 are administered at the same time, and 60% by some drug0- or drug0-containing drug0, when administered 1 hour before drug0",False, 
DDI-DrugBank.d721.s0.e0,DDI-DrugBank.d721.s0.e3,"The bioavailability of drug1 is decreased 80% by drug0, when drug0 and drug2 are administered at the same time, and 60% by some drug0- or drug0-containing drug0, when administered 1 hour before drug0",False, 
DDI-DrugBank.d721.s0.e4,DDI-DrugBank.d721.s0.e7,"The bioavailability of drug0 is decreased 80% by drug0, when drug0 and drug0 are administered at the same time, and 60% by some drug1- or drug0-containing drug0, when administered 1 hour before drug2",True,mechanism
DDI-DrugBank.d721.s0.e5,DDI-DrugBank.d721.s0.e7,"The bioavailability of drug0 is decreased 80% by drug0, when drug0 and drug0 are administered at the same time, and 60% by some drug0- or drug1-containing drug0, when administered 1 hour before drug2",True,mechanism
DDI-DrugBank.d721.s1.e0,DDI-DrugBank.d721.s1.e1,drug1 may decrease bioavailability of drug2 by up to 50% when taken 2 hours after drug0,True,mechanism
DDI-DrugBank.d721.s1.e0,DDI-DrugBank.d721.s1.e2,drug1 may decrease bioavailability of drug0 by up to 50% when taken 2 hours after drug2,False, 
DDI-DrugBank.d721.s1.e1,DDI-DrugBank.d721.s1.e2,drug0 may decrease bioavailability of drug1 by up to 50% when taken 2 hours after drug2,False, 
DDI-DrugBank.d721.s2.e0,DDI-DrugBank.d721.s2.e1,The bioavailability of drug1 is increased 2-4 fold by drug2 but is not significantly altered by coadministration of drug0,True,mechanism
DDI-DrugBank.d721.s2.e0,DDI-DrugBank.d721.s2.e2,The bioavailability of drug1 is increased 2-4 fold by drug0 but is not significantly altered by coadministration of drug2,False, 
DDI-DrugBank.d721.s2.e1,DDI-DrugBank.d721.s2.e2,The bioavailability of drug0 is increased 2-4 fold by drug1 but is not significantly altered by coadministration of drug2,False, 
DDI-DrugBank.d721.s3.e0,DDI-DrugBank.d721.s3.e1,The pharmacokinetic parameters of drug1 are not significantly modified by drug2,False, 
DDI-DrugBank.d721.s4.e0,DDI-DrugBank.d721.s4.e1,In vitro studies show that drug1 does not displace drug2,False, 
DDI-DrugBank.d753.s0.e0,DDI-DrugBank.d753.s0.e1,"The concomitant use of other drug1 including drug2, drug0, drug0, general drug0, drug0, other drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d753.s0.e0,DDI-DrugBank.d753.s0.e2,"The concomitant use of other drug1 including drug0, drug2, drug0, general drug0, drug0, other drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d753.s2.e0,DDI-DrugBank.d753.s2.e1,drug1 or other medications with anticholinergic activity when used concurrently with drug2,True,effect
DDI-DrugBank.d753.s3.e0,DDI-DrugBank.d753.s3.e1,It has been reported that the incidence of bradycardia was increased when drug1 was combined with drug2,True,effect
DDI-DrugBank.d753.s4.e0,DDI-DrugBank.d753.s4.e1,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of drug1 with drug2",True,effect
DDI-DrugBank.d656.s1.e0,DDI-DrugBank.d656.s1.e1,"Although this has not occurred in in vitro studies with drug1, interactions with drug2 have been reported with drug0 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering drug0 to patients on drug0",False, 
DDI-DrugBank.d656.s1.e0,DDI-DrugBank.d656.s1.e2,"Although this has not occurred in in vitro studies with drug1, interactions with drug0 have been reported with drug2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering drug0 to patients on drug0",False, 
DDI-DrugBank.d656.s1.e1,DDI-DrugBank.d656.s1.e2,"Although this has not occurred in in vitro studies with drug0, interactions with drug1 have been reported with drug2 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering drug0 to patients on drug0",True,int
DDI-DrugBank.d656.s1.e3,DDI-DrugBank.d656.s1.e4,"Although this has not occurred in in vitro studies with drug0, interactions with drug0 have been reported with drug0 since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering drug1 to patients on drug2",True,advise
DDI-DrugBank.d656.s2.e0,DDI-DrugBank.d656.s2.e1,"Plasma levels of drug1 are depressed to approximately 80% of their normal values when drug2 is administered in conjunction with drug0 (3900 mg/day), but concomitant administration of drug0 has no effect on drug0 plasma levels . drug0, including drug0, have been reported to increase steady state plasma drug0",False, 
DDI-DrugBank.d656.s2.e0,DDI-DrugBank.d656.s2.e2,"Plasma levels of drug1 are depressed to approximately 80% of their normal values when drug0 is administered in conjunction with drug2 (3900 mg/day), but concomitant administration of drug0 has no effect on drug0 plasma levels . drug0, including drug0, have been reported to increase steady state plasma drug0",False, 
DDI-DrugBank.d656.s2.e1,DDI-DrugBank.d656.s2.e2,"Plasma levels of drug0 are depressed to approximately 80% of their normal values when drug1 is administered in conjunction with drug2 (3900 mg/day), but concomitant administration of drug0 has no effect on drug0 plasma levels . drug0, including drug0, have been reported to increase steady state plasma drug0",True,mechanism
DDI-DrugBank.d656.s2.e5,DDI-DrugBank.d656.s2.e7,"Plasma levels of drug0 are depressed to approximately 80% of their normal values when drug0 is administered in conjunction with drug0 (3900 mg/day), but concomitant administration of drug0 has no effect on drug0 plasma levels . drug1, including drug0, have been reported to increase steady state plasma drug2",True,mechanism
DDI-DrugBank.d656.s2.e6,DDI-DrugBank.d656.s2.e7,"Plasma levels of drug0 are depressed to approximately 80% of their normal values when drug0 is administered in conjunction with drug0 (3900 mg/day), but concomitant administration of drug0 has no effect on drug0 plasma levels . drug0, including drug1, have been reported to increase steady state plasma drug2",True,mechanism
DDI-DrugBank.d656.s3.e0,DDI-DrugBank.d656.s3.e1,"It is recommended that plasma drug1 levels be monitored when initiating, adjusting and discontinuing drug2",True,advise
DDI-DrugBank.d611.s0.e0,DDI-DrugBank.d611.s0.e1,Other drug1 should not be used concomitantly with drug2    (drug0,True,advise
DDI-DrugBank.d611.s0.e0,DDI-DrugBank.d611.s0.e2,Other drug1 should not be used concomitantly with drug0    (drug2,True,advise
DDI-DrugBank.d611.s0.e1,DDI-DrugBank.d611.s0.e2,Other drug0 should not be used concomitantly with drug1    (drug2,False, 
DDI-DrugBank.d611.s1.e0,DDI-DrugBank.d611.s1.e1,"drug1 should be administered with caution to patients being treated with drug2 or drug0, since the action of drug0",True,advise
DDI-DrugBank.d611.s1.e0,DDI-DrugBank.d611.s1.e2,"drug1 should be administered with caution to patients being treated with drug0 or drug2, since the action of drug0",True,advise
DDI-DrugBank.d611.s1.e0,DDI-DrugBank.d611.s1.e3,"drug1 should be administered with caution to patients being treated with drug0 or drug0, since the action of drug2",False, 
DDI-DrugBank.d611.s1.e1,DDI-DrugBank.d611.s1.e2,"drug0 should be administered with caution to patients being treated with drug1 or drug2, since the action of drug0",False, 
DDI-DrugBank.d671.s0.e0,DDI-DrugBank.d671.s0.e1,The interaction of drug1 (drug2,False, 
DDI-DrugBank.d671.s2.e0,DDI-DrugBank.d671.s2.e1,Decreased seizure threshold has been reported in patients receiving drug1 concomitantly with drug2,True,effect
DDI-DrugBank.d629.s0.e0,DDI-DrugBank.d629.s0.e1,Oral drug1 has been reported to potentiate the anticoagulant effect of drug2 and drug0,True,effect
DDI-DrugBank.d629.s0.e0,DDI-DrugBank.d629.s0.e2,Oral drug1 has been reported to potentiate the anticoagulant effect of drug0 and drug2,True,effect
DDI-DrugBank.d629.s0.e1,DDI-DrugBank.d629.s0.e2,Oral drug0 has been reported to potentiate the anticoagulant effect of drug1 and drug2,False, 
DDI-DrugBank.d629.s1.e0,DDI-DrugBank.d629.s1.e1,"Drug interactions should be kept in mind when drug1 (drug2 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical drug0",False, 
DDI-DrugBank.d629.s1.e0,DDI-DrugBank.d629.s1.e2,"Drug interactions should be kept in mind when drug1 (drug0 gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical drug2",False, 
DDI-DrugBank.d666.s0.e0,DDI-DrugBank.d666.s0.e1,"Catecholamine-depleting drugs (e.g., drug1) may have an additive effect when given with drug2",True,effect
DDI-DrugBank.d666.s2.e0,DDI-DrugBank.d666.s2.e1,"drug1 has been used with a variety of drug2, including drug0, drug0, and drug0",False, 
DDI-DrugBank.d666.s2.e0,DDI-DrugBank.d666.s2.e2,"drug1 has been used with a variety of drug0, including drug2, drug0, and drug0",False, 
DDI-DrugBank.d666.s3.e0,DDI-DrugBank.d666.s3.e1,drug1 has been shown to increase serum drug2,True,mechanism
DDI-DrugBank.d670.s0.e0,DDI-DrugBank.d670.s0.e1,Potential for drug1    to Affect Other Drugs drug2,False, 
DDI-DrugBank.d670.s6.e0,DDI-DrugBank.d670.s6.e1,"Given the primary CNS effects of drug1, drug2    should be used with caution in combination with other drug0 and drug0",False, 
DDI-DrugBank.d670.s6.e0,DDI-DrugBank.d670.s6.e2,"Given the primary CNS effects of drug1, drug0    should be used with caution in combination with other drug2 and drug0",True,advise
DDI-DrugBank.d670.s6.e0,DDI-DrugBank.d670.s6.e3,"Given the primary CNS effects of drug1, drug0    should be used with caution in combination with other drug0 and drug2",True,advise
DDI-DrugBank.d670.s6.e1,DDI-DrugBank.d670.s6.e2,"Given the primary CNS effects of drug0, drug1    should be used with caution in combination with other drug2 and drug0",True,advise
DDI-DrugBank.d670.s6.e1,DDI-DrugBank.d670.s6.e3,"Given the primary CNS effects of drug0, drug1    should be used with caution in combination with other drug0 and drug2",True,advise
DDI-DrugBank.d670.s6.e2,DDI-DrugBank.d670.s6.e3,"Given the primary CNS effects of drug0, drug0    should be used with caution in combination with other drug1 and drug2",False, 
DDI-DrugBank.d670.s7.e0,DDI-DrugBank.d670.s7.e1,drug1 may antagonize the effect of drug2 and other drug0,True,effect
DDI-DrugBank.d670.s7.e0,DDI-DrugBank.d670.s7.e2,drug1 may antagonize the effect of drug0 and other drug2,True,effect
DDI-DrugBank.d670.s7.e1,DDI-DrugBank.d670.s7.e2,drug0 may antagonize the effect of drug1 and other drug2,False, 
DDI-DrugBank.d670.s9.e0,DDI-DrugBank.d670.s9.e1,Potential for Other Drugs to Affect drug1    drug2,False, 
DDI-DrugBank.d763.s1.e0,DDI-DrugBank.d763.s1.e1,"Because drug1 is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of drug2",False, 
DDI-DrugBank.d763.s3.e0,DDI-DrugBank.d763.s3.e1,"drug1, drug2, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug0, drug0, and drug0), the clearance of drug0 was significantly increased and drug0",False, 
DDI-DrugBank.d763.s3.e0,DDI-DrugBank.d763.s3.e2,"drug1, drug0, and drug2: In patients treated with potent inducers of CYP3A4 (i.e., drug0, drug0, and drug0), the clearance of drug0 was significantly increased and drug0",False, 
DDI-DrugBank.d763.s3.e3,DDI-DrugBank.d763.s3.e6,"drug0, drug0, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug1, drug0, and drug0), the clearance of drug2 was significantly increased and drug0",True,mechanism
DDI-DrugBank.d763.s3.e3,DDI-DrugBank.d763.s3.e7,"drug0, drug0, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug1, drug0, and drug0), the clearance of drug0 was significantly increased and drug2",True,mechanism
DDI-DrugBank.d763.s3.e4,DDI-DrugBank.d763.s3.e6,"drug0, drug0, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug0, drug1, and drug0), the clearance of drug2 was significantly increased and drug0",True,mechanism
DDI-DrugBank.d763.s3.e4,DDI-DrugBank.d763.s3.e7,"drug0, drug0, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug0, drug1, and drug0), the clearance of drug0 was significantly increased and drug2",True,mechanism
DDI-DrugBank.d763.s3.e5,DDI-DrugBank.d763.s3.e6,"drug0, drug0, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug0, drug0, and drug1), the clearance of drug2 was significantly increased and drug0",True,mechanism
DDI-DrugBank.d763.s3.e5,DDI-DrugBank.d763.s3.e7,"drug0, drug0, and drug0: In patients treated with potent inducers of CYP3A4 (i.e., drug0, drug0, and drug1), the clearance of drug0 was significantly increased and drug2",True,mechanism
DDI-DrugBank.d763.s4.e0,DDI-DrugBank.d763.s4.e1,"However, on the basis of available data, no dosage adjustment for drug1 is recommended for patients on these drugs.1,3  drug2: Although no pharmacokinetic drug interaction between drug0 and drug0 has been observed, data from 2 small studies indicate that drug0 may be associated with an increase in patient controlled administration of drug0.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by drug0",False, 
DDI-DrugBank.d763.s4.e0,DDI-DrugBank.d763.s4.e2,"However, on the basis of available data, no dosage adjustment for drug1 is recommended for patients on these drugs.1,3  drug0: Although no pharmacokinetic drug interaction between drug2 and drug0 has been observed, data from 2 small studies indicate that drug0 may be associated with an increase in patient controlled administration of drug0.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by drug0",False, 
DDI-DrugBank.d763.s4.e4,DDI-DrugBank.d763.s4.e5,"However, on the basis of available data, no dosage adjustment for drug0 is recommended for patients on these drugs.1,3  drug0: Although no pharmacokinetic drug interaction between drug0 and drug0 has been observed, data from 2 small studies indicate that drug1 may be associated with an increase in patient controlled administration of drug2.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by drug0",True,effect
DDI-DrugBank.d763.s5.e0,DDI-DrugBank.d763.s5.e1,"In humans, drug1, drug2, and drug0 do not affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d763.s5.e0,DDI-DrugBank.d763.s5.e2,"In humans, drug1, drug0, and drug2 do not affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d763.s7.e0,DDI-DrugBank.d763.s7.e1,drug1 did not increase blood levels of high-dose drug2,False, 
DDI-DrugBank.d713.s0.e0,DDI-DrugBank.d713.s0.e1,The concomitant use of drug1 with other drug2,True,effect
DDI-DrugBank.d713.s2.e0,DDI-DrugBank.d713.s2.e1,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug1 have not been conducted, drug2 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug0, drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d713.s2.e0,DDI-DrugBank.d713.s2.e2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug1 have not been conducted, drug0 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug2, drug0, drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e2,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug2, drug0, drug0, drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e3,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug2, drug0, drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e4,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug0, drug2, drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e5,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug0, drug0, drug2, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e6,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug0, drug0, drug0, drug2, drug0 and drug0",True,mechanism
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e7,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug0, drug0, drug0, drug0, drug2 and drug0",True,mechanism
DDI-DrugBank.d713.s2.e1,DDI-DrugBank.d713.s2.e8,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with drug0 have not been conducted, drug1 has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. drug0, drug0, drug0, drug0, drug0, drug0 and drug2",True,mechanism
DDI-DrugBank.d713.s3.e0,DDI-DrugBank.d713.s3.e1,Coadministration of drug1 with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of drug2,False, 
DDI-DrugBank.d752.s0.e0,DDI-DrugBank.d752.s0.e1,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when drug1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of drug2, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d752.s0.e0,DDI-DrugBank.d752.s0.e2,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when drug1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of drug0, drug2, drug0, and drug0",True,advise
DDI-DrugBank.d752.s0.e0,DDI-DrugBank.d752.s0.e3,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when drug1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of drug0, drug0, drug2, and drug0",True,advise
DDI-DrugBank.d752.s0.e0,DDI-DrugBank.d752.s0.e4,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when drug1 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of drug0, drug0, drug0, and drug2",True,advise
DDI-DrugBank.d752.s0.e1,DDI-DrugBank.d752.s0.e2,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when drug0 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of drug1, drug2, drug0, and drug0",False, 
DDI-DrugBank.d752.s0.e1,DDI-DrugBank.d752.s0.e3,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when drug0 is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of drug1, drug0, drug2, and drug0",False, 
DDI-DrugBank.d752.s1.e0,DDI-DrugBank.d752.s1.e1,"Drugs such as drug1, drug2, drug0, drug0, drug0 and drug0 were shown to significantly increase the C max and AUC of orally administered drug0",False, 
DDI-DrugBank.d752.s1.e0,DDI-DrugBank.d752.s1.e2,"Drugs such as drug1, drug0, drug2, drug0, drug0 and drug0 were shown to significantly increase the C max and AUC of orally administered drug0",False, 
DDI-DrugBank.d752.s1.e0,DDI-DrugBank.d752.s1.e6,"Drugs such as drug1, drug0, drug0, drug0, drug0 and drug0 were shown to significantly increase the C max and AUC of orally administered drug2",True,mechanism
DDI-DrugBank.d752.s1.e1,DDI-DrugBank.d752.s1.e6,"Drugs such as drug0, drug1, drug0, drug0, drug0 and drug0 were shown to significantly increase the C max and AUC of orally administered drug2",True,mechanism
DDI-DrugBank.d752.s1.e2,DDI-DrugBank.d752.s1.e6,"Drugs such as drug0, drug0, drug1, drug0, drug0 and drug0 were shown to significantly increase the C max and AUC of orally administered drug2",True,mechanism
DDI-DrugBank.d752.s1.e3,DDI-DrugBank.d752.s1.e6,"Drugs such as drug0, drug0, drug0, drug1, drug0 and drug0 were shown to significantly increase the C max and AUC of orally administered drug2",True,mechanism
DDI-DrugBank.d752.s1.e4,DDI-DrugBank.d752.s1.e6,"Drugs such as drug0, drug0, drug0, drug0, drug1 and drug0 were shown to significantly increase the C max and AUC of orally administered drug2",True,mechanism
DDI-DrugBank.d752.s1.e5,DDI-DrugBank.d752.s1.e6,"Drugs such as drug0, drug0, drug0, drug0, drug0 and drug1 were shown to significantly increase the C max and AUC of orally administered drug2",True,mechanism
DDI-DrugBank.d752.s3.e0,DDI-DrugBank.d752.s3.e1,"Although not studied, the potent cytochrome P450 3A4 inhibitors drug1 and drug2 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drug0",False, 
DDI-DrugBank.d752.s3.e0,DDI-DrugBank.d752.s3.e2,"Although not studied, the potent cytochrome P450 3A4 inhibitors drug1 and drug0 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drug2",True,mechanism
DDI-DrugBank.d752.s3.e1,DDI-DrugBank.d752.s3.e2,"Although not studied, the potent cytochrome P450 3A4 inhibitors drug0 and drug1 may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of drug2",True,mechanism
DDI-DrugBank.d752.s6.e0,DDI-DrugBank.d752.s6.e1,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as drug1, drug2, and drug0, induce metabolism and caused a markedly decreased C max and AUC of oral drug0",False, 
DDI-DrugBank.d752.s6.e0,DDI-DrugBank.d752.s6.e2,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as drug1, drug0, and drug2, induce metabolism and caused a markedly decreased C max and AUC of oral drug0",False, 
DDI-DrugBank.d752.s6.e0,DDI-DrugBank.d752.s6.e3,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as drug1, drug0, and drug0, induce metabolism and caused a markedly decreased C max and AUC of oral drug2",True,mechanism
DDI-DrugBank.d752.s6.e1,DDI-DrugBank.d752.s6.e3,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as drug0, drug1, and drug0, induce metabolism and caused a markedly decreased C max and AUC of oral drug2",True,mechanism
DDI-DrugBank.d752.s6.e2,DDI-DrugBank.d752.s6.e3,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as drug0, drug0, and drug1, induce metabolism and caused a markedly decreased C max and AUC of oral drug2",True,mechanism
DDI-DrugBank.d752.s9.e0,DDI-DrugBank.d752.s9.e1,The difficulty in achieving adequate sedation may have been the result of decreased absorption of the drug1 due to both the gastrointestinal effects and stimulant effects of drug2,False, 
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e1,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug2 (eg, drug0, drug0 and drug0), drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e2,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug2, drug0 and drug0), drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e3,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug2 and drug0), drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e4,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug0 and drug2), drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e5,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug0 and drug0), drug2, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e6,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug0 and drug0), drug0, drug2, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e7,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug0 and drug0), drug0, drug0, drug2, drug0 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e8,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug0 and drug0), drug0, drug0, drug0, drug2 and drug0",True,effect
DDI-DrugBank.d752.s10.e0,DDI-DrugBank.d752.s10.e9,"The sedative effect of drug1 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug0 (eg, drug0, drug0 and drug0), drug0, drug0, drug0, drug0 and drug2",True,effect
DDI-DrugBank.d752.s10.e1,DDI-DrugBank.d752.s10.e2,"The sedative effect of drug0 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug1 (eg, drug2, drug0 and drug0), drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d752.s10.e1,DDI-DrugBank.d752.s10.e3,"The sedative effect of drug0 is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly drug1 (eg, drug0, drug2 and drug0), drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d752.s12.e0,DDI-DrugBank.d752.s12.e1,"No significant adverse interactions with common premedications (such as drug1, drug2, drug0, drug0, drug0, and other drug0) or local drug0",False, 
DDI-DrugBank.d752.s12.e0,DDI-DrugBank.d752.s12.e2,"No significant adverse interactions with common premedications (such as drug1, drug0, drug2, drug0, drug0, and other drug0) or local drug0",False, 
DDI-DrugBank.d607.s1.e0,DDI-DrugBank.d607.s1.e1,"Drugs which may potentiate the myeloproliferative effects of drug1, such as drug2 and drug0",True,effect
DDI-DrugBank.d607.s1.e0,DDI-DrugBank.d607.s1.e2,"Drugs which may potentiate the myeloproliferative effects of drug1, such as drug0 and drug2",True,effect
DDI-DrugBank.d607.s1.e1,DDI-DrugBank.d607.s1.e2,"Drugs which may potentiate the myeloproliferative effects of drug0, such as drug1 and drug2",False, 
DDI-DrugBank.d604.s0.e0,DDI-DrugBank.d604.s0.e1,"drug1 has been reported to enhance the sedative activity of drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d604.s0.e0,DDI-DrugBank.d604.s0.e2,"drug1 has been reported to enhance the sedative activity of drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d604.s0.e0,DDI-DrugBank.d604.s0.e3,"drug1 has been reported to enhance the sedative activity of drug0, drug0, drug2, and drug0",False, 
DDI-DrugBank.d604.s2.e0,DDI-DrugBank.d604.s2.e1,"Oral drug1: In 10 healthy women, the pharmacokinetic profiles of drug2 and drug0 following administration of a single dose containing 1.0 mg of drug0 and 75    g of drug0",False, 
DDI-DrugBank.d604.s2.e0,DDI-DrugBank.d604.s2.e2,"Oral drug1: In 10 healthy women, the pharmacokinetic profiles of drug0 and drug2 following administration of a single dose containing 1.0 mg of drug0 and 75    g of drug0",False, 
DDI-DrugBank.d604.s4.e0,DDI-DrugBank.d604.s4.e1,"Important Non-drug1 Drug Interactions Drugs That Interfere with drug2: Concomitant use of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d604.s4.e0,DDI-DrugBank.d604.s4.e2,"Important Non-drug1 Drug Interactions Drugs That Interfere with drug0: Concomitant use of drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d604.s5.e0,DDI-DrugBank.d604.s5.e1,drug1 with drug2,True,effect
DDI-DrugBank.d726.s1.e0,DDI-DrugBank.d726.s1.e1,"A multiple dose drug-drug interaction study demonstrated that drug1 approximately doubled drug2 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug0 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",True,mechanism
DDI-DrugBank.d726.s1.e0,DDI-DrugBank.d726.s1.e2,"A multiple dose drug-drug interaction study demonstrated that drug1 approximately doubled drug0 AUC0-   . Since drug2 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug0 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d726.s1.e0,DDI-DrugBank.d726.s1.e3,"A multiple dose drug-drug interaction study demonstrated that drug1 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug2 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug0 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e5,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug2 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e6,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e7,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e8,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e9,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e10,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e11,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e12,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e13,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e14,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2 or drug0",True,advise
DDI-DrugBank.d726.s1.e4,DDI-DrugBank.d726.s1.e15,"A multiple dose drug-drug interaction study demonstrated that drug0 approximately doubled drug0 AUC0-   . Since drug0 is partially metabolized by CYP3A and drug0 le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing drug1 with drug0 and other strong P450 3A inhibitors including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug2",True,advise
DDI-DrugBank.d726.s2.e0,DDI-DrugBank.d726.s2.e1,"Dose adjustment of drug1 Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as drug2",True,advise
DDI-DrugBank.d726.s3.e0,DDI-DrugBank.d726.s3.e1,"Drugs that impair intestinal absorption of drug1, such as drug2, may interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d726.s3.e0,DDI-DrugBank.d726.s3.e2,"Drugs that impair intestinal absorption of drug1, such as drug0, may interfere with the absorption of drug2",False, 
DDI-DrugBank.d726.s3.e1,DDI-DrugBank.d726.s3.e2,"Drugs that impair intestinal absorption of drug0, such as drug1, may interfere with the absorption of drug2",True,mechanism
DDI-DrugBank.d717.s0.e0,DDI-DrugBank.d717.s0.e1,"drug1 has been reported to accelerate the metabolism of drug2 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for drug0",True,mechanism
DDI-DrugBank.d717.s0.e0,DDI-DrugBank.d717.s0.e2,"drug1 has been reported to accelerate the metabolism of drug0 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for drug2",False, 
DDI-DrugBank.d717.s0.e1,DDI-DrugBank.d717.s0.e2,"drug0 has been reported to accelerate the metabolism of drug1 by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for drug2",False, 
DDI-DrugBank.d717.s1.e0,DDI-DrugBank.d717.s1.e1,"Therefore, physicians should closely monitor patients for a change in drug1 dosage requirements when administering drug2 to patients on drug0",False, 
DDI-DrugBank.d717.s1.e0,DDI-DrugBank.d717.s1.e2,"Therefore, physicians should closely monitor patients for a change in drug1 dosage requirements when administering drug0 to patients on drug2",False, 
DDI-DrugBank.d717.s1.e1,DDI-DrugBank.d717.s1.e2,"Therefore, physicians should closely monitor patients for a change in drug0 dosage requirements when administering drug1 to patients on drug2",True,advise
DDI-DrugBank.d627.s0.e0,DDI-DrugBank.d627.s0.e1,drug1 should be administered with caution to patients taking drug2,True,advise
DDI-DrugBank.d627.s3.e0,DDI-DrugBank.d627.s3.e1,"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., drug1, inhaled drug2",False, 
DDI-DrugBank.d627.s4.e0,DDI-DrugBank.d627.s4.e1,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: drug1, artificial tears, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d627.s4.e0,DDI-DrugBank.d627.s4.e2,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: drug1, artificial tears, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d576.s1.e0,DDI-DrugBank.d576.s1.e1,drug1 AND OTHER drug2 WILL BE ADDITIVE TO drug0 AND MAY INCREASE PLASMA CONCENTRATIONS OF drug0,False, 
DDI-DrugBank.d576.s1.e0,DDI-DrugBank.d576.s1.e2,drug1 AND OTHER drug0 WILL BE ADDITIVE TO drug2 AND MAY INCREASE PLASMA CONCENTRATIONS OF drug0,True,effect
DDI-DrugBank.d576.s1.e0,DDI-DrugBank.d576.s1.e3,drug1 AND OTHER drug0 WILL BE ADDITIVE TO drug0 AND MAY INCREASE PLASMA CONCENTRATIONS OF drug2,False, 
DDI-DrugBank.d576.s1.e1,DDI-DrugBank.d576.s1.e2,drug0 AND OTHER drug1 WILL BE ADDITIVE TO drug2 AND MAY INCREASE PLASMA CONCENTRATIONS OF drug0,True,effect
DDI-DrugBank.d576.s4.e0,DDI-DrugBank.d576.s4.e1,drug1 given concomitantly with drug2,True,effect
DDI-DrugBank.d576.s5.e0,DDI-DrugBank.d576.s5.e1,drug1 may enhance the hypoglycemic effect of oral drug2,True,effect
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e1,"drug1 competes with a number of drugs for protein binding sites, notably drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e2,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e3,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e4,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e5,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e6,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e7,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e8,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e9,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, and possibly drug0",True,mechanism
DDI-DrugBank.d576.s6.e0,DDI-DrugBank.d576.s6.e10,"drug1 competes with a number of drugs for protein binding sites, notably drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and possibly drug2",True,mechanism
DDI-DrugBank.d576.s6.e1,DDI-DrugBank.d576.s6.e2,"drug0 competes with a number of drugs for protein binding sites, notably drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and possibly drug0",False, 
DDI-DrugBank.d576.s6.e1,DDI-DrugBank.d576.s6.e3,"drug0 competes with a number of drugs for protein binding sites, notably drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and possibly drug0",False, 
DDI-DrugBank.d658.s0.e0,DDI-DrugBank.d658.s0.e1,"When administered concurrently, drug1 may increase the effects of oral drug2",True,effect
DDI-DrugBank.d781.s0.e0,DDI-DrugBank.d781.s0.e1,"drug1: Patients on drug2, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of drug0",False, 
DDI-DrugBank.d781.s0.e0,DDI-DrugBank.d781.s0.e2,"drug1: Patients on drug0, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of drug2",False, 
DDI-DrugBank.d781.s0.e1,DDI-DrugBank.d781.s0.e2,"drug0: Patients on drug1, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of drug2",True,effect
DDI-DrugBank.d781.s1.e0,DDI-DrugBank.d781.s1.e1,The possibility of hypotensive effects can be minimized by either discontinuing the drug1 or increasing the salt intake prior to initiation of treatment with drug2,True,effect
DDI-DrugBank.d781.s2.e0,DDI-DrugBank.d781.s2.e1,"If drug1 cannot be interrupted, close medical supervision should be provided with the first dose of drug2",True,advise
DDI-DrugBank.d781.s3.e0,DDI-DrugBank.d781.s3.e1,The rate and extent of drug1 absorption and elimination are not affected by concomitant drug2,False, 
DDI-DrugBank.d781.s4.e0,DDI-DrugBank.d781.s4.e1,The bioavailability of drug1 was reduced by drug2,False, 
DDI-DrugBank.d781.s5.e0,DDI-DrugBank.d781.s5.e1,drug1 Supplements and drug2: drug0,False, 
DDI-DrugBank.d781.s5.e0,DDI-DrugBank.d781.s5.e2,drug1 Supplements and drug0: drug2,False, 
DDI-DrugBank.d781.s6.e0,DDI-DrugBank.d781.s6.e1,"Use of drug1 (drug2, drug0, drug0 and others), drug0 supplements or other drugs capable of increasing serum potassium (drug0, drug0, drug0",False, 
DDI-DrugBank.d781.s6.e0,DDI-DrugBank.d781.s6.e2,"Use of drug1 (drug0, drug2, drug0 and others), drug0 supplements or other drugs capable of increasing serum potassium (drug0, drug0, drug0",False, 
DDI-DrugBank.d781.s8.e0,DDI-DrugBank.d781.s8.e1,drug1: Increased serum drug2 and symptoms of drug0 toxicity have been reported in patients receiving concomitant drug0,False, 
DDI-DrugBank.d781.s8.e0,DDI-DrugBank.d781.s8.e2,drug1: Increased serum drug0 and symptoms of drug2 toxicity have been reported in patients receiving concomitant drug0,False, 
DDI-DrugBank.d781.s10.e0,DDI-DrugBank.d781.s10.e1,Use of a drug1 may further increase the risk of drug2,False, 
DDI-DrugBank.d781.s11.e0,DDI-DrugBank.d781.s11.e1,"drug1: A controlled pharmacokinetic study has shown no effect on plasma drug2 concentrations when coadministered with drug0    Tablets, but an effect of drug0 on the plasma concentration of drug0/drug0",False, 
DDI-DrugBank.d781.s11.e0,DDI-DrugBank.d781.s11.e2,"drug1: A controlled pharmacokinetic study has shown no effect on plasma drug0 concentrations when coadministered with drug2    Tablets, but an effect of drug0 on the plasma concentration of drug0/drug0",False, 
DDI-DrugBank.d781.s11.e3,DDI-DrugBank.d781.s11.e4,"drug0: A controlled pharmacokinetic study has shown no effect on plasma drug0 concentrations when coadministered with drug0    Tablets, but an effect of drug1 on the plasma concentration of drug2/drug0",True,mechanism
DDI-DrugBank.d781.s11.e3,DDI-DrugBank.d781.s11.e5,"drug0: A controlled pharmacokinetic study has shown no effect on plasma drug0 concentrations when coadministered with drug0    Tablets, but an effect of drug1 on the plasma concentration of drug0/drug2",True,mechanism
DDI-DrugBank.d781.s12.e0,DDI-DrugBank.d781.s12.e1,drug1: Animal data have suggested the possibility of interaction between drug2 and drug0,False, 
DDI-DrugBank.d781.s12.e0,DDI-DrugBank.d781.s12.e2,drug1: Animal data have suggested the possibility of interaction between drug0 and drug2,False, 
DDI-DrugBank.d781.s12.e1,DDI-DrugBank.d781.s12.e2,drug0: Animal data have suggested the possibility of interaction between drug1 and drug2,True,int
DDI-DrugBank.d781.s15.e0,DDI-DrugBank.d781.s15.e1,Food Interaction: Oral administration of drug1    Tablets with food does not significantly lower the rate or extent of drug2,False, 
DDI-DrugBank.d781.s16.e0,DDI-DrugBank.d781.s16.e1,"However, the extent of biotransformation of drug1 to the active metabolite, drug2",False, 
DDI-DrugBank.d578.s1.e0,DDI-DrugBank.d578.s1.e1,Mutual inhibition of metabolism occurs with concurrent use of drug1 and drug2,True,mechanism
DDI-DrugBank.d578.s3.e0,DDI-DrugBank.d578.s3.e1,convulsions have been reported with concurrent use of drug1 and drug2,True,effect
DDI-DrugBank.d578.s4.e0,DDI-DrugBank.d578.s4.e1,"Drugs that induce hepatic enzymes such as drug1, drug2, and drug0 may increase the clearance of drug0 and may require increased in drug0",False, 
DDI-DrugBank.d578.s4.e0,DDI-DrugBank.d578.s4.e2,"Drugs that induce hepatic enzymes such as drug1, drug0, and drug2 may increase the clearance of drug0 and may require increased in drug0",False, 
DDI-DrugBank.d578.s4.e0,DDI-DrugBank.d578.s4.e3,"Drugs that induce hepatic enzymes such as drug1, drug0, and drug0 may increase the clearance of drug2 and may require increased in drug0",True,mechanism
DDI-DrugBank.d578.s4.e0,DDI-DrugBank.d578.s4.e4,"Drugs that induce hepatic enzymes such as drug1, drug0, and drug0 may increase the clearance of drug0 and may require increased in drug2",True,advise
DDI-DrugBank.d578.s4.e1,DDI-DrugBank.d578.s4.e3,"Drugs that induce hepatic enzymes such as drug0, drug1, and drug0 may increase the clearance of drug2 and may require increased in drug0",True,mechanism
DDI-DrugBank.d578.s4.e1,DDI-DrugBank.d578.s4.e4,"Drugs that induce hepatic enzymes such as drug0, drug1, and drug0 may increase the clearance of drug0 and may require increased in drug2",True,advise
DDI-DrugBank.d578.s4.e2,DDI-DrugBank.d578.s4.e3,"Drugs that induce hepatic enzymes such as drug0, drug0, and drug1 may increase the clearance of drug2 and may require increased in drug0",True,mechanism
DDI-DrugBank.d578.s4.e2,DDI-DrugBank.d578.s4.e4,"Drugs that induce hepatic enzymes such as drug0, drug0, and drug1 may increase the clearance of drug0 and may require increased in drug2",True,advise
DDI-DrugBank.d578.s5.e0,DDI-DrugBank.d578.s5.e1,Drugs such as drug1 and drug2 may inhibit the metabolism of drug0,False, 
DDI-DrugBank.d578.s5.e0,DDI-DrugBank.d578.s5.e2,Drugs such as drug1 and drug0 may inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d578.s5.e1,DDI-DrugBank.d578.s5.e2,Drugs such as drug0 and drug1 may inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d578.s7.e0,DDI-DrugBank.d578.s7.e1,drug1 may increase the clearance of chronic high dose drug2,True,mechanism
DDI-DrugBank.d578.s8.e0,DDI-DrugBank.d578.s8.e1,This could lead to decreased drug1 serum levels or increase the risk of drug2 toxicity when drug0,False, 
DDI-DrugBank.d578.s8.e0,DDI-DrugBank.d578.s8.e2,This could lead to decreased drug1 serum levels or increase the risk of drug0 toxicity when drug2,False, 
DDI-DrugBank.d578.s8.e1,DDI-DrugBank.d578.s8.e2,This could lead to decreased drug0 serum levels or increase the risk of drug1 toxicity when drug2,True,effect
DDI-DrugBank.d578.s9.e0,DDI-DrugBank.d578.s9.e1,drug1 should be used cautiously in conjunction with drug2,True,advise
DDI-DrugBank.d578.s10.e0,DDI-DrugBank.d578.s10.e1,The effect of drug1 on oral drug2,False, 
DDI-DrugBank.d578.s11.e0,DDI-DrugBank.d578.s11.e1,There are reports of enhanced as well as diminished effects of drug1 when given concurrently with drug2,True,effect
DDI-DrugBank.d694.s0.e0,DDI-DrugBank.d694.s0.e1,"drug1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of drug2 with the co-administration of 100 mg drug0",False, 
DDI-DrugBank.d694.s0.e0,DDI-DrugBank.d694.s0.e2,"drug1: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of drug0 with the co-administration of 100 mg drug2",False, 
DDI-DrugBank.d694.s0.e1,DDI-DrugBank.d694.s0.e2,"drug0: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of drug1 with the co-administration of 100 mg drug2",True,mechanism
DDI-DrugBank.d694.s2.e0,DDI-DrugBank.d694.s2.e1,No dosage adjustment of drug1 or drug2,False, 
DDI-DrugBank.d603.s0.e0,DDI-DrugBank.d603.s0.e1,"When administered concomitantly with drug1   , drug2",True,effect
DDI-DrugBank.d603.s2.e0,DDI-DrugBank.d603.s2.e1,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug1, drug2, drug0, drug0 or drug0) may enhance or potentiate the pressor effects of drug0   . Therefore, caution should be used when drug0",False, 
DDI-DrugBank.d603.s2.e0,DDI-DrugBank.d603.s2.e2,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug1, drug0, drug2, drug0 or drug0) may enhance or potentiate the pressor effects of drug0   . Therefore, caution should be used when drug0",False, 
DDI-DrugBank.d603.s2.e0,DDI-DrugBank.d603.s2.e5,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug1, drug0, drug0, drug0 or drug0) may enhance or potentiate the pressor effects of drug2   . Therefore, caution should be used when drug0",True,effect
DDI-DrugBank.d603.s2.e1,DDI-DrugBank.d603.s2.e5,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug0, drug1, drug0, drug0 or drug0) may enhance or potentiate the pressor effects of drug2   . Therefore, caution should be used when drug0",True,effect
DDI-DrugBank.d603.s2.e2,DDI-DrugBank.d603.s2.e5,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug0, drug0, drug1, drug0 or drug0) may enhance or potentiate the pressor effects of drug2   . Therefore, caution should be used when drug0",True,effect
DDI-DrugBank.d603.s2.e3,DDI-DrugBank.d603.s2.e5,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug0, drug0, drug0, drug1 or drug0) may enhance or potentiate the pressor effects of drug2   . Therefore, caution should be used when drug0",True,effect
DDI-DrugBank.d603.s2.e4,DDI-DrugBank.d603.s2.e5,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., drug0, drug0, drug0, drug0 or drug1) may enhance or potentiate the pressor effects of drug2   . Therefore, caution should be used when drug0",True,effect
DDI-DrugBank.d603.s3.e0,DDI-DrugBank.d603.s3.e1,"drug1    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., drug2",False, 
DDI-DrugBank.d603.s5.e0,DDI-DrugBank.d603.s5.e1,"drug1. drug2, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug0 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d603.s5.e0,DDI-DrugBank.d603.s5.e2,"drug1. drug0, such as drug2, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug0 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d603.s5.e1,DDI-DrugBank.d603.s5.e5,"drug0. drug1, such as drug0, drug0, and drug0, can antagonize the effects of drug2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug0 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d603.s5.e2,DDI-DrugBank.d603.s5.e5,"drug0. drug0, such as drug1, drug0, and drug0, can antagonize the effects of drug2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug0 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d603.s5.e3,DDI-DrugBank.d603.s5.e5,"drug0. drug0, such as drug0, drug1, and drug0, can antagonize the effects of drug2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug0 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d603.s5.e4,DDI-DrugBank.d603.s5.e5,"drug0. drug0, such as drug0, drug0, and drug1, can antagonize the effects of drug2. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug0 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e7,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug2, drug0, drug0, drug0, drug0, drug0, and drug0",True,mechanism
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e8,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug2, drug0, drug0, drug0, drug0, and drug0",True,mechanism
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e9,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug2, drug0, drug0, drug0, and drug0",True,mechanism
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e10,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug2, drug0, drug0, and drug0",True,mechanism
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e11,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug2, drug0, and drug0",True,mechanism
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e12,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug2, and drug0",True,mechanism
DDI-DrugBank.d603.s5.e6,DDI-DrugBank.d603.s5.e13,"drug0. drug0, such as drug0, drug0, and drug0, can antagonize the effects of drug0. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of drug1 (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as drug0, drug0, drug0, drug0, drug0, drug0, and drug2",True,mechanism
DDI-DrugBank.d648.s0.e0,DDI-DrugBank.d648.s0.e1,drug1: drug2 causes a 60% reduction in the absorption and enterohepatic cycling of drug0 and should not be coadministered with drug0,False, 
DDI-DrugBank.d648.s0.e0,DDI-DrugBank.d648.s0.e2,drug1: drug0 causes a 60% reduction in the absorption and enterohepatic cycling of drug2 and should not be coadministered with drug0,False, 
DDI-DrugBank.d648.s0.e1,DDI-DrugBank.d648.s0.e2,drug0: drug1 causes a 60% reduction in the absorption and enterohepatic cycling of drug2 and should not be coadministered with drug0,True,mechanism
DDI-DrugBank.d648.s0.e1,DDI-DrugBank.d648.s0.e3,drug0: drug1 causes a 60% reduction in the absorption and enterohepatic cycling of drug0 and should not be coadministered with drug2,True,advise
DDI-DrugBank.d648.s1.e0,DDI-DrugBank.d648.s1.e1,drug1: The coadministration of drug2 and drug0,False, 
DDI-DrugBank.d648.s1.e0,DDI-DrugBank.d648.s1.e2,drug1: The coadministration of drug0 and drug2,False, 
DDI-DrugBank.d648.s3.e0,DDI-DrugBank.d648.s3.e1,If drug1 is given concurrently with drug2,True,advise
DDI-DrugBank.d648.s5.e0,DDI-DrugBank.d648.s5.e1,"In vitro, drug1 did not affect the binding of drug2, drug0, or drug0",False, 
DDI-DrugBank.d648.s5.e0,DDI-DrugBank.d648.s5.e2,"In vitro, drug1 did not affect the binding of drug0, drug2, or drug0",False, 
DDI-DrugBank.d648.s6.e0,DDI-DrugBank.d648.s6.e1,"Caution should be used when drug1 is coadministered with other highly protein-bound drugs, such as drug2, drug0, drug0, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d648.s6.e0,DDI-DrugBank.d648.s6.e2,"Caution should be used when drug1 is coadministered with other highly protein-bound drugs, such as drug0, drug2, drug0, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d648.s6.e0,DDI-DrugBank.d648.s6.e3,"Caution should be used when drug1 is coadministered with other highly protein-bound drugs, such as drug0, drug0, drug2, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d648.s6.e0,DDI-DrugBank.d648.s6.e4,"Caution should be used when drug1 is coadministered with other highly protein-bound drugs, such as drug0, drug0, drug0, drug2, drug0, and drug0",True,advise
DDI-DrugBank.d648.s6.e0,DDI-DrugBank.d648.s6.e5,"Caution should be used when drug1 is coadministered with other highly protein-bound drugs, such as drug0, drug0, drug0, drug0, drug2, and drug0",True,advise
DDI-DrugBank.d648.s6.e0,DDI-DrugBank.d648.s6.e6,"Caution should be used when drug1 is coadministered with other highly protein-bound drugs, such as drug0, drug0, drug0, drug0, drug0, and drug2",True,advise
DDI-DrugBank.d648.s6.e1,DDI-DrugBank.d648.s6.e2,"Caution should be used when drug0 is coadministered with other highly protein-bound drugs, such as drug1, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d648.s6.e1,DDI-DrugBank.d648.s6.e3,"Caution should be used when drug0 is coadministered with other highly protein-bound drugs, such as drug1, drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d647.s1.e0,DDI-DrugBank.d647.s1.e1,drug1 has been reported to prolong the elimination half-life of drug2,True,mechanism
DDI-DrugBank.d647.s2.e0,DDI-DrugBank.d647.s2.e1,a reduction of the drug1 dosage should be considered in patients receiving drug2,True,advise
DDI-DrugBank.d647.s3.e0,DDI-DrugBank.d647.s3.e1,The concurrent use of drug1 and drug2 has been reported in one case to result in reduced drug0,True,effect
DDI-DrugBank.d647.s3.e0,DDI-DrugBank.d647.s3.e2,The concurrent use of drug1 and drug0 has been reported in one case to result in reduced drug2,False, 
DDI-DrugBank.d647.s3.e1,DDI-DrugBank.d647.s3.e2,The concurrent use of drug0 and drug1 has been reported in one case to result in reduced drug2,False, 
DDI-DrugBank.d697.s0.e0,DDI-DrugBank.d697.s0.e1,"Interactions for drug1 (drug2):  drug0, Oral drug0, drug0, drug0",False, 
DDI-DrugBank.d697.s0.e0,DDI-DrugBank.d697.s0.e2,"Interactions for drug1 (drug0):  drug2, Oral drug0, drug0, drug0",True,int
DDI-DrugBank.d697.s0.e0,DDI-DrugBank.d697.s0.e3,"Interactions for drug1 (drug0):  drug0, Oral drug2, drug0, drug0",True,int
DDI-DrugBank.d697.s0.e0,DDI-DrugBank.d697.s0.e4,"Interactions for drug1 (drug0):  drug0, Oral drug0, drug2, drug0",True,int
DDI-DrugBank.d697.s0.e0,DDI-DrugBank.d697.s0.e5,"Interactions for drug1 (drug0):  drug0, Oral drug0, drug0, drug2",True,int
DDI-DrugBank.d697.s0.e1,DDI-DrugBank.d697.s0.e2,"Interactions for drug0 (drug1):  drug2, Oral drug0, drug0, drug0",True,int
DDI-DrugBank.d697.s0.e1,DDI-DrugBank.d697.s0.e3,"Interactions for drug0 (drug1):  drug0, Oral drug2, drug0, drug0",True,int
DDI-DrugBank.d697.s0.e1,DDI-DrugBank.d697.s0.e4,"Interactions for drug0 (drug1):  drug0, Oral drug0, drug2, drug0",True,int
DDI-DrugBank.d697.s0.e1,DDI-DrugBank.d697.s0.e5,"Interactions for drug0 (drug1):  drug0, Oral drug0, drug0, drug2",True,int
DDI-DrugBank.d697.s0.e2,DDI-DrugBank.d697.s0.e3,"Interactions for drug0 (drug0):  drug1, Oral drug2, drug0, drug0",False, 
DDI-DrugBank.d696.s0.e0,DDI-DrugBank.d696.s0.e1,drug1 may reverse the analgesic activity of drug2,True,effect
DDI-DrugBank.d696.s1.e0,DDI-DrugBank.d696.s1.e1,"Concurrent use with drug1 including drug2, drug0, and drug0",False, 
DDI-DrugBank.d696.s1.e0,DDI-DrugBank.d696.s1.e2,"Concurrent use with drug1 including drug0, drug2, and drug0",False, 
DDI-DrugBank.d575.s0.e0,DDI-DrugBank.d575.s0.e1,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of drug1, drug2 and drug0 displaced protein-bound drug0",False, 
DDI-DrugBank.d575.s0.e0,DDI-DrugBank.d575.s0.e2,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of drug1, drug0 and drug2 displaced protein-bound drug0",False, 
DDI-DrugBank.d575.s0.e0,DDI-DrugBank.d575.s0.e3,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of drug1, drug0 and drug0 displaced protein-bound drug2",True,mechanism
DDI-DrugBank.d575.s0.e1,DDI-DrugBank.d575.s0.e3,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of drug0, drug1 and drug0 displaced protein-bound drug2",True,mechanism
DDI-DrugBank.d575.s0.e2,DDI-DrugBank.d575.s0.e3,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of drug0, drug0 and drug1 displaced protein-bound drug2",True,mechanism
DDI-DrugBank.d575.s2.e0,DDI-DrugBank.d575.s2.e1,"Therefore, caution should be used in administering drug1 (drug2",False, 
DDI-DrugBank.d575.s3.e0,DDI-DrugBank.d575.s3.e1,There was no change in the plasma kinetics of drug1 when coadministered with drug2,False, 
DDI-DrugBank.d575.s5.e0,DDI-DrugBank.d575.s5.e1,An increase in intracellular levels of drug1 was observed in vitro in the presence of drug2,True,mechanism
DDI-DrugBank.d661.s0.e0,DDI-DrugBank.d661.s0.e1,"Drug Interactions: The use of drug1    (drug2) Injection before drug0, for the purpose of attenuating some of the side effects of drug0",False, 
DDI-DrugBank.d661.s0.e0,DDI-DrugBank.d661.s0.e2,"Drug Interactions: The use of drug1    (drug0) Injection before drug2, for the purpose of attenuating some of the side effects of drug0",False, 
DDI-DrugBank.d661.s1.e0,DDI-DrugBank.d661.s1.e1,"If drug1    is administered following administration of drug2, it should not be given until recovery from drug0",True,advise
DDI-DrugBank.d661.s1.e0,DDI-DrugBank.d661.s1.e2,"If drug1    is administered following administration of drug0, it should not be given until recovery from drug2",False, 
DDI-DrugBank.d661.s1.e1,DDI-DrugBank.d661.s1.e2,"If drug0    is administered following administration of drug1, it should not be given until recovery from drug2",False, 
DDI-DrugBank.d661.s2.e0,DDI-DrugBank.d661.s2.e1,The median duration of action of drug1    0.6 mg/kg administered after a 1 mg/kg dose of drug2,False, 
DDI-DrugBank.d661.s4.e0,DDI-DrugBank.d661.s4.e1,There are no controlled studies documenting the use of drug1    before or after other drug2,False, 
DDI-DrugBank.d645.s0.e0,DDI-DrugBank.d645.s0.e1,"In vitro studies with human liver microsomes showed that drug1 does not inhibit the metabolism of drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d645.s0.e0,DDI-DrugBank.d645.s0.e2,"In vitro studies with human liver microsomes showed that drug1 does not inhibit the metabolism of drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d645.s2.e0,DDI-DrugBank.d645.s2.e1,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as drug1,    -blockers, drug2 (drug0), and drug0",False, 
DDI-DrugBank.d645.s2.e0,DDI-DrugBank.d645.s2.e2,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as drug1,    -blockers, drug0 (drug2), and drug0",False, 
DDI-DrugBank.d645.s3.e0,DDI-DrugBank.d645.s3.e1,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that drug1 does not affect the clearance of drug2 or drug0,False, 
DDI-DrugBank.d645.s3.e0,DDI-DrugBank.d645.s3.e2,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that drug1 does not affect the clearance of drug0 or drug2,False, 
DDI-DrugBank.d645.s4.e0,DDI-DrugBank.d645.s4.e1,drug1 decreases the clearance of drug2,True,mechanism
DDI-DrugBank.d645.s5.e0,DDI-DrugBank.d645.s5.e1,drug1 increases the clearance of drug2,True,mechanism
DDI-DrugBank.d645.s6.e0,DDI-DrugBank.d645.s6.e1,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral drug1 and drug2, however, a causal relationship between drug0",True,effect
DDI-DrugBank.d645.s6.e0,DDI-DrugBank.d645.s6.e2,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral drug1 and drug0, however, a causal relationship between drug2",False, 
DDI-DrugBank.d645.s6.e1,DDI-DrugBank.d645.s6.e2,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral drug0 and drug1, however, a causal relationship between drug2",False, 
DDI-DrugBank.d645.s7.e0,DDI-DrugBank.d645.s7.e1,"drug1 clearance is increased 100% by drug2, a CyP450 enzyme inducer, and decreased 33% by drug0",True,mechanism
DDI-DrugBank.d645.s7.e0,DDI-DrugBank.d645.s7.e2,"drug1 clearance is increased 100% by drug0, a CyP450 enzyme inducer, and decreased 33% by drug2",True,mechanism
DDI-DrugBank.d645.s7.e1,DDI-DrugBank.d645.s7.e2,"drug0 clearance is increased 100% by drug1, a CyP450 enzyme inducer, and decreased 33% by drug2",False, 
DDI-DrugBank.d645.s8.e0,DDI-DrugBank.d645.s8.e1,drug1 clearance is unaffected by drug2,False, 
DDI-DrugBank.d645.s9.e0,DDI-DrugBank.d645.s9.e1,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral drug1, hormone replacement therapies, drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d645.s9.e0,DDI-DrugBank.d645.s9.e2,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral drug1, hormone replacement therapies, drug0, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d695.s0.e0,DDI-DrugBank.d695.s0.e1,"While co-administration of drug1    appeared to increase the clearance of drug2 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drug0",True,mechanism
DDI-DrugBank.d695.s0.e0,DDI-DrugBank.d695.s0.e2,"While co-administration of drug1    appeared to increase the clearance of drug0 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drug2",False, 
DDI-DrugBank.d695.s0.e1,DDI-DrugBank.d695.s0.e2,"While co-administration of drug0    appeared to increase the clearance of drug1 by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of drug2",False, 
DDI-DrugBank.d695.s1.e0,DDI-DrugBank.d695.s1.e1,Combination therapy with drug1    (drug2) and drug0,False, 
DDI-DrugBank.d695.s1.e0,DDI-DrugBank.d695.s1.e2,Combination therapy with drug1    (drug0) and drug2,True,advise
DDI-DrugBank.d695.s1.e1,DDI-DrugBank.d695.s1.e2,Combination therapy with drug0    (drug1) and drug2,True,advise
DDI-DrugBank.d630.s1.e0,DDI-DrugBank.d630.s1.e1,"Caution is advised for patients receiving high-dose drug1 and drug2 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose drug0 and drug0",True,advise
DDI-DrugBank.d630.s1.e0,DDI-DrugBank.d630.s1.e2,"Caution is advised for patients receiving high-dose drug1 and drug0 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose drug2 and drug0",False, 
DDI-DrugBank.d630.s1.e0,DDI-DrugBank.d630.s1.e3,"Caution is advised for patients receiving high-dose drug1 and drug0 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose drug0 and drug2",False, 
DDI-DrugBank.d630.s1.e2,DDI-DrugBank.d630.s1.e3,"Caution is advised for patients receiving high-dose drug0 and drug0 concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose drug1 and drug2",True,effect
DDI-DrugBank.d715.s0.e0,DDI-DrugBank.d715.s0.e1,Caution should be observed in administering drug1 to patients receiving drug2 or drug0,True,advise
DDI-DrugBank.d715.s0.e0,DDI-DrugBank.d715.s0.e2,Caution should be observed in administering drug1 to patients receiving drug0 or drug2,True,advise
DDI-DrugBank.d715.s0.e1,DDI-DrugBank.d715.s0.e2,Caution should be observed in administering drug0 to patients receiving drug1 or drug2,False, 
DDI-DrugBank.d715.s1.e0,DDI-DrugBank.d715.s1.e1,Concurrent use of drug1 with drug2 or other drug0,True,effect
DDI-DrugBank.d715.s1.e0,DDI-DrugBank.d715.s1.e2,Concurrent use of drug1 with drug0 or other drug2,True,effect
DDI-DrugBank.d715.s1.e1,DDI-DrugBank.d715.s1.e2,Concurrent use of drug0 with drug1 or other drug2,False, 
DDI-DrugBank.d675.s0.e0,DDI-DrugBank.d675.s0.e1,CYP 3A4 Inhibitors (e.g. drug1 and drug2) There have been rare reports of serious adverse events in connection with the coadministration of certain drug0 (e.g. drug0 and drug0,False, 
DDI-DrugBank.d675.s0.e0,DDI-DrugBank.d675.s0.e2,CYP 3A4 Inhibitors (e.g. drug1 and drug0) There have been rare reports of serious adverse events in connection with the coadministration of certain drug2 (e.g. drug0 and drug0,False, 
DDI-DrugBank.d675.s2.e0,DDI-DrugBank.d675.s2.e1,"Examples of some of the more potent CYP 3A4 inhibitors include drug1 (e.g., drug2, drug0, drug0), drug0 or drug0 (e.g., drug0, drug0, drug0, drug0) or drug0 (e.g., drug0, drug0, drug0",False, 
DDI-DrugBank.d675.s2.e0,DDI-DrugBank.d675.s2.e2,"Examples of some of the more potent CYP 3A4 inhibitors include drug1 (e.g., drug0, drug2, drug0), drug0 or drug0 (e.g., drug0, drug0, drug0, drug0) or drug0 (e.g., drug0, drug0, drug0",False, 
DDI-DrugBank.d675.s4.e0,DDI-DrugBank.d675.s4.e1,"Less potent inhibitors include drug1, drug2, drug0, grapefruit juice, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d675.s4.e0,DDI-DrugBank.d675.s4.e2,"Less potent inhibitors include drug1, drug0, drug2, grapefruit juice, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d675.s7.e0,DDI-DrugBank.d675.s7.e1,Caution should be exercised when drug1    (drug2) is used concurrently with other drug0 or drug0,False, 
DDI-DrugBank.d675.s7.e0,DDI-DrugBank.d675.s7.e2,Caution should be exercised when drug1    (drug0) is used concurrently with other drug2 or drug0,True,advise
DDI-DrugBank.d675.s7.e0,DDI-DrugBank.d675.s7.e3,Caution should be exercised when drug1    (drug0) is used concurrently with other drug0 or drug2,True,advise
DDI-DrugBank.d675.s7.e1,DDI-DrugBank.d675.s7.e2,Caution should be exercised when drug0    (drug1) is used concurrently with other drug2 or drug0,True,advise
DDI-DrugBank.d675.s7.e1,DDI-DrugBank.d675.s7.e3,Caution should be exercised when drug0    (drug1) is used concurrently with other drug0 or drug2,False, 
DDI-DrugBank.d572.s0.e0,DDI-DrugBank.d572.s0.e1,drug1: Concomitant drug2 administration decreased the mean AUC of total drug0,False, 
DDI-DrugBank.d572.s0.e0,DDI-DrugBank.d572.s0.e2,drug1: Concomitant drug0 administration decreased the mean AUC of total drug2,False, 
DDI-DrugBank.d572.s0.e1,DDI-DrugBank.d572.s0.e2,drug0: Concomitant drug1 administration decreased the mean AUC of total drug2,True,mechanism
DDI-DrugBank.d572.s1.e0,DDI-DrugBank.d572.s1.e1,The incremental LDL-C reduction due to adding drug1 to drug2,True,effect
DDI-DrugBank.d572.s2.e0,DDI-DrugBank.d572.s2.e1,drug1: The safety and effectiveness of drug2 administered with drug0,False, 
DDI-DrugBank.d572.s2.e0,DDI-DrugBank.d572.s2.e2,drug1: The safety and effectiveness of drug0 administered with drug2,False, 
DDI-DrugBank.d572.s5.e0,DDI-DrugBank.d572.s5.e1,Co-administration of drug1 with drug2,True,advise
DDI-DrugBank.d572.s6.e0,DDI-DrugBank.d572.s6.e1,"drug1: In a pharmacokinetic study, concomitant drug2 administration increased total drug0",False, 
DDI-DrugBank.d572.s6.e0,DDI-DrugBank.d572.s6.e2,"drug1: In a pharmacokinetic study, concomitant drug0 administration increased total drug2",False, 
DDI-DrugBank.d572.s6.e1,DDI-DrugBank.d572.s6.e2,"drug0: In a pharmacokinetic study, concomitant drug1 administration increased total drug2",True,mechanism
DDI-DrugBank.d572.s7.e0,DDI-DrugBank.d572.s7.e1,"drug1: In a pharmacokinetic study, concomitant drug2 administration increased total drug0",False, 
DDI-DrugBank.d572.s7.e0,DDI-DrugBank.d572.s7.e2,"drug1: In a pharmacokinetic study, concomitant drug0 administration increased total drug2",False, 
DDI-DrugBank.d572.s8.e0,DDI-DrugBank.d572.s8.e1,"drug1: No clinically significant pharmacokinetic interactions were seen when drug2 was co-administered with drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d572.s8.e0,DDI-DrugBank.d572.s8.e2,"drug1: No clinically significant pharmacokinetic interactions were seen when drug0 was co-administered with drug2, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d572.s9.e0,DDI-DrugBank.d572.s9.e1,"drug1: The total drug2 level increased 12-fold in one renal transplant patient receiving multiple medications, including drug0",False, 
DDI-DrugBank.d572.s9.e0,DDI-DrugBank.d572.s9.e2,"drug1: The total drug0 level increased 12-fold in one renal transplant patient receiving multiple medications, including drug2",False, 
DDI-DrugBank.d572.s9.e1,DDI-DrugBank.d572.s9.e2,"drug0: The total drug1 level increased 12-fold in one renal transplant patient receiving multiple medications, including drug2",True,mechanism
DDI-DrugBank.d572.s10.e0,DDI-DrugBank.d572.s10.e1,Patients who take both drug1 and drug2,True,advise
DDI-DrugBank.d572.s11.e0,DDI-DrugBank.d572.s11.e1,"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with drug1 was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total drug2",False, 
DDI-DrugBank.d572.s12.e0,DDI-DrugBank.d572.s12.e1,A 104-week dietary carcinogenicity study with drug1 was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total drug2,False, 
DDI-DrugBank.d572.s17.e0,DDI-DrugBank.d572.s17.e1,"In oral (gavage) fertility studies of drug1 conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total drug2",False, 
DDI-DrugBank.d572.s22.e0,DDI-DrugBank.d572.s22.e1,"In rabbits treated with drug1, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total drug2",False, 
DDI-DrugBank.d572.s24.e0,DDI-DrugBank.d572.s24.e1,Multiple dose studies of drug1 given in combination with drug2 (drug0) in rats and rabbits during organogenesis result in higher drug0,False, 
DDI-DrugBank.d572.s24.e0,DDI-DrugBank.d572.s24.e2,Multiple dose studies of drug1 given in combination with drug0 (drug2) in rats and rabbits during organogenesis result in higher drug0,False, 
DDI-DrugBank.d572.s27.e0,DDI-DrugBank.d572.s27.e1,"When drug1 is administered with an drug2 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the drug0",False, 
DDI-DrugBank.d572.s27.e0,DDI-DrugBank.d572.s27.e2,"When drug1 is administered with an drug0 in a woman of childbearing potential, refer to the pregnancy category and package labeling for the drug2",False, 
DDI-DrugBank.d653.s1.e0,DDI-DrugBank.d653.s1.e1,"Drugs that induce hepatic enzymes such as drug1, drug2 and drug0 may increase the clearance of drug0 and may require increases in drug0",False, 
DDI-DrugBank.d653.s1.e0,DDI-DrugBank.d653.s1.e2,"Drugs that induce hepatic enzymes such as drug1, drug0 and drug2 may increase the clearance of drug0 and may require increases in drug0",False, 
DDI-DrugBank.d653.s1.e0,DDI-DrugBank.d653.s1.e3,"Drugs that induce hepatic enzymes such as drug1, drug0 and drug0 may increase the clearance of drug2 and may require increases in drug0",True,mechanism
DDI-DrugBank.d653.s1.e0,DDI-DrugBank.d653.s1.e4,"Drugs that induce hepatic enzymes such as drug1, drug0 and drug0 may increase the clearance of drug0 and may require increases in drug2",True,mechanism
DDI-DrugBank.d653.s1.e1,DDI-DrugBank.d653.s1.e3,"Drugs that induce hepatic enzymes such as drug0, drug1 and drug0 may increase the clearance of drug2 and may require increases in drug0",True,mechanism
DDI-DrugBank.d653.s1.e1,DDI-DrugBank.d653.s1.e4,"Drugs that induce hepatic enzymes such as drug0, drug1 and drug0 may increase the clearance of drug0 and may require increases in drug2",True,mechanism
DDI-DrugBank.d653.s1.e2,DDI-DrugBank.d653.s1.e3,"Drugs that induce hepatic enzymes such as drug0, drug0 and drug1 may increase the clearance of drug2 and may require increases in drug0",True,mechanism
DDI-DrugBank.d653.s1.e2,DDI-DrugBank.d653.s1.e4,"Drugs that induce hepatic enzymes such as drug0, drug0 and drug1 may increase the clearance of drug0 and may require increases in drug2",True,mechanism
DDI-DrugBank.d653.s2.e0,DDI-DrugBank.d653.s2.e1,Drugs such as drug1 and drug2 may inhibit the metabolism of drug0,False, 
DDI-DrugBank.d653.s2.e0,DDI-DrugBank.d653.s2.e2,Drugs such as drug1 and drug0 may inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d653.s2.e1,DDI-DrugBank.d653.s2.e2,Drugs such as drug0 and drug1 may inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d653.s4.e0,DDI-DrugBank.d653.s4.e1,drug1 may increase the clearance of chronic high dose drug2,True,mechanism
DDI-DrugBank.d653.s5.e0,DDI-DrugBank.d653.s5.e1,This could lead to decreased drug1 serum levels or increase the risk of drug2 toxicity when drug0,False, 
DDI-DrugBank.d653.s5.e0,DDI-DrugBank.d653.s5.e2,This could lead to decreased drug1 serum levels or increase the risk of drug0 toxicity when drug2,False, 
DDI-DrugBank.d653.s5.e1,DDI-DrugBank.d653.s5.e2,This could lead to decreased drug0 serum levels or increase the risk of drug1 toxicity when drug2,True,effect
DDI-DrugBank.d653.s6.e0,DDI-DrugBank.d653.s6.e1,drug1 should be used cautiously in conjunction with drug2,True,advise
DDI-DrugBank.d653.s7.e0,DDI-DrugBank.d653.s7.e1,The effect of drug1 on oral drug2,True,effect
DDI-DrugBank.d653.s8.e0,DDI-DrugBank.d653.s8.e1,There are reports of enhanced as well as diminished effects of drug1 when given concurrently with drug2,True,effect
DDI-DrugBank.d770.s4.e0,DDI-DrugBank.d770.s4.e1,"however, in patients with Paget's Disease prior drug1 use appears to reduce the anti-resorptive response to drug2",True,effect
DDI-DrugBank.d628.s0.e0,DDI-DrugBank.d628.s0.e1,"The induction dose requirements of drug1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with drug2 (eg, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d628.s0.e0,DDI-DrugBank.d628.s0.e2,"The induction dose requirements of drug1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with drug0 (eg, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d628.s0.e0,DDI-DrugBank.d628.s0.e3,"The induction dose requirements of drug1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with drug0 (eg, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d628.s0.e0,DDI-DrugBank.d628.s0.e4,"The induction dose requirements of drug1 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with drug0 (eg, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d628.s0.e1,DDI-DrugBank.d628.s0.e2,"The induction dose requirements of drug0 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with drug1 (eg, drug2, drug0, and drug0",False, 
DDI-DrugBank.d628.s0.e1,DDI-DrugBank.d628.s0.e3,"The induction dose requirements of drug0 Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with drug1 (eg, drug0, drug2, and drug0",False, 
DDI-DrugBank.d628.s1.e0,DDI-DrugBank.d628.s1.e1,"and combinations of drug1 and drug2 (eg, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d628.s1.e0,DDI-DrugBank.d628.s1.e2,"and combinations of drug1 and drug0 (eg, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d628.s3.e0,DDI-DrugBank.d628.s3.e1,"During maintenance of anesthesia or sedation, the rate of drug1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drug2 (eg, drug0 or drug0",True,advise
DDI-DrugBank.d628.s3.e0,DDI-DrugBank.d628.s3.e2,"During maintenance of anesthesia or sedation, the rate of drug1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drug0 (eg, drug2 or drug0",True,advise
DDI-DrugBank.d628.s3.e0,DDI-DrugBank.d628.s3.e3,"During maintenance of anesthesia or sedation, the rate of drug1 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drug0 (eg, drug0 or drug2",True,advise
DDI-DrugBank.d628.s3.e1,DDI-DrugBank.d628.s3.e2,"During maintenance of anesthesia or sedation, the rate of drug0 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drug1 (eg, drug2 or drug0",False, 
DDI-DrugBank.d628.s3.e1,DDI-DrugBank.d628.s3.e3,"During maintenance of anesthesia or sedation, the rate of drug0 Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental drug1 (eg, drug0 or drug2",False, 
DDI-DrugBank.d628.s4.e0,DDI-DrugBank.d628.s4.e1,"The concurrent administration of potent inhalational agents (eg, drug1, drug2, and drug0) during maintenance with drug0",False, 
DDI-DrugBank.d628.s4.e0,DDI-DrugBank.d628.s4.e2,"The concurrent administration of potent inhalational agents (eg, drug1, drug0, and drug2) during maintenance with drug0",False, 
DDI-DrugBank.d628.s6.e0,DDI-DrugBank.d628.s6.e1,"drug1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used drug2 (eg, drug0 and drug0",False, 
DDI-DrugBank.d628.s6.e0,DDI-DrugBank.d628.s6.e2,"drug1 Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used drug0 (eg, drug2 and drug0",False, 
DDI-DrugBank.d628.s7.e0,DDI-DrugBank.d628.s7.e1,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of drug1, inhalational agents, drug2, and local drug0",False, 
DDI-DrugBank.d628.s7.e0,DDI-DrugBank.d628.s7.e2,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of drug1, inhalational agents, drug0, and local drug2",False, 
DDI-DrugBank.d678.s1.e0,DDI-DrugBank.d678.s1.e1,The metabolism of drug1 is accelerated by drug2,True,mechanism
DDI-DrugBank.d678.s4.e0,DDI-DrugBank.d678.s4.e1,drug1 inhibits the glucuronidation of drug2 and could possibly potentiate drug0,True,mechanism
DDI-DrugBank.d678.s4.e0,DDI-DrugBank.d678.s4.e2,drug1 inhibits the glucuronidation of drug0 and could possibly potentiate drug2,True,effect
DDI-DrugBank.d678.s4.e1,DDI-DrugBank.d678.s4.e2,drug0 inhibits the glucuronidation of drug1 and could possibly potentiate drug2,False, 
DDI-DrugBank.d710.s0.e0,DDI-DrugBank.d710.s0.e1,drug1: The effects of chronic drug2 use on the metabolism of drug0,False, 
DDI-DrugBank.d710.s0.e0,DDI-DrugBank.d710.s0.e2,drug1: The effects of chronic drug0 use on the metabolism of drug2,False, 
DDI-DrugBank.d710.s1.e0,DDI-DrugBank.d710.s1.e1,"When a single 100 mg dose of drug1 was administered one hour after the initiation of drug2 (300 mg four times a day), the apparent total drug0 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total drug0 clearance in the same subjects in the absence of drug0",True,mechanism
DDI-DrugBank.d710.s1.e0,DDI-DrugBank.d710.s1.e2,"When a single 100 mg dose of drug1 was administered one hour after the initiation of drug0 (300 mg four times a day), the apparent total drug2 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total drug0 clearance in the same subjects in the absence of drug0",False, 
DDI-DrugBank.d710.s1.e0,DDI-DrugBank.d710.s1.e3,"When a single 100 mg dose of drug1 was administered one hour after the initiation of drug0 (300 mg four times a day), the apparent total drug0 clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total drug2 clearance in the same subjects in the absence of drug0",False, 
DDI-DrugBank.d710.s2.e0,DDI-DrugBank.d710.s2.e1,drug1: drug2,False, 
DDI-DrugBank.d710.s5.e0,DDI-DrugBank.d710.s5.e1,Coadministration with drug1 reduced the peak concentration and AUC values for drug2,True,mechanism
DDI-DrugBank.d710.s6.e0,DDI-DrugBank.d710.s6.e1,drug1: drug2,False, 
DDI-DrugBank.d710.s9.e0,DDI-DrugBank.d710.s9.e1,Peak plasma concentrations and AUC of drug1 were reduced approximately 10% in the presence of drug2,True,mechanism
DDI-DrugBank.d608.s0.e0,DDI-DrugBank.d608.s0.e1,"The in vitro binding of drug1 to human plasma proteins is unaffected by drug2, and drug0",False, 
DDI-DrugBank.d608.s0.e0,DDI-DrugBank.d608.s0.e2,"The in vitro binding of drug1 to human plasma proteins is unaffected by drug0, and drug2",False, 
DDI-DrugBank.d608.s1.e0,DDI-DrugBank.d608.s1.e1,"However, increased prothrombin time and bleeding have been reported in patients on concomitant drug1 and drug2",True,effect
DDI-DrugBank.d608.s2.e0,DDI-DrugBank.d608.s2.e1,"Therefore, caution should be exercised when administering drug1 to patients on drug2",True,advise
DDI-DrugBank.d608.s3.e0,DDI-DrugBank.d608.s3.e1,In adult diabetic patients under treatment with either drug1 or drug2 there is no change in the clinical effects of either drug0 or the drug0,False, 
DDI-DrugBank.d608.s3.e0,DDI-DrugBank.d608.s3.e2,In adult diabetic patients under treatment with either drug1 or drug0 there is no change in the clinical effects of either drug2 or the drug0,False, 
DDI-DrugBank.d608.s4.e0,DDI-DrugBank.d608.s4.e1,Caution should be used if drug1 is administered concomitantly with drug2,True,advise
DDI-DrugBank.d608.s5.e0,DDI-DrugBank.d608.s5.e1,"drug1 and other drug2 have been reported to reduce the tubular secretion of drug0 in an animal model, possibly enhancing the toxicity of drug0",False, 
DDI-DrugBank.d608.s5.e0,DDI-DrugBank.d608.s5.e2,"drug1 and other drug0 have been reported to reduce the tubular secretion of drug2 in an animal model, possibly enhancing the toxicity of drug0",True,mechanism
DDI-DrugBank.d608.s5.e0,DDI-DrugBank.d608.s5.e3,"drug1 and other drug0 have been reported to reduce the tubular secretion of drug0 in an animal model, possibly enhancing the toxicity of drug2",False, 
DDI-DrugBank.d608.s5.e1,DDI-DrugBank.d608.s5.e2,"drug0 and other drug1 have been reported to reduce the tubular secretion of drug2 in an animal model, possibly enhancing the toxicity of drug0",True,mechanism
DDI-DrugBank.d597.s0.e0,DDI-DrugBank.d597.s0.e1,drug1 Reports suggest that drug2 may diminish the antihypertensive effect of drug0,False, 
DDI-DrugBank.d597.s0.e0,DDI-DrugBank.d597.s0.e2,drug1 Reports suggest that drug0 may diminish the antihypertensive effect of drug2,False, 
DDI-DrugBank.d597.s0.e1,DDI-DrugBank.d597.s0.e2,drug0 Reports suggest that drug1 may diminish the antihypertensive effect of drug2,True,effect
DDI-DrugBank.d597.s1.e0,DDI-DrugBank.d597.s1.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d597.s2.e0,DDI-DrugBank.d597.s2.e1,drug1: Concomitant administration of drug2 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of drug0,False, 
DDI-DrugBank.d597.s2.e0,DDI-DrugBank.d597.s2.e2,drug1: Concomitant administration of drug0 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of drug2,False, 
DDI-DrugBank.d597.s2.e1,DDI-DrugBank.d597.s2.e2,drug0: Concomitant administration of drug1 (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of drug2,True,mechanism
DDI-DrugBank.d597.s4.e0,DDI-DrugBank.d597.s4.e1,"however, as with other drug1, concomitant administration of drug2 and drug0",False, 
DDI-DrugBank.d597.s4.e0,DDI-DrugBank.d597.s4.e2,"however, as with other drug1, concomitant administration of drug0 and drug2",True,advise
DDI-DrugBank.d597.s4.e1,DDI-DrugBank.d597.s4.e2,"however, as with other drug0, concomitant administration of drug1 and drug2",True,advise
DDI-DrugBank.d597.s5.e0,DDI-DrugBank.d597.s5.e1,"Concomitant administration of low-dose drug1 with drug2 may result in an increased rate of GI ulceration or other complications, compared to use of drug0",True,effect
DDI-DrugBank.d597.s5.e0,DDI-DrugBank.d597.s5.e2,"Concomitant administration of low-dose drug1 with drug0 may result in an increased rate of GI ulceration or other complications, compared to use of drug2",False, 
DDI-DrugBank.d597.s5.e1,DDI-DrugBank.d597.s5.e2,"Concomitant administration of low-dose drug0 with drug1 may result in an increased rate of GI ulceration or other complications, compared to use of drug2",False, 
DDI-DrugBank.d597.s6.e0,DDI-DrugBank.d597.s6.e1,drug1 is not a substitute for drug2,False, 
DDI-DrugBank.d597.s7.e0,DDI-DrugBank.d597.s7.e1,drug1: Pretreatment for four days with drug2 significantly increased the clearance of drug0,False, 
DDI-DrugBank.d597.s7.e0,DDI-DrugBank.d597.s7.e2,drug1: Pretreatment for four days with drug0 significantly increased the clearance of drug2,False, 
DDI-DrugBank.d597.s7.e1,DDI-DrugBank.d597.s7.e2,drug0: Pretreatment for four days with drug1 significantly increased the clearance of drug2,True,mechanism
DDI-DrugBank.d597.s11.e0,DDI-DrugBank.d597.s11.e1,drug1: Concomitant administration of 200 mg drug2 QID did not alter the single-dose pharmacokinetics of 30 mg drug0,False, 
DDI-DrugBank.d597.s11.e0,DDI-DrugBank.d597.s11.e2,drug1: Concomitant administration of 200 mg drug0 QID did not alter the single-dose pharmacokinetics of 30 mg drug2,False, 
DDI-DrugBank.d597.s12.e0,DDI-DrugBank.d597.s12.e1,drug1: drug2 15 mg once daily for 7 days did not alter the plasma concentration profile of drug0,False, 
DDI-DrugBank.d597.s12.e0,DDI-DrugBank.d597.s12.e2,drug1: drug0 15 mg once daily for 7 days did not alter the plasma concentration profile of drug2,False, 
DDI-DrugBank.d597.s13.e0,DDI-DrugBank.d597.s13.e1,In vitro testing found no protein binding drug interaction between drug1 and drug2,False, 
DDI-DrugBank.d597.s14.e0,DDI-DrugBank.d597.s14.e1,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug2 can reduce the natriuretic effect of drug0 and drug0",False, 
DDI-DrugBank.d597.s14.e0,DDI-DrugBank.d597.s14.e2,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug0 can reduce the natriuretic effect of drug2 and drug0",False, 
DDI-DrugBank.d597.s14.e1,DDI-DrugBank.d597.s14.e2,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug2 and drug0",True,effect
DDI-DrugBank.d597.s14.e1,DDI-DrugBank.d597.s14.e3,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug0 and drug2",True,effect
DDI-DrugBank.d597.s16.e0,DDI-DrugBank.d597.s16.e1,Studies with drug1 agents and drug2,False, 
DDI-DrugBank.d597.s17.e0,DDI-DrugBank.d597.s17.e1,drug1: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of drug2,False, 
DDI-DrugBank.d597.s18.e0,DDI-DrugBank.d597.s18.e1,"Nevertheless, during concomitant therapy with drug1 and drug2",True,advise
DDI-DrugBank.d597.s19.e0,DDI-DrugBank.d597.s19.e1,"drug1: In clinical trials, drug2 have produced an elevation of plasma drug0 levels and a reduction in renal drug0",False, 
DDI-DrugBank.d597.s19.e0,DDI-DrugBank.d597.s19.e2,"drug1: In clinical trials, drug0 have produced an elevation of plasma drug2 levels and a reduction in renal drug0",False, 
DDI-DrugBank.d597.s19.e1,DDI-DrugBank.d597.s19.e2,"drug0: In clinical trials, drug1 have produced an elevation of plasma drug2 levels and a reduction in renal drug0",True,mechanism
DDI-DrugBank.d597.s20.e0,DDI-DrugBank.d597.s20.e1,"In a study conducted in healthy subjects, mean pre-dose drug1 concentration and AUC were increased by 21% in subjects receiving drug2 doses ranging from 804 to 1072 mg BID with drug0 15 mg QD as compared to subjects receiving drug0",False, 
DDI-DrugBank.d597.s20.e0,DDI-DrugBank.d597.s20.e2,"In a study conducted in healthy subjects, mean pre-dose drug1 concentration and AUC were increased by 21% in subjects receiving drug0 doses ranging from 804 to 1072 mg BID with drug2 15 mg QD as compared to subjects receiving drug0",False, 
DDI-DrugBank.d597.s20.e1,DDI-DrugBank.d597.s20.e2,"In a study conducted in healthy subjects, mean pre-dose drug0 concentration and AUC were increased by 21% in subjects receiving drug1 doses ranging from 804 to 1072 mg BID with drug2 15 mg QD as compared to subjects receiving drug0",True,mechanism
DDI-DrugBank.d597.s22.e0,DDI-DrugBank.d597.s22.e1,Patients on drug1 treatment should be closely monitored when drug2,True,advise
DDI-DrugBank.d597.s23.e0,DDI-DrugBank.d597.s23.e1,drug1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of drug2 on the pharmacokinetics of drug0,False, 
DDI-DrugBank.d597.s23.e0,DDI-DrugBank.d597.s23.e2,drug1: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of drug0 on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d597.s24.e0,DDI-DrugBank.d597.s24.e1,drug1 did not have a significant effect on the pharmacokinetics of single doses of drug2,False, 
DDI-DrugBank.d597.s25.e0,DDI-DrugBank.d597.s25.e1,"In vitro, drug1 did not displace drug2",False, 
DDI-DrugBank.d597.s26.e0,DDI-DrugBank.d597.s26.e1,"drug1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing drug2 therapy in patients receiving drug0",False, 
DDI-DrugBank.d597.s26.e0,DDI-DrugBank.d597.s26.e2,"drug1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing drug0 therapy in patients receiving drug2",False, 
DDI-DrugBank.d597.s26.e1,DDI-DrugBank.d597.s26.e2,"drug0: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing drug1 therapy in patients receiving drug2",True,advise
DDI-DrugBank.d597.s27.e0,DDI-DrugBank.d597.s27.e1,The effect of drug1 on the anticoagulant effect of drug2 was studied in a group of healthy subjects receiving daily doses of drug0,False, 
DDI-DrugBank.d597.s27.e0,DDI-DrugBank.d597.s27.e2,The effect of drug1 on the anticoagulant effect of drug0 was studied in a group of healthy subjects receiving daily doses of drug2,False, 
DDI-DrugBank.d597.s28.e0,DDI-DrugBank.d597.s28.e1,"In these subjects, drug1 did not alter drug2 pharmacokinetics and the average anticoagulant effect of drug0",False, 
DDI-DrugBank.d597.s28.e0,DDI-DrugBank.d597.s28.e2,"In these subjects, drug1 did not alter drug0 pharmacokinetics and the average anticoagulant effect of drug2",False, 
DDI-DrugBank.d597.s30.e0,DDI-DrugBank.d597.s30.e1,Caution should be used when administering drug1 with drug2 since patients on drug0,True,advise
DDI-DrugBank.d597.s30.e0,DDI-DrugBank.d597.s30.e2,Caution should be used when administering drug1 with drug0 since patients on drug2,False, 
DDI-DrugBank.d597.s30.e1,DDI-DrugBank.d597.s30.e2,Caution should be used when administering drug0 with drug1 since patients on drug2,False, 
DDI-DrugBank.d587.s0.e0,DDI-DrugBank.d587.s0.e1,"Since drug1 (drug2) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg drug0 may increase the plasma concentrations of drug0 and drug0",False, 
DDI-DrugBank.d587.s0.e0,DDI-DrugBank.d587.s0.e2,"Since drug1 (drug0) may interact with concurrently administered drug2, periodic serum level determinations of these drugs may be necessary (eg drug0 may increase the plasma concentrations of drug0 and drug0",True,advise
DDI-DrugBank.d587.s0.e0,DDI-DrugBank.d587.s0.e3,"Since drug1 (drug0) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg drug2 may increase the plasma concentrations of drug0 and drug0",False, 
DDI-DrugBank.d587.s0.e1,DDI-DrugBank.d587.s0.e2,"Since drug0 (drug1) may interact with concurrently administered drug2, periodic serum level determinations of these drugs may be necessary (eg drug0 may increase the plasma concentrations of drug0 and drug0",True,advise
DDI-DrugBank.d587.s0.e3,DDI-DrugBank.d587.s0.e4,"Since drug0 (drug0) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg drug1 may increase the plasma concentrations of drug2 and drug0",True,mechanism
DDI-DrugBank.d587.s0.e3,DDI-DrugBank.d587.s0.e5,"Since drug0 (drug0) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg drug1 may increase the plasma concentrations of drug0 and drug2",True,mechanism
DDI-DrugBank.d595.s1.e0,DDI-DrugBank.d595.s1.e1,drug1 and drug2 are incompatible with drug0,False, 
DDI-DrugBank.d595.s1.e0,DDI-DrugBank.d595.s1.e2,drug1 and drug0 are incompatible with drug2,True,int
DDI-DrugBank.d595.s1.e1,DDI-DrugBank.d595.s1.e2,drug0 and drug1 are incompatible with drug2,True,int
DDI-DrugBank.d595.s2.e0,DDI-DrugBank.d595.s2.e1,The addition of drug1 to parenteral solutions containing drug2,False, 
DDI-DrugBank.d734.s0.e0,DDI-DrugBank.d734.s0.e1,drug1 may accentuate the orthostatic hypotension that may occur with drug2,True,effect
DDI-DrugBank.d734.s1.e0,DDI-DrugBank.d734.s1.e1,Antihypertensive effects of drug1 and related compounds may be counteracted when drug2,True,effect
DDI-DrugBank.d734.s2.e0,DDI-DrugBank.d734.s2.e1,Concomitant administration of drug1 with drug2,True,mechanism
DDI-DrugBank.d640.s0.e0,DDI-DrugBank.d640.s0.e1,drug1: Excessive reductions in blood pressure may occur in patients on diuretic therapy when drug2,False, 
DDI-DrugBank.d640.s1.e0,DDI-DrugBank.d640.s1.e1,"The possibility of hypotensive effects with drug1    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with drug2   . If this is not possible, the starting dose of drug0",False, 
DDI-DrugBank.d640.s1.e0,DDI-DrugBank.d640.s1.e2,"The possibility of hypotensive effects with drug1    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with drug0   . If this is not possible, the starting dose of drug2",False, 
DDI-DrugBank.d640.s2.e0,DDI-DrugBank.d640.s2.e1,drug1 Supplements and drug2: drug0,False, 
DDI-DrugBank.d640.s2.e0,DDI-DrugBank.d640.s2.e2,drug1 Supplements and drug0: drug2,False, 
DDI-DrugBank.d640.s3.e0,DDI-DrugBank.d640.s3.e1,"Use of drug1 (drug2, drug0, drug0) or drug0 supplements concomitantly with drug0",False, 
DDI-DrugBank.d640.s3.e0,DDI-DrugBank.d640.s3.e2,"Use of drug1 (drug0, drug2, drug0) or drug0 supplements concomitantly with drug0",False, 
DDI-DrugBank.d640.s3.e0,DDI-DrugBank.d640.s3.e5,"Use of drug1 (drug0, drug0, drug0) or drug0 supplements concomitantly with drug2",True,effect
DDI-DrugBank.d640.s3.e1,DDI-DrugBank.d640.s3.e5,"Use of drug0 (drug1, drug0, drug0) or drug0 supplements concomitantly with drug2",True,effect
DDI-DrugBank.d640.s3.e2,DDI-DrugBank.d640.s3.e5,"Use of drug0 (drug0, drug1, drug0) or drug0 supplements concomitantly with drug2",True,effect
DDI-DrugBank.d640.s3.e3,DDI-DrugBank.d640.s3.e5,"Use of drug0 (drug0, drug0, drug1) or drug0 supplements concomitantly with drug2",True,effect
DDI-DrugBank.d640.s3.e4,DDI-DrugBank.d640.s3.e5,"Use of drug0 (drug0, drug0, drug0) or drug1 supplements concomitantly with drug2",True,effect
DDI-DrugBank.d640.s5.e0,DDI-DrugBank.d640.s5.e1,Oral drug1: Interaction studies with drug2 failed to identify any clinically important effect on the serum concentrations of the drug0,False, 
DDI-DrugBank.d640.s5.e0,DDI-DrugBank.d640.s5.e2,Oral drug1: Interaction studies with drug0 failed to identify any clinically important effect on the serum concentrations of the drug2,False, 
DDI-DrugBank.d640.s6.e0,DDI-DrugBank.d640.s6.e1,drug1: Increased serum drug2 levels and symptoms of drug0 toxicity have been reported in patients receiving drug0 during therapy with drug0,False, 
DDI-DrugBank.d640.s6.e0,DDI-DrugBank.d640.s6.e2,drug1: Increased serum drug0 levels and symptoms of drug2 toxicity have been reported in patients receiving drug0 during therapy with drug0,False, 
DDI-DrugBank.d640.s6.e3,DDI-DrugBank.d640.s6.e4,drug0: Increased serum drug0 levels and symptoms of drug0 toxicity have been reported in patients receiving drug1 during therapy with drug2,True,effect
DDI-DrugBank.d640.s8.e0,DDI-DrugBank.d640.s8.e1,"If a drug1 is also used, the risk of drug2",True,effect
DDI-DrugBank.d640.s9.e0,DDI-DrugBank.d640.s9.e1,"Other Agents: No clinically important pharmacokinetic interactions occurred when drug1    was administered concomitantly with drug2, drug0, or drug0",False, 
DDI-DrugBank.d640.s9.e0,DDI-DrugBank.d640.s9.e2,"Other Agents: No clinically important pharmacokinetic interactions occurred when drug1    was administered concomitantly with drug0, drug2, or drug0",False, 
DDI-DrugBank.d640.s10.e0,DDI-DrugBank.d640.s10.e1,"drug1    has been used in clinical trials concomitantly with drug2, drug0, drug0, drug0, oral drug0",False, 
DDI-DrugBank.d640.s10.e0,DDI-DrugBank.d640.s10.e2,"drug1    has been used in clinical trials concomitantly with drug0, drug2, drug0, drug0, oral drug0",False, 
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e1,"drug1 may enhance the sedative effects of drug2 including drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e2,"drug1 may enhance the sedative effects of drug0 including drug2, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e3,"drug1 may enhance the sedative effects of drug0 including drug0, drug2, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e4,"drug1 may enhance the sedative effects of drug0 including drug0, drug0, drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e5,"drug1 may enhance the sedative effects of drug0 including drug0, drug0, drug0, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e6,"drug1 may enhance the sedative effects of drug0 including drug0, drug0, drug0, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d615.s0.e0,DDI-DrugBank.d615.s0.e7,"drug1 may enhance the sedative effects of drug0 including drug0, drug0, drug0, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d615.s0.e1,DDI-DrugBank.d615.s0.e2,"drug0 may enhance the sedative effects of drug1 including drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d615.s0.e1,DDI-DrugBank.d615.s0.e3,"drug0 may enhance the sedative effects of drug1 including drug0, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d615.s1.e0,DDI-DrugBank.d615.s1.e1,"The effects of drug1, such as drug2 and drug0 may be enhanced by the concomitant administration of drug0",False, 
DDI-DrugBank.d615.s1.e0,DDI-DrugBank.d615.s1.e2,"The effects of drug1, such as drug0 and drug2 may be enhanced by the concomitant administration of drug0",False, 
DDI-DrugBank.d615.s1.e0,DDI-DrugBank.d615.s1.e3,"The effects of drug1, such as drug0 and drug0 may be enhanced by the concomitant administration of drug2",True,effect
DDI-DrugBank.d615.s1.e1,DDI-DrugBank.d615.s1.e3,"The effects of drug0, such as drug1 and drug0 may be enhanced by the concomitant administration of drug2",True,effect
DDI-DrugBank.d615.s1.e2,DDI-DrugBank.d615.s1.e3,"The effects of drug0, such as drug0 and drug1 may be enhanced by the concomitant administration of drug2",True,effect
DDI-DrugBank.d668.s0.e0,DDI-DrugBank.d668.s0.e1,"Although specific drug or food interactions with drug1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that drug2, drug0, drug0, and grapefruit juice may inhibit its metabolism (increasing serum levels of drug0",False, 
DDI-DrugBank.d668.s0.e0,DDI-DrugBank.d668.s0.e2,"Although specific drug or food interactions with drug1 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that drug0, drug2, drug0, and grapefruit juice may inhibit its metabolism (increasing serum levels of drug0",False, 
DDI-DrugBank.d668.s0.e1,DDI-DrugBank.d668.s0.e4,"Although specific drug or food interactions with drug0 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that drug1, drug0, drug0, and grapefruit juice may inhibit its metabolism (increasing serum levels of drug2",True,mechanism
DDI-DrugBank.d668.s0.e2,DDI-DrugBank.d668.s0.e4,"Although specific drug or food interactions with drug0 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that drug0, drug1, drug0, and grapefruit juice may inhibit its metabolism (increasing serum levels of drug2",True,mechanism
DDI-DrugBank.d668.s0.e3,DDI-DrugBank.d668.s0.e4,"Although specific drug or food interactions with drug0 have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that drug0, drug0, drug1, and grapefruit juice may inhibit its metabolism (increasing serum levels of drug2",True,mechanism
DDI-DrugBank.d668.s1.e0,DDI-DrugBank.d668.s1.e1,"Furthermore, drug1, drug2",False, 
DDI-DrugBank.d668.s2.e0,DDI-DrugBank.d668.s2.e1,"John   s Wort, and certain drug1 (drug2, drug0, drug0) may induce drug0 metabolism (lowering serum levels of drug0",False, 
DDI-DrugBank.d668.s2.e0,DDI-DrugBank.d668.s2.e2,"John   s Wort, and certain drug1 (drug0, drug2, drug0) may induce drug0 metabolism (lowering serum levels of drug0",False, 
DDI-DrugBank.d668.s2.e0,DDI-DrugBank.d668.s2.e4,"John   s Wort, and certain drug1 (drug0, drug0, drug0) may induce drug2 metabolism (lowering serum levels of drug0",True,mechanism
DDI-DrugBank.d668.s2.e1,DDI-DrugBank.d668.s2.e4,"John   s Wort, and certain drug0 (drug1, drug0, drug0) may induce drug2 metabolism (lowering serum levels of drug0",True,mechanism
DDI-DrugBank.d668.s2.e2,DDI-DrugBank.d668.s2.e4,"John   s Wort, and certain drug0 (drug0, drug1, drug0) may induce drug2 metabolism (lowering serum levels of drug0",True,mechanism
DDI-DrugBank.d668.s2.e3,DDI-DrugBank.d668.s2.e4,"John   s Wort, and certain drug0 (drug0, drug0, drug1) may induce drug2 metabolism (lowering serum levels of drug0",True,mechanism
DDI-DrugBank.d584.s0.e0,DDI-DrugBank.d584.s0.e1,drug1 drug2 may increase sensitivity to oral drug0,False, 
DDI-DrugBank.d584.s0.e0,DDI-DrugBank.d584.s0.e2,drug1 drug0 may increase sensitivity to oral drug2,False, 
DDI-DrugBank.d584.s0.e1,DDI-DrugBank.d584.s0.e2,drug0 drug1 may increase sensitivity to oral drug2,True,effect
DDI-DrugBank.d584.s3.e0,DDI-DrugBank.d584.s3.e1,"drug1: A multidose study of drug2, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with drug0, resulted in a mean increase in drug0 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in drug0",False, 
DDI-DrugBank.d584.s3.e0,DDI-DrugBank.d584.s3.e2,"drug1: A multidose study of drug0, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with drug2, resulted in a mean increase in drug0 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in drug0",False, 
DDI-DrugBank.d584.s3.e1,DDI-DrugBank.d584.s3.e2,"drug0: A multidose study of drug1, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with drug2, resulted in a mean increase in drug0 half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in drug0",True,mechanism
DDI-DrugBank.d584.s5.e0,DDI-DrugBank.d584.s5.e1,A 5.5-fold decrease in the mean drug1 dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of drug2,False, 
DDI-DrugBank.d584.s6.e0,DDI-DrugBank.d584.s6.e1,"When drug1 therapy is initiated in a patient already receiving treatment with drug2, the INR or prothrombin time (PT) should be monitored closely and the dose of drug0",True,advise
DDI-DrugBank.d584.s6.e0,DDI-DrugBank.d584.s6.e2,"When drug1 therapy is initiated in a patient already receiving treatment with drug0, the INR or prothrombin time (PT) should be monitored closely and the dose of drug2",False, 
DDI-DrugBank.d584.s6.e1,DDI-DrugBank.d584.s6.e2,"When drug0 therapy is initiated in a patient already receiving treatment with drug1, the INR or prothrombin time (PT) should be monitored closely and the dose of drug2",False, 
DDI-DrugBank.d584.s7.e0,DDI-DrugBank.d584.s7.e1,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the drug1 dosage if indicated are recommended when the drug2",True,advise
DDI-DrugBank.d584.s9.e0,DDI-DrugBank.d584.s9.e1,Oral drug1 drug2 may inhibit the metabolism of oral drug0,False, 
DDI-DrugBank.d584.s9.e0,DDI-DrugBank.d584.s9.e2,Oral drug1 drug0 may inhibit the metabolism of oral drug2,False, 
DDI-DrugBank.d584.s9.e1,DDI-DrugBank.d584.s9.e2,Oral drug0 drug1 may inhibit the metabolism of oral drug2,True,mechanism
DDI-DrugBank.d584.s10.e0,DDI-DrugBank.d584.s10.e1,"drug1 or drug2 In patients with edema, concomitant administration with drug0 or drug0",False, 
DDI-DrugBank.d584.s10.e0,DDI-DrugBank.d584.s10.e2,"drug1 or drug0 In patients with edema, concomitant administration with drug2 or drug0",False, 
DDI-DrugBank.d631.s0.e0,DDI-DrugBank.d631.s0.e1,"drug1 may be used with drug2, drug0 and other drug0, and with other drug0",False, 
DDI-DrugBank.d631.s0.e0,DDI-DrugBank.d631.s0.e2,"drug1 may be used with drug0, drug2 and other drug0, and with other drug0",False, 
DDI-DrugBank.d631.s2.e0,DDI-DrugBank.d631.s2.e1,drug1 (drug2,False, 
DDI-DrugBank.d631.s3.e0,DDI-DrugBank.d631.s3.e1,Mild hepatotoxicity has been reported in some patients when drug1 and drug2,True,effect
DDI-DrugBank.d686.s0.e0,DDI-DrugBank.d686.s0.e1,"drug1 may compete with other drugs, such as drug2",True,mechanism
DDI-DrugBank.d686.s1.e0,DDI-DrugBank.d686.s1.e1,"Therefore, when concomitant use of drug1 and drug2",True,advise
DDI-DrugBank.d581.s2.e0,DDI-DrugBank.d581.s2.e1,patients receiving drug1 and drug2,True,advise
DDI-DrugBank.d702.s1.e0,DDI-DrugBank.d702.s1.e1,"These include drug1, drug2, and oral and inhaled drug0",False, 
DDI-DrugBank.d702.s1.e0,DDI-DrugBank.d702.s1.e2,"These include drug1, drug0, and oral and inhaled drug2",False, 
DDI-DrugBank.d702.s2.e0,DDI-DrugBank.d702.s2.e1,"However, the co   administration of drug1 with other drug2   containing drugs (e.g., drug0",True,advise
DDI-DrugBank.d702.s2.e0,DDI-DrugBank.d702.s2.e2,"However, the co   administration of drug1 with other drug0   containing drugs (e.g., drug2",True,advise
DDI-DrugBank.d702.s2.e1,DDI-DrugBank.d702.s2.e2,"However, the co   administration of drug0 with other drug1   containing drugs (e.g., drug2",False, 
DDI-DrugBank.d679.s0.e0,DDI-DrugBank.d679.s0.e1,Preliminary evidence suggests that drug1 inhibits drug2 metabolism and may result in an increase in plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d679.s0.e0,DDI-DrugBank.d679.s0.e2,Preliminary evidence suggests that drug1 inhibits drug0 metabolism and may result in an increase in plasma concentrations of drug2,False, 
DDI-DrugBank.d679.s0.e1,DDI-DrugBank.d679.s0.e2,Preliminary evidence suggests that drug0 inhibits drug1 metabolism and may result in an increase in plasma concentrations of drug2,False, 
DDI-DrugBank.d777.s0.e0,DDI-DrugBank.d777.s0.e1,"The interaction of drug1, drug2",False, 
DDI-DrugBank.d777.s1.e0,DDI-DrugBank.d777.s1.e1,"Use of drug1 and drug2 -- drug0, drug0, alone or in combination with drug0 and drug0",False, 
DDI-DrugBank.d777.s1.e0,DDI-DrugBank.d777.s1.e2,"Use of drug1 and drug0 -- drug2, drug0, alone or in combination with drug0 and drug0",False, 
DDI-DrugBank.d777.s1.e2,DDI-DrugBank.d777.s1.e4,"Use of drug0 and drug0 -- drug1, drug0, alone or in combination with drug2 and drug0",True,effect
DDI-DrugBank.d777.s1.e2,DDI-DrugBank.d777.s1.e5,"Use of drug0 and drug0 -- drug1, drug0, alone or in combination with drug0 and drug2",True,effect
DDI-DrugBank.d777.s1.e3,DDI-DrugBank.d777.s1.e4,"Use of drug0 and drug0 -- drug0, drug1, alone or in combination with drug2 and drug0",True,effect
DDI-DrugBank.d777.s1.e3,DDI-DrugBank.d777.s1.e5,"Use of drug0 and drug0 -- drug0, drug1, alone or in combination with drug0 and drug2",True,effect
DDI-DrugBank.d777.s3.e0,DDI-DrugBank.d777.s3.e1,"In the treatment of acute MI, drug1, when not otherwise contraindicated, should be administered with drug2",False, 
DDI-DrugBank.d777.s4.e0,DDI-DrugBank.d777.s4.e1,"Anticoagulation and drug1 After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of drug2",False, 
DDI-DrugBank.d777.s5.e0,DDI-DrugBank.d777.s5.e1,The addition of drug1 to drug2,True,effect
DDI-DrugBank.d784.s0.e0,DDI-DrugBank.d784.s0.e1,The concomitant use of drug1 with other drug2,True,effect
DDI-DrugBank.d784.s3.e0,DDI-DrugBank.d784.s3.e1,Mean drug1 plasma concentrations were approximately 2 fold higher when drug2 was administered with drug0,False, 
DDI-DrugBank.d784.s3.e0,DDI-DrugBank.d784.s3.e2,Mean drug1 plasma concentrations were approximately 2 fold higher when drug0 was administered with drug2,False, 
DDI-DrugBank.d784.s3.e1,DDI-DrugBank.d784.s3.e2,Mean drug0 plasma concentrations were approximately 2 fold higher when drug1 was administered with drug2,True,mechanism
DDI-DrugBank.d784.s4.e0,DDI-DrugBank.d784.s4.e1,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug1 (e.g., drug2 and drug0) or drug0 (e.g., drug0 and drug0), may alter drug0",False, 
DDI-DrugBank.d784.s4.e0,DDI-DrugBank.d784.s4.e2,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug1 (e.g., drug0 and drug2) or drug0 (e.g., drug0 and drug0), may alter drug0",False, 
DDI-DrugBank.d784.s4.e0,DDI-DrugBank.d784.s4.e6,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug1 (e.g., drug0 and drug0) or drug0 (e.g., drug0 and drug0), may alter drug2",True,mechanism
DDI-DrugBank.d784.s4.e1,DDI-DrugBank.d784.s4.e6,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug0 (e.g., drug1 and drug0) or drug0 (e.g., drug0 and drug0), may alter drug2",True,mechanism
DDI-DrugBank.d784.s4.e2,DDI-DrugBank.d784.s4.e6,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug0 (e.g., drug0 and drug1) or drug0 (e.g., drug0 and drug0), may alter drug2",True,mechanism
DDI-DrugBank.d784.s4.e3,DDI-DrugBank.d784.s4.e6,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug0 (e.g., drug0 and drug0) or drug1 (e.g., drug0 and drug0), may alter drug2",True,mechanism
DDI-DrugBank.d784.s4.e4,DDI-DrugBank.d784.s4.e6,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug0 (e.g., drug0 and drug0) or drug0 (e.g., drug1 and drug0), may alter drug2",True,mechanism
DDI-DrugBank.d784.s4.e5,DDI-DrugBank.d784.s4.e6,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as drug0 (e.g., drug0 and drug0) or drug0 (e.g., drug0 and drug1), may alter drug2",True,mechanism
DDI-DrugBank.d784.s7.e0,DDI-DrugBank.d784.s7.e1,"Concurrent ingestion of drug1 (20 mL of drug2 containing drug0, drug0, and drug0) did not significantly affect the exposure of drug0 or drug0",False, 
DDI-DrugBank.d784.s7.e0,DDI-DrugBank.d784.s7.e2,"Concurrent ingestion of drug1 (20 mL of drug0 containing drug2, drug0, and drug0) did not significantly affect the exposure of drug0 or drug0",False, 
DDI-DrugBank.d596.s0.e0,DDI-DrugBank.d596.s0.e1,Drug-Drug Interactions Effect of drug1    (drug2) on the Metabolism of Other Drugs: drug0,False, 
DDI-DrugBank.d596.s0.e0,DDI-DrugBank.d596.s0.e2,Drug-Drug Interactions Effect of drug1    (drug0) on the Metabolism of Other Drugs: drug2,False, 
DDI-DrugBank.d596.s3.e0,DDI-DrugBank.d596.s3.e1,"No pharmacokinetic interaction was observed between drug1 and drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d596.s3.e0,DDI-DrugBank.d596.s3.e2,"No pharmacokinetic interaction was observed between drug1 and drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d596.s4.e0,DDI-DrugBank.d596.s4.e1,The elevation of prothrombin time induced by drug1 is not affected by administration of drug2,False, 
DDI-DrugBank.d596.s5.e0,DDI-DrugBank.d596.s5.e1,Effect of Other Drugs on the Metabolism of drug1: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of drug2,False, 
DDI-DrugBank.d596.s6.e0,DDI-DrugBank.d596.s6.e1,"Single dose pharmacokinetic studies demonstrated that the metabolism of drug1 is not significantly affected by concurrent administration of drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d596.s6.e0,DDI-DrugBank.d596.s6.e2,"Single dose pharmacokinetic studies demonstrated that the metabolism of drug1 is not significantly affected by concurrent administration of drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d596.s7.e0,DDI-DrugBank.d596.s7.e1,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of drug1 were not influenced by commonly prescribed medications such as drug2 (n=77), drug0 (n=72), drug0 (n=75), drug0 (n=21), drug0 (n=79), drug0 (n=70), drug0 (n=177), drug0 (n=35), and drug0",False, 
DDI-DrugBank.d596.s7.e0,DDI-DrugBank.d596.s7.e2,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of drug1 were not influenced by commonly prescribed medications such as drug0 (n=77), drug2 (n=72), drug0 (n=75), drug0 (n=21), drug0 (n=79), drug0 (n=70), drug0 (n=177), drug0 (n=35), and drug0",False, 
DDI-DrugBank.d596.s8.e0,DDI-DrugBank.d596.s8.e1,"Use with drug1: Because of their mechanism of action, drug2 have the potential to interfere with the activity of drug0",False, 
DDI-DrugBank.d596.s8.e0,DDI-DrugBank.d596.s8.e2,"Use with drug1: Because of their mechanism of action, drug0 have the potential to interfere with the activity of drug2",False, 
DDI-DrugBank.d596.s8.e1,DDI-DrugBank.d596.s8.e2,"Use with drug0: Because of their mechanism of action, drug1 have the potential to interfere with the activity of drug2",True,int
DDI-DrugBank.d596.s9.e0,DDI-DrugBank.d596.s9.e1,"Use with drug1 and Other drug2: A synergistic effect may be expected when drug0 are given concurrently with drug0, similar drug0 or drug0 such as drug0",False, 
DDI-DrugBank.d596.s9.e0,DDI-DrugBank.d596.s9.e2,"Use with drug1 and Other drug0: A synergistic effect may be expected when drug2 are given concurrently with drug0, similar drug0 or drug0 such as drug0",False, 
DDI-DrugBank.d596.s9.e2,DDI-DrugBank.d596.s9.e3,"Use with drug0 and Other drug0: A synergistic effect may be expected when drug1 are given concurrently with drug2, similar drug0 or drug0 such as drug0",True,effect
DDI-DrugBank.d596.s9.e2,DDI-DrugBank.d596.s9.e4,"Use with drug0 and Other drug0: A synergistic effect may be expected when drug1 are given concurrently with drug0, similar drug2 or drug0 such as drug0",True,effect
DDI-DrugBank.d596.s9.e2,DDI-DrugBank.d596.s9.e5,"Use with drug0 and Other drug0: A synergistic effect may be expected when drug1 are given concurrently with drug0, similar drug0 or drug2 such as drug0",True,effect
DDI-DrugBank.d596.s9.e2,DDI-DrugBank.d596.s9.e6,"Use with drug0 and Other drug0: A synergistic effect may be expected when drug1 are given concurrently with drug0, similar drug0 or drug0 such as drug2",True,effect
DDI-DrugBank.d779.s0.e0,DDI-DrugBank.d779.s0.e1,When drug1 is used with other drug2,True,effect
DDI-DrugBank.d779.s2.e0,DDI-DrugBank.d779.s2.e1,Patients may require reduced doses of drug1 when on drug2,True,advise
DDI-DrugBank.d779.s5.e0,DDI-DrugBank.d779.s5.e1,When drug1 and drug2 are given concomitantly the patient should be carefully monitored for symptoms of drug0,True,advise
DDI-DrugBank.d779.s5.e0,DDI-DrugBank.d779.s5.e2,When drug1 and drug0 are given concomitantly the patient should be carefully monitored for symptoms of drug2,False, 
DDI-DrugBank.d779.s5.e1,DDI-DrugBank.d779.s5.e2,When drug0 and drug1 are given concomitantly the patient should be carefully monitored for symptoms of drug2,False, 
DDI-DrugBank.d779.s7.e0,DDI-DrugBank.d779.s7.e1,Several studies demonstrate a decrease in the bioavailability of drug1 when it is ingested with drug2 or drug0,True,mechanism
DDI-DrugBank.d779.s7.e0,DDI-DrugBank.d779.s7.e2,Several studies demonstrate a decrease in the bioavailability of drug1 when it is ingested with drug0 or drug2,True,mechanism
DDI-DrugBank.d779.s7.e1,DDI-DrugBank.d779.s7.e2,Several studies demonstrate a decrease in the bioavailability of drug0 when it is ingested with drug1 or drug2,False, 
DDI-DrugBank.d779.s9.e0,DDI-DrugBank.d779.s9.e1,Coadministration of drug1 with drug2 or drug0,True,advise
DDI-DrugBank.d779.s9.e0,DDI-DrugBank.d779.s9.e2,Coadministration of drug1 with drug0 or drug2,True,advise
DDI-DrugBank.d779.s9.e1,DDI-DrugBank.d779.s9.e2,Coadministration of drug0 with drug1 or drug2,False, 
DDI-DrugBank.d779.s16.e0,DDI-DrugBank.d779.s16.e1,"drug1 does not interfere with measurement of drug2 (drug0), a test for pheochromocytoma, by those methods which convert drug0 to drug0",False, 
DDI-DrugBank.d779.s16.e0,DDI-DrugBank.d779.s16.e2,"drug1 does not interfere with measurement of drug0 (drug2), a test for pheochromocytoma, by those methods which convert drug0 to drug0",False, 
DDI-DrugBank.d649.s0.e0,DDI-DrugBank.d649.s0.e1,"drug1 may increase the effects of drug2, drug0, and drug0",True,effect
DDI-DrugBank.d649.s0.e0,DDI-DrugBank.d649.s0.e2,"drug1 may increase the effects of drug0, drug2, and drug0",True,effect
DDI-DrugBank.d649.s0.e0,DDI-DrugBank.d649.s0.e3,"drug1 may increase the effects of drug0, drug0, and drug2",True,effect
DDI-DrugBank.d649.s0.e1,DDI-DrugBank.d649.s0.e2,"drug0 may increase the effects of drug1, drug2, and drug0",False, 
DDI-DrugBank.d649.s0.e1,DDI-DrugBank.d649.s0.e3,"drug0 may increase the effects of drug1, drug0, and drug2",False, 
DDI-DrugBank.d649.s1.e0,DDI-DrugBank.d649.s1.e1,"It may also interact with drug1 (increased thrombocytopenia), drug2 (increased nephrotoxicity), drug0 (increased hypoglycemic response), drug0 (increased anticoagulant effect), drug0 (decreased renal excretion of drug0), drug0 (decreased hepatic clearance of drug0",False, 
DDI-DrugBank.d649.s1.e0,DDI-DrugBank.d649.s1.e2,"It may also interact with drug1 (increased thrombocytopenia), drug0 (increased nephrotoxicity), drug2 (increased hypoglycemic response), drug0 (increased anticoagulant effect), drug0 (decreased renal excretion of drug0), drug0 (decreased hepatic clearance of drug0",False, 
DDI-DrugBank.d651.s0.e0,DDI-DrugBank.d651.s0.e1,Drug Interactions: Women on oral drug1 have shown a significant increase in plasma drug2,True,mechanism
DDI-DrugBank.d725.s0.e0,DDI-DrugBank.d725.s0.e1,"drug1, particularly drug2, may cause serious cardiac arrhythmias during drug0",False, 
DDI-DrugBank.d725.s0.e0,DDI-DrugBank.d725.s0.e2,"drug1, particularly drug0, may cause serious cardiac arrhythmias during drug2",True,effect
DDI-DrugBank.d725.s0.e1,DDI-DrugBank.d725.s0.e2,"drug0, particularly drug1, may cause serious cardiac arrhythmias during drug2",True,effect
DDI-DrugBank.d725.s1.e0,DDI-DrugBank.d725.s1.e1,drug1: The pressor effect of drug2 is markedly potentiated in patients receiving drug0 (drug0,False, 
DDI-DrugBank.d725.s1.e0,DDI-DrugBank.d725.s1.e2,drug1: The pressor effect of drug0 is markedly potentiated in patients receiving drug2 (drug0,False, 
DDI-DrugBank.d725.s1.e1,DDI-DrugBank.d725.s1.e2,drug0: The pressor effect of drug1 is markedly potentiated in patients receiving drug2 (drug0,True,effect
DDI-DrugBank.d725.s1.e1,DDI-DrugBank.d725.s1.e3,drug0: The pressor effect of drug1 is markedly potentiated in patients receiving drug0 (drug2,True,effect
DDI-DrugBank.d725.s3.e0,DDI-DrugBank.d725.s3.e1,The pressor response of drug1 may also be potentiated by drug2,True,effect
DDI-DrugBank.d599.s4.e0,DDI-DrugBank.d599.s4.e1,"If drug1 replacement is required, the drug2",False, 
DDI-DrugBank.d599.s6.e0,DDI-DrugBank.d599.s6.e1,Limited published data indicate that drug1 treatment increases cytochrome P450 (CP450) mediated drug2,True,mechanism
DDI-DrugBank.d599.s7.e0,DDI-DrugBank.d599.s7.e1,"These data suggest that drug1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., drug2, drug0, drug0, drug0",True,mechanism
DDI-DrugBank.d599.s7.e0,DDI-DrugBank.d599.s7.e2,"These data suggest that drug1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., drug0, drug2, drug0, drug0",True,mechanism
DDI-DrugBank.d599.s7.e0,DDI-DrugBank.d599.s7.e3,"These data suggest that drug1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., drug0, drug0, drug2, drug0",True,mechanism
DDI-DrugBank.d599.s7.e0,DDI-DrugBank.d599.s7.e4,"These data suggest that drug1 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., drug0, drug0, drug0, drug2",True,mechanism
DDI-DrugBank.d599.s7.e1,DDI-DrugBank.d599.s7.e2,"These data suggest that drug0 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., drug1, drug2, drug0, drug0",False, 
DDI-DrugBank.d599.s7.e1,DDI-DrugBank.d599.s7.e3,"These data suggest that drug0 administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., drug1, drug0, drug2, drug0",False, 
DDI-DrugBank.d650.s0.e0,DDI-DrugBank.d650.s0.e1,"drug1, such as the drug2 (drug0, drug0, drug0 ) or drug0, ordinarily should not be administered concurrently with drug0 (a drug0",False, 
DDI-DrugBank.d650.s0.e0,DDI-DrugBank.d650.s0.e2,"drug1, such as the drug0 (drug2, drug0, drug0 ) or drug0, ordinarily should not be administered concurrently with drug0 (a drug0",False, 
DDI-DrugBank.d650.s0.e0,DDI-DrugBank.d650.s0.e6,"drug1, such as the drug0 (drug0, drug0, drug0 ) or drug0, ordinarily should not be administered concurrently with drug2 (a drug0",True,advise
DDI-DrugBank.d650.s0.e1,DDI-DrugBank.d650.s0.e6,"drug0, such as the drug1 (drug0, drug0, drug0 ) or drug0, ordinarily should not be administered concurrently with drug2 (a drug0",True,advise
DDI-DrugBank.d650.s0.e2,DDI-DrugBank.d650.s0.e6,"drug0, such as the drug0 (drug1, drug0, drug0 ) or drug0, ordinarily should not be administered concurrently with drug2 (a drug0",True,advise
DDI-DrugBank.d650.s0.e3,DDI-DrugBank.d650.s0.e6,"drug0, such as the drug0 (drug0, drug1, drug0 ) or drug0, ordinarily should not be administered concurrently with drug2 (a drug0",True,advise
DDI-DrugBank.d650.s0.e4,DDI-DrugBank.d650.s0.e6,"drug0, such as the drug0 (drug0, drug0, drug1 ) or drug0, ordinarily should not be administered concurrently with drug2 (a drug0",True,advise
DDI-DrugBank.d650.s0.e5,DDI-DrugBank.d650.s0.e6,"drug0, such as the drug0 (drug0, drug0, drug0 ) or drug1, ordinarily should not be administered concurrently with drug2 (a drug0",True,advise
DDI-DrugBank.d650.s2.e0,DDI-DrugBank.d650.s2.e1,"Because drug1 is approximately 90% bound to plasma proteins, caution should be exercised if drug2",False, 
DDI-DrugBank.d747.s0.e0,DDI-DrugBank.d747.s0.e1,"drug1, a bacteriostatic drug2, may antagonize the bactericidal effect of drug0",False, 
DDI-DrugBank.d747.s0.e0,DDI-DrugBank.d747.s0.e2,"drug1, a bacteriostatic drug0, may antagonize the bactericidal effect of drug2",True,effect
DDI-DrugBank.d747.s0.e1,DDI-DrugBank.d747.s0.e2,"drug0, a bacteriostatic drug1, may antagonize the bactericidal effect of drug2",False, 
DDI-DrugBank.d625.s0.e0,DDI-DrugBank.d625.s0.e1,DRUG INTERACTIONS  There are no known drug/drug interactions with oral drug1  Vaccinations with drug2 are not recommended in immunocompromised individuals  drug0 together with high-dose intravenous drug0,False, 
DDI-DrugBank.d625.s0.e0,DDI-DrugBank.d625.s0.e2,DRUG INTERACTIONS  There are no known drug/drug interactions with oral drug1  Vaccinations with drug0 are not recommended in immunocompromised individuals  drug2 together with high-dose intravenous drug0,False, 
DDI-DrugBank.d625.s0.e2,DDI-DrugBank.d625.s0.e3,DRUG INTERACTIONS  There are no known drug/drug interactions with oral drug0  Vaccinations with drug0 are not recommended in immunocompromised individuals  drug1 together with high-dose intravenous drug2,True,effect
DDI-DrugBank.d625.s1.e0,DDI-DrugBank.d625.s1.e1,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous drug1 and who subsequently received drug2,True,effect
DDI-DrugBank.d742.s2.e0,DDI-DrugBank.d742.s2.e1,Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of drug1    (drug2,False, 
DDI-DrugBank.d742.s5.e0,DDI-DrugBank.d742.s5.e1,"While in vitro studies have shown that drug1 is not a potent inhibitor of any of these enzymes, an indication that drug2 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of drug0",False, 
DDI-DrugBank.d742.s5.e0,DDI-DrugBank.d742.s5.e2,"While in vitro studies have shown that drug1 is not a potent inhibitor of any of these enzymes, an indication that drug0 is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of drug2",False, 
DDI-DrugBank.d742.s7.e0,DDI-DrugBank.d742.s7.e1,drug1: Concomitant administration of drug2 (equivalent to 60 g) had a minimal effect on plasma levels of drug0,False, 
DDI-DrugBank.d742.s7.e0,DDI-DrugBank.d742.s7.e2,drug1: Concomitant administration of drug0 (equivalent to 60 g) had a minimal effect on plasma levels of drug2,False, 
DDI-DrugBank.d742.s7.e1,DDI-DrugBank.d742.s7.e2,drug0: Concomitant administration of drug1 (equivalent to 60 g) had a minimal effect on plasma levels of drug2,True,mechanism
DDI-DrugBank.d742.s8.e0,DDI-DrugBank.d742.s8.e1,"However, the impairment of cognitive and motor skills produced by drug1    were shown to be additive with those produced by drug2",True,effect
DDI-DrugBank.d742.s9.e0,DDI-DrugBank.d742.s9.e1,"Accordingly, patients should be advised to avoid drug1 while taking drug2. drug0: Concomitant administration of drug0 (15 mg) had a minimal effect on plasma levels of drug0",True,advise
DDI-DrugBank.d742.s9.e0,DDI-DrugBank.d742.s9.e2,"Accordingly, patients should be advised to avoid drug1 while taking drug0. drug2: Concomitant administration of drug0 (15 mg) had a minimal effect on plasma levels of drug0",False, 
DDI-DrugBank.d742.s9.e0,DDI-DrugBank.d742.s9.e3,"Accordingly, patients should be advised to avoid drug1 while taking drug0. drug0: Concomitant administration of drug2 (15 mg) had a minimal effect on plasma levels of drug0",False, 
DDI-DrugBank.d742.s9.e3,DDI-DrugBank.d742.s9.e4,"Accordingly, patients should be advised to avoid drug0 while taking drug0. drug0: Concomitant administration of drug1 (15 mg) had a minimal effect on plasma levels of drug2",True,mechanism
DDI-DrugBank.d742.s10.e0,DDI-DrugBank.d742.s10.e1,"However, the impairment of motor skills produced by drug1 has been shown to be additive with those caused by drug2",True,effect
DDI-DrugBank.d742.s11.e0,DDI-DrugBank.d742.s11.e1,"Accordingly, patients should be advised to avoid drug1 and other similar drugs while taking drug2",True,advise
DDI-DrugBank.d759.s0.e0,DDI-DrugBank.d759.s0.e1,Limited evidence suggests that drug1 may influence the intensity and duration of action of drug2,True,mechanism
DDI-DrugBank.d709.s1.e0,DDI-DrugBank.d709.s1.e1,Concomitant administrations not recommended:  - drug1 and drug2: Certain drug0 interact with drug0 and drug0,False, 
DDI-DrugBank.d709.s1.e0,DDI-DrugBank.d709.s1.e2,Concomitant administrations not recommended:  - drug1 and drug0: Certain drug2 interact with drug0 and drug0,False, 
DDI-DrugBank.d709.s1.e2,DDI-DrugBank.d709.s1.e3,Concomitant administrations not recommended:  - drug0 and drug0: Certain drug1 interact with drug2 and drug0,True,int
DDI-DrugBank.d709.s1.e2,DDI-DrugBank.d709.s1.e4,Concomitant administrations not recommended:  - drug0 and drug0: Certain drug1 interact with drug0 and drug2,True,int
DDI-DrugBank.d709.s3.e0,DDI-DrugBank.d709.s3.e1,"Although such a reaction has not been demonstrated with drug1, concomitant administration of drug2 with drug0 or drug0",False, 
DDI-DrugBank.d709.s3.e0,DDI-DrugBank.d709.s3.e2,"Although such a reaction has not been demonstrated with drug1, concomitant administration of drug0 with drug2 or drug0",False, 
DDI-DrugBank.d709.s3.e1,DDI-DrugBank.d709.s3.e2,"Although such a reaction has not been demonstrated with drug0, concomitant administration of drug1 with drug2 or drug0",True,advise
DDI-DrugBank.d709.s3.e1,DDI-DrugBank.d709.s3.e3,"Although such a reaction has not been demonstrated with drug0, concomitant administration of drug1 with drug0 or drug2",True,advise
DDI-DrugBank.d709.s4.e0,DDI-DrugBank.d709.s4.e1,"- drug1, drug2: Other drugs such as drug0 or drug0, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some drug0",False, 
DDI-DrugBank.d709.s4.e0,DDI-DrugBank.d709.s4.e2,"- drug1, drug0: Other drugs such as drug2 or drug0, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some drug0",False, 
DDI-DrugBank.d709.s4.e1,DDI-DrugBank.d709.s4.e4,"- drug0, drug1: Other drugs such as drug0 or drug0, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some drug2",True,mechanism
DDI-DrugBank.d709.s4.e2,DDI-DrugBank.d709.s4.e4,"- drug0, drug0: Other drugs such as drug1 or drug0, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some drug2",True,mechanism
DDI-DrugBank.d709.s5.e0,DDI-DrugBank.d709.s5.e1,"Although such a risk is not verified for drug1, combination of drug2",False, 
DDI-DrugBank.d602.s0.e0,DDI-DrugBank.d602.s0.e1,Caution is recommended when administering drug1 with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. drug2,True,advise
DDI-DrugBank.d602.s1.e0,DDI-DrugBank.d602.s1.e1,Concomitant treatment with drug1 resulted in a 21% increase in the AUC of drug2,True,mechanism
DDI-DrugBank.d602.s2.e0,DDI-DrugBank.d602.s2.e1,Caution is recommended when administering drug1 with drug2,True,advise
DDI-DrugBank.d783.s0.e0,DDI-DrugBank.d783.s0.e1,"drug1 inhibits some of the liver's ability to metabolize some other drugs - drug2, drug0, drug0, drug0, and drug0",True,mechanism
DDI-DrugBank.d783.s0.e0,DDI-DrugBank.d783.s0.e2,"drug1 inhibits some of the liver's ability to metabolize some other drugs - drug0, drug2, drug0, drug0, and drug0",True,mechanism
DDI-DrugBank.d783.s0.e0,DDI-DrugBank.d783.s0.e3,"drug1 inhibits some of the liver's ability to metabolize some other drugs - drug0, drug0, drug2, drug0, and drug0",True,mechanism
DDI-DrugBank.d783.s0.e0,DDI-DrugBank.d783.s0.e4,"drug1 inhibits some of the liver's ability to metabolize some other drugs - drug0, drug0, drug0, drug2, and drug0",True,mechanism
DDI-DrugBank.d783.s0.e0,DDI-DrugBank.d783.s0.e5,"drug1 inhibits some of the liver's ability to metabolize some other drugs - drug0, drug0, drug0, drug0, and drug2",True,mechanism
DDI-DrugBank.d783.s0.e1,DDI-DrugBank.d783.s0.e2,"drug0 inhibits some of the liver's ability to metabolize some other drugs - drug1, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d783.s0.e1,DDI-DrugBank.d783.s0.e3,"drug0 inhibits some of the liver's ability to metabolize some other drugs - drug1, drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d711.s0.e0,DDI-DrugBank.d711.s0.e1,"Because drug1 have been shown to depress plasma prothrombin activity, patients who are on drug2 therapy may require downward adjustment of their drug0",True,advise
DDI-DrugBank.d711.s0.e0,DDI-DrugBank.d711.s0.e2,"Because drug1 have been shown to depress plasma prothrombin activity, patients who are on drug0 therapy may require downward adjustment of their drug2",False, 
DDI-DrugBank.d711.s0.e1,DDI-DrugBank.d711.s0.e2,"Because drug0 have been shown to depress plasma prothrombin activity, patients who are on drug1 therapy may require downward adjustment of their drug2",False, 
DDI-DrugBank.d711.s1.e0,DDI-DrugBank.d711.s1.e1,"Since bacteriostatic drugs may interfere with the bactericidal action of drug1, it is advisable to avoid giving drug2 in conjunction with drug0",False, 
DDI-DrugBank.d711.s1.e0,DDI-DrugBank.d711.s1.e2,"Since bacteriostatic drugs may interfere with the bactericidal action of drug1, it is advisable to avoid giving drug0 in conjunction with drug2",False, 
DDI-DrugBank.d711.s1.e1,DDI-DrugBank.d711.s1.e2,"Since bacteriostatic drugs may interfere with the bactericidal action of drug0, it is advisable to avoid giving drug1 in conjunction with drug2",True,advise
DDI-DrugBank.d711.s2.e0,DDI-DrugBank.d711.s2.e1,"Absorption of drug1 is impaired by drug2 containing drug0, drug0 or drug0, and drug0",False, 
DDI-DrugBank.d711.s2.e0,DDI-DrugBank.d711.s2.e2,"Absorption of drug1 is impaired by drug0 containing drug2, drug0 or drug0, and drug0",True,mechanism
DDI-DrugBank.d711.s2.e0,DDI-DrugBank.d711.s2.e3,"Absorption of drug1 is impaired by drug0 containing drug0, drug2 or drug0, and drug0",True,mechanism
DDI-DrugBank.d711.s2.e0,DDI-DrugBank.d711.s2.e4,"Absorption of drug1 is impaired by drug0 containing drug0, drug0 or drug2, and drug0",True,mechanism
DDI-DrugBank.d711.s2.e0,DDI-DrugBank.d711.s2.e5,"Absorption of drug1 is impaired by drug0 containing drug0, drug0 or drug0, and drug2",True,mechanism
DDI-DrugBank.d711.s2.e1,DDI-DrugBank.d711.s2.e2,"Absorption of drug0 is impaired by drug1 containing drug2, drug0 or drug0, and drug0",False, 
DDI-DrugBank.d711.s3.e0,DDI-DrugBank.d711.s3.e1,The concurrent use of drug1 and drug2,True,effect
DDI-DrugBank.d711.s4.e0,DDI-DrugBank.d711.s4.e1,Concurrent use of drug1 with oral drug2 may render oral drug0,True,effect
DDI-DrugBank.d711.s4.e0,DDI-DrugBank.d711.s4.e2,Concurrent use of drug1 with oral drug0 may render oral drug2,False, 
DDI-DrugBank.d711.s4.e1,DDI-DrugBank.d711.s4.e2,Concurrent use of drug0 with oral drug1 may render oral drug2,False, 
DDI-DrugBank.d744.s0.e0,DDI-DrugBank.d744.s0.e1,Acromegalic patients with diabetes mellitus being treated with drug1 and/or oral drug2 agents may require dose reductions of these therapeutic agents after the initiation of therapy with drug0,False, 
DDI-DrugBank.d744.s0.e0,DDI-DrugBank.d744.s0.e2,Acromegalic patients with diabetes mellitus being treated with drug1 and/or oral drug0 agents may require dose reductions of these therapeutic agents after the initiation of therapy with drug2,True,advise
DDI-DrugBank.d744.s0.e1,DDI-DrugBank.d744.s0.e2,Acromegalic patients with diabetes mellitus being treated with drug0 and/or oral drug1 agents may require dose reductions of these therapeutic agents after the initiation of therapy with drug2,True,advise
DDI-DrugBank.d744.s1.e0,DDI-DrugBank.d744.s1.e1,"In clinical studies, patients on drug1 often needed higher serum drug2 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving drug0",True,mechanism
DDI-DrugBank.d744.s1.e0,DDI-DrugBank.d744.s1.e2,"In clinical studies, patients on drug1 often needed higher serum drug0 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving drug2",False, 
DDI-DrugBank.d744.s1.e1,DDI-DrugBank.d744.s1.e2,"In clinical studies, patients on drug0 often needed higher serum drug1 concentrations to achieve appropriate IGF-I suppression compared with patients not receiving drug2",False, 
DDI-DrugBank.d775.s0.e0,DDI-DrugBank.d775.s0.e1,"Although drug1 (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between drug2 and drug0",False, 
DDI-DrugBank.d775.s0.e0,DDI-DrugBank.d775.s0.e2,"Although drug1 (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between drug0 and drug2",False, 
DDI-DrugBank.d775.s1.e0,DDI-DrugBank.d775.s1.e1,Prior administration of drug1 can potentiate the neuromuscular blocking effects of drug2,True,effect
DDI-DrugBank.d775.s2.e0,DDI-DrugBank.d775.s2.e1,Evidence of spontaneous recovery from drug1 should be observed before the administration of drug2,True,advise
DDI-DrugBank.d775.s3.e0,DDI-DrugBank.d775.s3.e1,The use of drug1 before drug2 to attenuate some of the side effects of drug0,False, 
DDI-DrugBank.d775.s3.e0,DDI-DrugBank.d775.s3.e2,The use of drug1 before drug0 to attenuate some of the side effects of drug2,False, 
DDI-DrugBank.d775.s4.e0,DDI-DrugBank.d775.s4.e1,There are no clinical data on the use of drug1 with other drug2,False, 
DDI-DrugBank.d775.s5.e0,DDI-DrugBank.d775.s5.e1,drug1 and drug2 (administered with drug0/drug0,False, 
DDI-DrugBank.d775.s5.e0,DDI-DrugBank.d775.s5.e2,drug1 and drug0 (administered with drug2/drug0,False, 
DDI-DrugBank.d775.s8.e0,DDI-DrugBank.d775.s8.e1,A greater potentiation of the neuromuscular blocking effects of drug1 may be expected with higher concentrations of drug2 or drug0,False, 
DDI-DrugBank.d775.s8.e0,DDI-DrugBank.d775.s8.e2,A greater potentiation of the neuromuscular blocking effects of drug1 may be expected with higher concentrations of drug0 or drug2,False, 
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e1,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",False, 
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e2,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug2 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e3,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e4,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e5,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e6,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e7,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e8,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e9,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e10,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e11,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug2 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e12,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug2, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e13,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug2, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e14,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug2, and drug0",True,int
DDI-DrugBank.d775.s10.e0,DDI-DrugBank.d775.s10.e15,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug2",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e2,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug2 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e3,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e4,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e5,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e6,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e7,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e8,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e9,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e10,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2), drug0 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e11,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug2 salts, drug0, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e12,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug2, local drug0, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e13,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug2, drug0, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e14,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug2, and drug0",True,int
DDI-DrugBank.d775.s10.e1,DDI-DrugBank.d775.s10.e15,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug2",True,int
DDI-DrugBank.d775.s10.e2,DDI-DrugBank.d775.s10.e3,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug0 include certain drug1 (e.g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",False, 
DDI-DrugBank.d775.s11.e0,DDI-DrugBank.d775.s11.e1,"The neuromuscular blocking effect of drug1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug2, drug0, or certain drug0) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug0 has been demonstrated in patients chronically administered drug0 or drug0",True,effect
DDI-DrugBank.d775.s11.e0,DDI-DrugBank.d775.s11.e2,"The neuromuscular blocking effect of drug1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug0, drug2, or certain drug0) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug0 has been demonstrated in patients chronically administered drug0 or drug0",True,effect
DDI-DrugBank.d775.s11.e0,DDI-DrugBank.d775.s11.e3,"The neuromuscular blocking effect of drug1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug0, drug0, or certain drug2) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug0 has been demonstrated in patients chronically administered drug0 or drug0",True,effect
DDI-DrugBank.d775.s11.e0,DDI-DrugBank.d775.s11.e4,"The neuromuscular blocking effect of drug1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug0, drug0, or certain drug0) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug2 has been demonstrated in patients chronically administered drug0 or drug0",False, 
DDI-DrugBank.d775.s11.e0,DDI-DrugBank.d775.s11.e5,"The neuromuscular blocking effect of drug1 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug0, drug0, or certain drug0) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug0 has been demonstrated in patients chronically administered drug2 or drug0",False, 
DDI-DrugBank.d775.s11.e4,DDI-DrugBank.d775.s11.e5,"The neuromuscular blocking effect of drug0 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug0, drug0, or certain drug0) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug1 has been demonstrated in patients chronically administered drug2 or drug0",True,effect
DDI-DrugBank.d775.s11.e4,DDI-DrugBank.d775.s11.e6,"The neuromuscular blocking effect of drug0 may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral drug0, drug0, or certain drug0) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing drug1 has been demonstrated in patients chronically administered drug0 or drug2",True,effect
DDI-DrugBank.d775.s12.e0,DDI-DrugBank.d775.s12.e1,While the effects of chronic drug1 or drug2 therapy on the action of drug0,False, 
DDI-DrugBank.d775.s12.e0,DDI-DrugBank.d775.s12.e2,While the effects of chronic drug1 or drug0 therapy on the action of drug2,True,effect
DDI-DrugBank.d775.s12.e1,DDI-DrugBank.d775.s12.e2,While the effects of chronic drug0 or drug1 therapy on the action of drug2,True,effect
DDI-DrugBank.d775.s13.e0,DDI-DrugBank.d775.s13.e1,Some drug interactions are:  - birth control pills - drug1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drug2 or drug0 - certain drug0 given by injection - drug0 - drug0 - drug0 - drug0 or drug0 - local drug0 such as drug0 - general drug0 - drug0 or other drug0,False, 
DDI-DrugBank.d775.s13.e0,DDI-DrugBank.d775.s13.e2,Some drug interactions are:  - birth control pills - drug1 - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as drug0 or drug2 - certain drug0 given by injection - drug0 - drug0 - drug0 - drug0 or drug0 - local drug0 such as drug0 - general drug0 - drug0 or other drug0,False, 
DDI-DrugBank.d757.s0.e0,DDI-DrugBank.d757.s0.e1,"Usage with drug1: Due to the potential for increased CNS depressants effects, drug2 should be used with caution in patients who are currently receiving drug0",False, 
DDI-DrugBank.d757.s0.e0,DDI-DrugBank.d757.s0.e2,"Usage with drug1: Due to the potential for increased CNS depressants effects, drug0 should be used with caution in patients who are currently receiving drug2",False, 
DDI-DrugBank.d757.s0.e1,DDI-DrugBank.d757.s0.e2,"Usage with drug0: Due to the potential for increased CNS depressants effects, drug1 should be used with caution in patients who are currently receiving drug2",True,advise
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e1,"drug1 may interact with the following drugs: drug2 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e2,"drug1 may interact with the following drugs: drug0 and other drug2 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e3,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug2 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",False, 
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e4,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug2 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e5,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug2 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",False, 
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e6,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug2 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e8,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug2 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e9,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug2 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e12,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug2 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e0,DDI-DrugBank.d643.s0.e13,"drug1 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug2 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,int
DDI-DrugBank.d643.s0.e10,DDI-DrugBank.d643.s0.e11,"drug0 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug1 with drug2 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug0 and drug0 may interfere with the efficacy of the drug0",True,effect
DDI-DrugBank.d643.s0.e14,DDI-DrugBank.d643.s0.e15,"drug0 may interact with the following drugs: drug0 and other drug0 (may lower drug0 levels), drug0 (bioavailability of oral drug0 is increased with coadministration), drug0 (may decrease drug0 levels), drug0 (reports of psychotic episodes when coadministered), drug0 (coadministration of drug0 with drug0 can inhibit ovarian function in women), drug0 and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and drug0 (coadministration of drug1 and drug2 may interfere with the efficacy of the drug0",True,effect
DDI-DrugBank.d743.s0.e0,DDI-DrugBank.d743.s0.e1,drug1: Spontaneous adverse reaction reports of patients taking concomitant drug2 with recommended doses of drug0,False, 
DDI-DrugBank.d743.s0.e0,DDI-DrugBank.d743.s0.e2,drug1: Spontaneous adverse reaction reports of patients taking concomitant drug0 with recommended doses of drug2,False, 
DDI-DrugBank.d743.s0.e1,DDI-DrugBank.d743.s0.e2,drug0: Spontaneous adverse reaction reports of patients taking concomitant drug1 with recommended doses of drug2,True,effect
DDI-DrugBank.d743.s2.e0,DDI-DrugBank.d743.s2.e1,"Pharmacokinetic data indicate that drug1 markedly inhibits the metabolism of drug2, resulting in elevated plasma drug0",True,mechanism
DDI-DrugBank.d743.s2.e0,DDI-DrugBank.d743.s2.e2,"Pharmacokinetic data indicate that drug1 markedly inhibits the metabolism of drug0, resulting in elevated plasma drug2",False, 
DDI-DrugBank.d743.s2.e1,DDI-DrugBank.d743.s2.e2,"Pharmacokinetic data indicate that drug0 markedly inhibits the metabolism of drug1, resulting in elevated plasma drug2",False, 
DDI-DrugBank.d743.s4.e0,DDI-DrugBank.d743.s4.e1,Concomitant administration of drug1 and drug2,True,advise
DDI-DrugBank.d743.s5.e0,DDI-DrugBank.d743.s5.e1,drug1: Torsades de pointes and elevated parent drug2 levels have been reported during concomitant use of drug0 and drug0 in clinical trials of drug0,False, 
DDI-DrugBank.d743.s5.e0,DDI-DrugBank.d743.s5.e2,drug1: Torsades de pointes and elevated parent drug0 levels have been reported during concomitant use of drug2 and drug0 in clinical trials of drug0,False, 
DDI-DrugBank.d743.s5.e2,DDI-DrugBank.d743.s5.e3,drug0: Torsades de pointes and elevated parent drug0 levels have been reported during concomitant use of drug1 and drug2 in clinical trials of drug0,True,mechanism
DDI-DrugBank.d743.s7.e0,DDI-DrugBank.d743.s7.e1,Concomitant administration of drug1 and drug2,True,advise
DDI-DrugBank.d743.s8.e0,DDI-DrugBank.d743.s8.e1,"Due to the chemical similarity of other drug1 (including drug2, drug0, and drug0) to drug0, and drug0, concomitant use of these products with drug0",False, 
DDI-DrugBank.d743.s8.e0,DDI-DrugBank.d743.s8.e2,"Due to the chemical similarity of other drug1 (including drug0, drug2, and drug0) to drug0, and drug0, concomitant use of these products with drug0",False, 
DDI-DrugBank.d743.s8.e0,DDI-DrugBank.d743.s8.e6,"Due to the chemical similarity of other drug1 (including drug0, drug0, and drug0) to drug0, and drug0, concomitant use of these products with drug2",True,advise
DDI-DrugBank.d743.s8.e1,DDI-DrugBank.d743.s8.e6,"Due to the chemical similarity of other drug0 (including drug1, drug0, and drug0) to drug0, and drug0, concomitant use of these products with drug2",True,advise
DDI-DrugBank.d743.s8.e2,DDI-DrugBank.d743.s8.e6,"Due to the chemical similarity of other drug0 (including drug0, drug1, and drug0) to drug0, and drug0, concomitant use of these products with drug2",True,advise
DDI-DrugBank.d743.s8.e3,DDI-DrugBank.d743.s8.e6,"Due to the chemical similarity of other drug0 (including drug0, drug0, and drug1) to drug0, and drug0, concomitant use of these products with drug2",True,advise
DDI-DrugBank.d743.s9.e0,DDI-DrugBank.d743.s9.e1,drug1: Clinical drug interaction studies indicate that drug2 and drug0 can exert an effect on drug0 metabolism by a mechanism which may be similar to that of drug0,False, 
DDI-DrugBank.d743.s9.e0,DDI-DrugBank.d743.s9.e2,drug1: Clinical drug interaction studies indicate that drug0 and drug2 can exert an effect on drug0 metabolism by a mechanism which may be similar to that of drug0,False, 
DDI-DrugBank.d743.s9.e1,DDI-DrugBank.d743.s9.e3,drug0: Clinical drug interaction studies indicate that drug1 and drug0 can exert an effect on drug2 metabolism by a mechanism which may be similar to that of drug0,True,mechanism
DDI-DrugBank.d743.s9.e2,DDI-DrugBank.d743.s9.e3,drug0: Clinical drug interaction studies indicate that drug0 and drug1 can exert an effect on drug2 metabolism by a mechanism which may be similar to that of drug0,True,mechanism
DDI-DrugBank.d743.s11.e0,DDI-DrugBank.d743.s11.e1,"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving drug1 or drug2",False, 
DDI-DrugBank.d743.s12.e0,DDI-DrugBank.d743.s12.e1,"Concomitant administration of drug1 with drug2, drug0, or drug0 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug0 with other drug0, including drug0",True,advise
DDI-DrugBank.d743.s12.e0,DDI-DrugBank.d743.s12.e2,"Concomitant administration of drug1 with drug0, drug2, or drug0 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug0 with other drug0, including drug0",True,advise
DDI-DrugBank.d743.s12.e0,DDI-DrugBank.d743.s12.e3,"Concomitant administration of drug1 with drug0, drug0, or drug2 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug0 with other drug0, including drug0",True,advise
DDI-DrugBank.d743.s12.e0,DDI-DrugBank.d743.s12.e4,"Concomitant administration of drug1 with drug0, drug0, or drug0 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug2 with other drug0, including drug0",False, 
DDI-DrugBank.d743.s12.e0,DDI-DrugBank.d743.s12.e5,"Concomitant administration of drug1 with drug0, drug0, or drug0 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug0 with other drug2, including drug0",False, 
DDI-DrugBank.d743.s12.e4,DDI-DrugBank.d743.s12.e5,"Concomitant administration of drug0 with drug0, drug0, or drug0 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug1 with other drug2, including drug0",True,advise
DDI-DrugBank.d743.s12.e4,DDI-DrugBank.d743.s12.e6,"Concomitant administration of drug0 with drug0, drug0, or drug0 is contraindicated: Pending full characterization of potential interactions, concomitant administration of drug1 with other drug0, including drug2",True,advise
DDI-DrugBank.d743.s13.e0,DDI-DrugBank.d743.s13.e1,Studies to evaluate potential interactions of drug1 with drug2,False, 
DDI-DrugBank.d735.s0.e0,DDI-DrugBank.d735.s0.e1,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drug1 and drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d735.s0.e0,DDI-DrugBank.d735.s0.e2,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between drug1 and drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d735.s2.e0,DDI-DrugBank.d735.s2.e1,"There was no effect of a single dose or multiple doses of drug1 on drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d735.s2.e0,DDI-DrugBank.d735.s2.e2,"There was no effect of a single dose or multiple doses of drug1 on drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d735.s3.e0,DDI-DrugBank.d735.s3.e1,drug1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state drug2 compared with drug0,True,mechanism
DDI-DrugBank.d735.s3.e0,DDI-DrugBank.d735.s3.e2,drug1 AUC was increased by 21% with no effect on Cmax in the presence of steady-state drug0 compared with drug2,False, 
DDI-DrugBank.d735.s3.e1,DDI-DrugBank.d735.s3.e2,drug0 AUC was increased by 21% with no effect on Cmax in the presence of steady-state drug1 compared with drug2,False, 
DDI-DrugBank.d735.s4.e0,DDI-DrugBank.d735.s4.e1,"drug1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state drug2 compared with drug0",True,mechanism
DDI-DrugBank.d735.s4.e0,DDI-DrugBank.d735.s4.e2,"drug1 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state drug0 compared with drug2",False, 
DDI-DrugBank.d735.s4.e1,DDI-DrugBank.d735.s4.e2,"drug0 AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state drug1 compared with drug2",False, 
DDI-DrugBank.d735.s5.e0,DDI-DrugBank.d735.s5.e1,Patients receiving drug1 or drug2 in combination with drug0 should be monitored for drug0 or drug0 toxicity and drug0 or drug0,False, 
DDI-DrugBank.d735.s5.e0,DDI-DrugBank.d735.s5.e2,Patients receiving drug1 or drug0 in combination with drug2 should be monitored for drug0 or drug0 toxicity and drug0 or drug0,True,advise
DDI-DrugBank.d735.s5.e0,DDI-DrugBank.d735.s5.e3,Patients receiving drug1 or drug0 in combination with drug0 should be monitored for drug2 or drug0 toxicity and drug0 or drug0,False, 
DDI-DrugBank.d735.s5.e1,DDI-DrugBank.d735.s5.e2,Patients receiving drug0 or drug1 in combination with drug2 should be monitored for drug0 or drug0 toxicity and drug0 or drug0,True,advise
DDI-DrugBank.d765.s0.e0,DDI-DrugBank.d765.s0.e1,"CYP3A4 Inhibitors: drug1, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of drug2",True,mechanism
DDI-DrugBank.d765.s1.e0,DDI-DrugBank.d765.s1.e1,"For patients receiving drug1 or other potent CYP3A4 inhibitors such as other drug2 (eg, drug0, drug0) or drug0 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug0",False, 
DDI-DrugBank.d765.s1.e0,DDI-DrugBank.d765.s1.e2,"For patients receiving drug1 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug2, drug0) or drug0 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug0",False, 
DDI-DrugBank.d765.s1.e0,DDI-DrugBank.d765.s1.e9,"For patients receiving drug1 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug0) or drug0 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e1,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug1 (eg, drug0, drug0) or drug0 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e2,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug1, drug0) or drug0 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e3,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug1) or drug0 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e4,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug0) or drug1 (eg, drug0, drug0) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e5,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug0) or drug0 (eg, drug1, drug0) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e6,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug0) or drug0 (eg, drug0, drug1) or drug0 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e7,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug0) or drug0 (eg, drug0, drug0) or drug1 or drug0, the recommended dose of drug2",True,advise
DDI-DrugBank.d765.s1.e8,DDI-DrugBank.d765.s1.e9,"For patients receiving drug0 or other potent CYP3A4 inhibitors such as other drug0 (eg, drug0, drug0) or drug0 (eg, drug0, drug0) or drug0 or drug1, the recommended dose of drug2",True,advise
DDI-DrugBank.d606.s0.e0,DDI-DrugBank.d606.s0.e1,drug1 and drug2 increase the effects of drug0,False, 
DDI-DrugBank.d606.s0.e0,DDI-DrugBank.d606.s0.e2,drug1 and drug0 increase the effects of drug2,True,effect
DDI-DrugBank.d606.s0.e1,DDI-DrugBank.d606.s0.e2,drug0 and drug1 increase the effects of drug2,True,effect
DDI-DrugBank.d606.s1.e0,DDI-DrugBank.d606.s1.e1,"drug1 may reduce the antihypertensive effects of drug2, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d606.s1.e0,DDI-DrugBank.d606.s1.e2,"drug1 may reduce the antihypertensive effects of drug0, drug2, drug0 and drug0",True,effect
DDI-DrugBank.d606.s1.e0,DDI-DrugBank.d606.s1.e3,"drug1 may reduce the antihypertensive effects of drug0, drug0, drug2 and drug0",True,effect
DDI-DrugBank.d606.s1.e0,DDI-DrugBank.d606.s1.e4,"drug1 may reduce the antihypertensive effects of drug0, drug0, drug0 and drug2",True,effect
DDI-DrugBank.d606.s1.e1,DDI-DrugBank.d606.s1.e2,"drug0 may reduce the antihypertensive effects of drug1, drug2, drug0 and drug0",False, 
DDI-DrugBank.d606.s1.e1,DDI-DrugBank.d606.s1.e3,"drug0 may reduce the antihypertensive effects of drug1, drug0, drug2 and drug0",False, 
DDI-DrugBank.d728.s1.e0,DDI-DrugBank.d728.s1.e1,No pharmacokinetic interaction between 85 mg/m2 drug1 and infusional drug2,False, 
DDI-DrugBank.d728.s2.e0,DDI-DrugBank.d728.s2.e1,Increases of drug1 plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 drug2,True,mechanism
DDI-DrugBank.d738.s0.e0,DDI-DrugBank.d738.s0.e1,Do not exceed a 5 mg daily dose of drug1 when administered with therapeutic doses of drug2,True,advise
DDI-DrugBank.d738.s1.e0,DDI-DrugBank.d738.s1.e1,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of drug1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with drug2 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of drug0 30 mg did not appear as large as that of the positive control drug0",False, 
DDI-DrugBank.d738.s1.e0,DDI-DrugBank.d738.s1.e2,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of drug1 on the QT interval in 76 healthy women, the QT prolonging effect appeared less with drug0 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of drug2 30 mg did not appear as large as that of the positive control drug0",False, 
DDI-DrugBank.d722.s0.e0,DDI-DrugBank.d722.s0.e1,There is usually complete cross-resistance between drug1 (drug2) and drug0 brand drug0,False, 
DDI-DrugBank.d722.s0.e0,DDI-DrugBank.d722.s0.e2,There is usually complete cross-resistance between drug1 (drug0) and drug2 brand drug0,True,effect
DDI-DrugBank.d722.s0.e0,DDI-DrugBank.d722.s0.e3,There is usually complete cross-resistance between drug1 (drug0) and drug0 brand drug2,True,effect
DDI-DrugBank.d722.s0.e1,DDI-DrugBank.d722.s0.e2,There is usually complete cross-resistance between drug0 (drug1) and drug2 brand drug0,True,effect
DDI-DrugBank.d722.s0.e1,DDI-DrugBank.d722.s0.e3,There is usually complete cross-resistance between drug0 (drug1) and drug0 brand drug2,True,effect
DDI-DrugBank.d722.s0.e2,DDI-DrugBank.d722.s0.e3,There is usually complete cross-resistance between drug0 (drug0) and drug1 brand drug2,False, 
DDI-DrugBank.d722.s1.e0,DDI-DrugBank.d722.s1.e1,"As there is in vitro evidence that drug1 (e.g., drug2, drug0, or drug0) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent drug0",False, 
DDI-DrugBank.d722.s1.e0,DDI-DrugBank.d722.s1.e2,"As there is in vitro evidence that drug1 (e.g., drug0, drug2, or drug0) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent drug0",False, 
DDI-DrugBank.d722.s1.e0,DDI-DrugBank.d722.s1.e4,"As there is in vitro evidence that drug1 (e.g., drug0, drug0, or drug0) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent drug2",True,mechanism
DDI-DrugBank.d722.s1.e1,DDI-DrugBank.d722.s1.e4,"As there is in vitro evidence that drug0 (e.g., drug1, drug0, or drug0) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent drug2",True,mechanism
DDI-DrugBank.d722.s1.e2,DDI-DrugBank.d722.s1.e4,"As there is in vitro evidence that drug0 (e.g., drug0, drug1, or drug0) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent drug2",True,mechanism
DDI-DrugBank.d722.s1.e3,DDI-DrugBank.d722.s1.e4,"As there is in vitro evidence that drug0 (e.g., drug0, drug0, or drug1) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent drug2",True,mechanism
DDI-DrugBank.d682.s0.e0,DDI-DrugBank.d682.s0.e1,"drug1 may increase the effects of drug2, drug0, and drug0",True,effect
DDI-DrugBank.d682.s0.e0,DDI-DrugBank.d682.s0.e2,"drug1 may increase the effects of drug0, drug2, and drug0",True,effect
DDI-DrugBank.d682.s0.e0,DDI-DrugBank.d682.s0.e3,"drug1 may increase the effects of drug0, drug0, and drug2",True,effect
DDI-DrugBank.d682.s0.e1,DDI-DrugBank.d682.s0.e2,"drug0 may increase the effects of drug1, drug2, and drug0",False, 
DDI-DrugBank.d682.s0.e1,DDI-DrugBank.d682.s0.e3,"drug0 may increase the effects of drug1, drug0, and drug2",False, 
DDI-DrugBank.d682.s1.e0,DDI-DrugBank.d682.s1.e1,"It may also interact with drug1 (increased thrombocytopenia), drug2 (increased nephrotoxicity), drug0 (increased hypoglycemic response), drug0 (increased anticoagulant effect), drug0 (decreased renal excretion of drug0), drug0 (decreased hepatic clearance of drug0",False, 
DDI-DrugBank.d682.s1.e0,DDI-DrugBank.d682.s1.e2,"It may also interact with drug1 (increased thrombocytopenia), drug0 (increased nephrotoxicity), drug2 (increased hypoglycemic response), drug0 (increased anticoagulant effect), drug0 (decreased renal excretion of drug0), drug0 (decreased hepatic clearance of drug0",False, 
DDI-DrugBank.d609.s0.e0,DDI-DrugBank.d609.s0.e1,An inhibitor of CYP2C8 (such as drug1) may increase the AUC of drug2 and an inducer of CYP2C8 (such as drug0) may decrease the AUC of drug0,True,mechanism
DDI-DrugBank.d609.s0.e0,DDI-DrugBank.d609.s0.e2,An inhibitor of CYP2C8 (such as drug1) may increase the AUC of drug0 and an inducer of CYP2C8 (such as drug2) may decrease the AUC of drug0,False, 
DDI-DrugBank.d609.s0.e0,DDI-DrugBank.d609.s0.e3,An inhibitor of CYP2C8 (such as drug1) may increase the AUC of drug0 and an inducer of CYP2C8 (such as drug0) may decrease the AUC of drug2,False, 
DDI-DrugBank.d609.s0.e2,DDI-DrugBank.d609.s0.e3,An inhibitor of CYP2C8 (such as drug0) may increase the AUC of drug0 and an inducer of CYP2C8 (such as drug1) may decrease the AUC of drug2,True,mechanism
DDI-DrugBank.d774.s0.e0,DDI-DrugBank.d774.s0.e1,drug1 may interact with drug2 or drug0,True,int
DDI-DrugBank.d774.s0.e0,DDI-DrugBank.d774.s0.e2,drug1 may interact with drug0 or drug2,True,int
DDI-DrugBank.d774.s0.e1,DDI-DrugBank.d774.s0.e2,drug0 may interact with drug1 or drug2,False, 
DDI-DrugBank.d773.s1.e0,DDI-DrugBank.d773.s1.e1,Patients studied in clinical trials of drug1 were routinely treated with drug2 and drug0,False, 
DDI-DrugBank.d773.s1.e0,DDI-DrugBank.d773.s1.e2,Patients studied in clinical trials of drug1 were routinely treated with drug0 and drug2,False, 
DDI-DrugBank.d773.s2.e0,DDI-DrugBank.d773.s2.e1,"drug1 (such as drug2 and drug0) and drugs that alter platelet function (such as drug0, drug0, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug0",False, 
DDI-DrugBank.d773.s2.e0,DDI-DrugBank.d773.s2.e2,"drug1 (such as drug0 and drug2) and drugs that alter platelet function (such as drug0, drug0, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug0",False, 
DDI-DrugBank.d773.s2.e0,DDI-DrugBank.d773.s2.e5,"drug1 (such as drug0 and drug0) and drugs that alter platelet function (such as drug0, drug0, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug2",True,effect
DDI-DrugBank.d773.s2.e1,DDI-DrugBank.d773.s2.e5,"drug0 (such as drug1 and drug0) and drugs that alter platelet function (such as drug0, drug0, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug2",True,effect
DDI-DrugBank.d773.s2.e2,DDI-DrugBank.d773.s2.e5,"drug0 (such as drug0 and drug1) and drugs that alter platelet function (such as drug0, drug0, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug2",True,effect
DDI-DrugBank.d773.s2.e3,DDI-DrugBank.d773.s2.e5,"drug0 (such as drug0 and drug0) and drugs that alter platelet function (such as drug1, drug0, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug2",True,effect
DDI-DrugBank.d773.s2.e4,DDI-DrugBank.d773.s2.e5,"drug0 (such as drug0 and drug0) and drugs that alter platelet function (such as drug0, drug1, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after drug2",True,effect
DDI-DrugBank.d669.s0.e0,DDI-DrugBank.d669.s0.e1,Concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d669.s1.e0,DDI-DrugBank.d669.s1.e1,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as drug1, drug2, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d669.s1.e0,DDI-DrugBank.d669.s1.e2,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as drug1, drug0, drug2, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d712.s1.e0,DDI-DrugBank.d712.s1.e1,Administration of drug1 in combination with drug2 resulted in a two-fold decrease in drug0 clearance in a non-human primate study and in a 1.5-fold increase in drug0,True,mechanism
DDI-DrugBank.d712.s1.e0,DDI-DrugBank.d712.s1.e2,Administration of drug1 in combination with drug0 resulted in a two-fold decrease in drug2 clearance in a non-human primate study and in a 1.5-fold increase in drug0,False, 
DDI-DrugBank.d712.s1.e0,DDI-DrugBank.d712.s1.e3,Administration of drug1 in combination with drug0 resulted in a two-fold decrease in drug0 clearance in a non-human primate study and in a 1.5-fold increase in drug2,False, 
DDI-DrugBank.d613.s0.e0,DDI-DrugBank.d613.s0.e1,A study published in 2002 found that drug1 causes a statistically significant increase in plasma clearance of drug2,True,mechanism
DDI-DrugBank.d613.s1.e0,DDI-DrugBank.d613.s1.e1,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering drug1 with drug2 lowered the serum drug0",True,mechanism
DDI-DrugBank.d613.s1.e0,DDI-DrugBank.d613.s1.e2,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering drug1 with drug0 lowered the serum drug2",False, 
DDI-DrugBank.d613.s1.e1,DDI-DrugBank.d613.s1.e2,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering drug0 with drug1 lowered the serum drug2",False, 
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e1,"drug1 may interact with drug2 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e2,"drug1 may interact with drug0 (drug2 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e3,"drug1 may interact with drug0 (drug0 type), drug2 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e4,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug2, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e5,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug2, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e6,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug2, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e7,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug2, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e8,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug2, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e9,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug2), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e10,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug2, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e11,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug2, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e12,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug2 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e13,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug2), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e14,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug2, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e15,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug2 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e16,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug2, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e17,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug2 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e18,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug2-drug0), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e19,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug2), drug0 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e20,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug2 (e.g., drug0, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e21,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug2, drug0",True,int
DDI-DrugBank.d655.s0.e0,DDI-DrugBank.d655.s0.e22,"drug1 may interact with drug0 (drug0 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug2",True,int
DDI-DrugBank.d655.s0.e1,DDI-DrugBank.d655.s0.e2,"drug0 may interact with drug1 (drug2 type), drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0, drug0, drug0 (e.g., drug0), other drug0, drug0 supplements, drug0, drug0 (e.g., drug0-drug0), drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d761.s0.e0,DDI-DrugBank.d761.s0.e1,"drug1: In a multiple-dose study in 30 normal weight subjects, coadministration of drug2 and 40 grams of drug0 (e.g., approximately 3 glasses of wine) did not result in alteration of drug0 pharmacokinetics, drug0 pharmacodynamics (fecal fat excretion), or systemic exposure to drug0",False, 
DDI-DrugBank.d761.s0.e0,DDI-DrugBank.d761.s0.e2,"drug1: In a multiple-dose study in 30 normal weight subjects, coadministration of drug0 and 40 grams of drug2 (e.g., approximately 3 glasses of wine) did not result in alteration of drug0 pharmacokinetics, drug0 pharmacodynamics (fecal fat excretion), or systemic exposure to drug0",False, 
DDI-DrugBank.d761.s1.e0,DDI-DrugBank.d761.s1.e1,drug1: Preliminary data from a drug2 and drug0 drug interaction study indicate a reduction in drug0 plasma levels when drug0 was coadministered with drug0,False, 
DDI-DrugBank.d761.s1.e0,DDI-DrugBank.d761.s1.e2,drug1: Preliminary data from a drug0 and drug2 drug interaction study indicate a reduction in drug0 plasma levels when drug0 was coadministered with drug0,False, 
DDI-DrugBank.d761.s1.e4,DDI-DrugBank.d761.s1.e5,drug0: Preliminary data from a drug0 and drug0 drug interaction study indicate a reduction in drug0 plasma levels when drug1 was coadministered with drug2,True,mechanism
DDI-DrugBank.d761.s2.e0,DDI-DrugBank.d761.s2.e1,"drug1: In 12 normal-weight subjects receiving drug2 120 mg three times a day for 6 days, drug0 did not alter the pharmacokinetics of a single dose of drug0",False, 
DDI-DrugBank.d761.s2.e0,DDI-DrugBank.d761.s2.e2,"drug1: In 12 normal-weight subjects receiving drug0 120 mg three times a day for 6 days, drug2 did not alter the pharmacokinetics of a single dose of drug0",False, 
DDI-DrugBank.d761.s3.e0,DDI-DrugBank.d761.s3.e1,drug1 and Analogues: A pharmacokinetic interaction study showed a 30% reduction in drug2 supplement absorption when concomitantly administered with drug0,False, 
DDI-DrugBank.d761.s3.e0,DDI-DrugBank.d761.s3.e2,drug1 and Analogues: A pharmacokinetic interaction study showed a 30% reduction in drug0 supplement absorption when concomitantly administered with drug2,False, 
DDI-DrugBank.d761.s3.e1,DDI-DrugBank.d761.s3.e2,drug0 and Analogues: A pharmacokinetic interaction study showed a 30% reduction in drug1 supplement absorption when concomitantly administered with drug2,True,mechanism
DDI-DrugBank.d761.s4.e0,DDI-DrugBank.d761.s4.e1,drug1 inhibited absorption of a drug2,True,mechanism
DDI-DrugBank.d761.s5.e0,DDI-DrugBank.d761.s5.e1,"The effect of drug1 on the absorption of supplemental drug2, drug0, and nutritionally-derived drug0",False, 
DDI-DrugBank.d761.s5.e0,DDI-DrugBank.d761.s5.e2,"The effect of drug1 on the absorption of supplemental drug0, drug2, and nutritionally-derived drug0",False, 
DDI-DrugBank.d761.s6.e0,DDI-DrugBank.d761.s6.e1,"drug1: In 12 normal-weight subjects receiving drug2 80 mg three times a day for 5 days, drug0 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of drug0",False, 
DDI-DrugBank.d761.s6.e0,DDI-DrugBank.d761.s6.e2,"drug1: In 12 normal-weight subjects receiving drug0 80 mg three times a day for 5 days, drug2 did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of drug0",False, 
DDI-DrugBank.d761.s7.e0,DDI-DrugBank.d761.s7.e1,"drug1 (extended-release tablets): In 17 normal-weight subjects receiving drug2 120 mg three times a day for 6 days, drug0 did not alter the bioavailability of drug0",False, 
DDI-DrugBank.d761.s7.e0,DDI-DrugBank.d761.s7.e2,"drug1 (extended-release tablets): In 17 normal-weight subjects receiving drug0 120 mg three times a day for 6 days, drug2 did not alter the bioavailability of drug0",False, 
DDI-DrugBank.d761.s8.e0,DDI-DrugBank.d761.s8.e1,"Oral drug1: In 20 normal-weight female subjects, the treatment of drug2 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral drug0",False, 
DDI-DrugBank.d761.s8.e0,DDI-DrugBank.d761.s8.e2,"Oral drug1: In 20 normal-weight female subjects, the treatment of drug0 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral drug2",False, 
DDI-DrugBank.d761.s9.e0,DDI-DrugBank.d761.s9.e1,"drug1: In 12 normal-weight subjects receiving drug2 120 mg three times a day for 7 days, drug0 did not alter the pharmacokinetics of a single 300-mg dose of drug0",False, 
DDI-DrugBank.d761.s9.e0,DDI-DrugBank.d761.s9.e2,"drug1: In 12 normal-weight subjects receiving drug0 120 mg three times a day for 7 days, drug2 did not alter the pharmacokinetics of a single 300-mg dose of drug0",False, 
DDI-DrugBank.d761.s10.e0,DDI-DrugBank.d761.s10.e1,"drug1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving drug2 120 mg three times a day for 6 days, drug0 did not affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d761.s10.e0,DDI-DrugBank.d761.s10.e2,"drug1: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving drug0 120 mg three times a day for 6 days, drug2 did not affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d761.s11.e0,DDI-DrugBank.d761.s11.e1,"drug1: In 12 normal-weight subjects, administration of drug2 120 mg three times a day for 16 days did not result in any change in either drug0",False, 
DDI-DrugBank.d761.s11.e0,DDI-DrugBank.d761.s11.e2,"drug1: In 12 normal-weight subjects, administration of drug0 120 mg three times a day for 16 days did not result in any change in either drug2",False, 
DDI-DrugBank.d761.s12.e0,DDI-DrugBank.d761.s12.e1,"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with drug1 administration, vitamin K levels tended to decline in subjects taking drug2",False, 
DDI-DrugBank.d761.s13.e0,DDI-DrugBank.d761.s13.e1,"Therefore, as drug1 absorption may be decreased with drug2, patients on chronic stable doses of drug0 who are prescribed drug0",True,mechanism
DDI-DrugBank.d761.s13.e0,DDI-DrugBank.d761.s13.e2,"Therefore, as drug1 absorption may be decreased with drug0, patients on chronic stable doses of drug2 who are prescribed drug0",False, 
DDI-DrugBank.d761.s13.e0,DDI-DrugBank.d761.s13.e3,"Therefore, as drug1 absorption may be decreased with drug0, patients on chronic stable doses of drug0 who are prescribed drug2",False, 
DDI-DrugBank.d761.s13.e2,DDI-DrugBank.d761.s13.e3,"Therefore, as drug0 absorption may be decreased with drug0, patients on chronic stable doses of drug1 who are prescribed drug2",True,advise
DDI-DrugBank.d677.s0.e0,DDI-DrugBank.d677.s0.e1,"drug1 are capable of potentiating drug2 (e.g., drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d677.s0.e0,DDI-DrugBank.d677.s0.e2,"drug1 are capable of potentiating drug0 (e.g., drug2, drug0, drug0, drug0",True,effect
DDI-DrugBank.d677.s0.e0,DDI-DrugBank.d677.s0.e3,"drug1 are capable of potentiating drug0 (e.g., drug0, drug2, drug0, drug0",True,effect
DDI-DrugBank.d677.s0.e0,DDI-DrugBank.d677.s0.e4,"drug1 are capable of potentiating drug0 (e.g., drug0, drug0, drug2, drug0",True,effect
DDI-DrugBank.d677.s0.e0,DDI-DrugBank.d677.s0.e5,"drug1 are capable of potentiating drug0 (e.g., drug0, drug0, drug0, drug2",True,effect
DDI-DrugBank.d677.s0.e1,DDI-DrugBank.d677.s0.e2,"drug0 are capable of potentiating drug1 (e.g., drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d677.s0.e1,DDI-DrugBank.d677.s0.e3,"drug0 are capable of potentiating drug1 (e.g., drug0, drug2, drug0, drug0",False, 
DDI-DrugBank.d677.s1.e0,DDI-DrugBank.d677.s1.e1,as well as drug1 and drug2,False, 
DDI-DrugBank.d737.s0.e0,DDI-DrugBank.d737.s0.e1,drug1/drug2: drug0/drug0 does not influence the pharmacokinetics of drug0,False, 
DDI-DrugBank.d737.s0.e0,DDI-DrugBank.d737.s0.e2,drug1/drug0: drug2/drug0 does not influence the pharmacokinetics of drug0,False, 
DDI-DrugBank.d737.s2.e0,DDI-DrugBank.d737.s2.e1,"drug1: In healthy volunteers (N= 11), drug2 did not influence the pharmacokinetics of drug0",False, 
DDI-DrugBank.d737.s2.e0,DDI-DrugBank.d737.s2.e2,"drug1: In healthy volunteers (N= 11), drug0 did not influence the pharmacokinetics of drug2",False, 
DDI-DrugBank.d737.s3.e0,DDI-DrugBank.d737.s3.e1,drug1: Population pharmacokinetic analysis suggests that drug2 is unlikely to alter the oral clearance of drug0,False, 
DDI-DrugBank.d737.s3.e0,DDI-DrugBank.d737.s3.e2,drug1: Population pharmacokinetic analysis suggests that drug0 is unlikely to alter the oral clearance of drug2,False, 
DDI-DrugBank.d737.s4.e0,DDI-DrugBank.d737.s4.e1,"drug1: drug2, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in drug0",False, 
DDI-DrugBank.d737.s4.e0,DDI-DrugBank.d737.s4.e2,"drug1: drug0, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in drug2",False, 
DDI-DrugBank.d737.s4.e1,DDI-DrugBank.d737.s4.e2,"drug0: drug1, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in drug2",True,mechanism
DDI-DrugBank.d737.s5.e0,DDI-DrugBank.d737.s5.e1,"drug1: drug2, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence drug0",False, 
DDI-DrugBank.d737.s5.e0,DDI-DrugBank.d737.s5.e2,"drug1: drug0, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence drug2",False, 
DDI-DrugBank.d737.s6.e0,DDI-DrugBank.d737.s6.e1,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug1, drug2, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",False, 
DDI-DrugBank.d737.s6.e0,DDI-DrugBank.d737.s6.e2,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug1, drug0, drug2, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",False, 
DDI-DrugBank.d737.s6.e0,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug1, drug0, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e1,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug1, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e2,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug1, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e3,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug1, drug0, drug0, and drug0) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e4,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug1, drug0, and drug0) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e5,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug1, and drug0) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e6,DDI-DrugBank.d737.s6.e7,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug0, and drug1) decreases the oral clearance of drug2 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug0",True,mechanism
DDI-DrugBank.d737.s6.e8,DDI-DrugBank.d737.s6.e13,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug1, drug0, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug2",True,mechanism
DDI-DrugBank.d737.s6.e9,DDI-DrugBank.d737.s6.e13,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug1, drug0, drug0, and drug0) are likely to have little effect on the oral clearance of drug2",True,mechanism
DDI-DrugBank.d737.s6.e10,DDI-DrugBank.d737.s6.e13,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug1, drug0, and drug0) are likely to have little effect on the oral clearance of drug2",True,mechanism
DDI-DrugBank.d737.s6.e11,DDI-DrugBank.d737.s6.e13,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug1, and drug0) are likely to have little effect on the oral clearance of drug2",True,mechanism
DDI-DrugBank.d737.s6.e12,DDI-DrugBank.d737.s6.e13,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., drug0, drug0, drug0, drug0, drug0, drug0, and drug0) decreases the oral clearance of drug0 by about 20%, while those secreted by the anionic transport system (e.g., drug0, drug0, drug0, drug0, and drug1) are likely to have little effect on the oral clearance of drug2",True,mechanism
DDI-DrugBank.d737.s7.e0,DDI-DrugBank.d737.s7.e1,CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect drug1 elimination because drug2,False, 
DDI-DrugBank.d737.s10.e0,DDI-DrugBank.d737.s10.e1,"drug1: Since drug2 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug0, drug0) or drug0, may diminish the effectiveness of drug0",False, 
DDI-DrugBank.d737.s10.e0,DDI-DrugBank.d737.s10.e2,"drug1: Since drug0 is a drug2, it is possible that drug0, such as the drug0 (drug0, drug0, drug0) or drug0, may diminish the effectiveness of drug0",False, 
DDI-DrugBank.d737.s10.e3,DDI-DrugBank.d737.s10.e9,"drug0: Since drug0 is a drug0, it is possible that drug1, such as the drug0 (drug0, drug0, drug0) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d737.s10.e4,DDI-DrugBank.d737.s10.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug1 (drug0, drug0, drug0) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d737.s10.e5,DDI-DrugBank.d737.s10.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug1, drug0, drug0) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d737.s10.e6,DDI-DrugBank.d737.s10.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug1, drug0) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d737.s10.e7,DDI-DrugBank.d737.s10.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug0, drug1) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d737.s10.e8,DDI-DrugBank.d737.s10.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug0, drug0) or drug1, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d580.s1.e0,DDI-DrugBank.d580.s1.e1,"However, drug1, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of drug2",True,mechanism
DDI-DrugBank.d727.s0.e0,DDI-DrugBank.d727.s0.e1,drug1 competitively inhibits the intracellular phosphorylation of drug2,True,effect
DDI-DrugBank.d727.s1.e0,DDI-DrugBank.d727.s1.e1,"Therefore, use of drug1 in combination with drug2",True,advise
DDI-DrugBank.d727.s2.e0,DDI-DrugBank.d727.s2.e1,In vitro data indicate that the phosphorylation of drug1 is also inhibited at relevant concentrations by drug2 and drug0,True,effect
DDI-DrugBank.d727.s2.e0,DDI-DrugBank.d727.s2.e2,In vitro data indicate that the phosphorylation of drug1 is also inhibited at relevant concentrations by drug0 and drug2,True,effect
DDI-DrugBank.d727.s2.e1,DDI-DrugBank.d727.s2.e2,In vitro data indicate that the phosphorylation of drug0 is also inhibited at relevant concentrations by drug1 and drug2,False, 
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e1,"The following agents may increase certain actions or side effects of drug1: drug2, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e2,"The following agents may increase certain actions or side effects of drug1: drug0, drug2 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e3,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug2), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e4,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug2, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e5,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug2 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e6,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug2), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e7,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug2, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e8,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug2, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e9,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug2 (e.g., drug0), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e10,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug2), drug0 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e11,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug2 and drug0, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e12,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug2, drug0, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e13,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug2, drug0",True,effect
DDI-DrugBank.d585.s0.e0,DDI-DrugBank.d585.s0.e14,"The following agents may increase certain actions or side effects of drug1: drug0, drug0 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug2",True,effect
DDI-DrugBank.d585.s0.e1,DDI-DrugBank.d585.s0.e2,"The following agents may increase certain actions or side effects of drug0: drug1, drug2 (e.g., drug0), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",False, 
DDI-DrugBank.d585.s0.e1,DDI-DrugBank.d585.s0.e3,"The following agents may increase certain actions or side effects of drug0: drug1, drug0 (e.g., drug2), drug0, drug0 (e.g., drug0), drug0, drug0, drug0 (e.g., drug0), drug0 and drug0, drug0, drug0",False, 
DDI-DrugBank.d585.s1.e0,DDI-DrugBank.d585.s1.e1,drug1 antagonize the effects of drug2,True,effect
DDI-DrugBank.d585.s2.e0,DDI-DrugBank.d585.s2.e1,drug1 in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as drug2,True,effect
DDI-DrugBank.d585.s3.e0,DDI-DrugBank.d585.s3.e1,"drug1 may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of drug2",True,mechanism
DDI-DrugBank.d585.s5.e0,DDI-DrugBank.d585.s5.e1,"drug1 may antagonize the effects of drugs that alter gastrointestinal motility, such as drug2",True,effect
DDI-DrugBank.d585.s6.e0,DDI-DrugBank.d585.s6.e1,Because drug1 may interfere with the absorption of drug2,True,mechanism
DDI-DrugBank.d637.s0.e0,DDI-DrugBank.d637.s0.e1,"Use with Other drug1: The depressant effects of drug2 are potentiated by the presence of other drug0 such as drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d637.s0.e0,DDI-DrugBank.d637.s0.e2,"Use with Other drug1: The depressant effects of drug0 are potentiated by the presence of other drug2 such as drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d637.s0.e1,DDI-DrugBank.d637.s0.e2,"Use with Other drug0: The depressant effects of drug1 are potentiated by the presence of other drug2 such as drug0, drug0, drug0, or drug0",True,effect
DDI-DrugBank.d637.s0.e1,DDI-DrugBank.d637.s0.e3,"Use with Other drug0: The depressant effects of drug1 are potentiated by the presence of other drug0 such as drug2, drug0, drug0, or drug0",True,effect
DDI-DrugBank.d637.s0.e1,DDI-DrugBank.d637.s0.e4,"Use with Other drug0: The depressant effects of drug1 are potentiated by the presence of other drug0 such as drug0, drug2, drug0, or drug0",True,effect
DDI-DrugBank.d637.s0.e1,DDI-DrugBank.d637.s0.e5,"Use with Other drug0: The depressant effects of drug1 are potentiated by the presence of other drug0 such as drug0, drug0, drug2, or drug0",True,effect
DDI-DrugBank.d637.s0.e1,DDI-DrugBank.d637.s0.e6,"Use with Other drug0: The depressant effects of drug1 are potentiated by the presence of other drug0 such as drug0, drug0, drug0, or drug2",True,effect
DDI-DrugBank.d637.s1.e0,DDI-DrugBank.d637.s1.e1,Use of drug1 in conjunction with oral drug2,True,effect
DDI-DrugBank.d637.s2.e0,DDI-DrugBank.d637.s2.e1,"Interaction with drug1: drug2 (i.e., drug0, drug0, drug0, or drug0) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug0",False, 
DDI-DrugBank.d637.s2.e0,DDI-DrugBank.d637.s2.e2,"Interaction with drug1: drug0 (i.e., drug2, drug0, drug0, or drug0) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug0",False, 
DDI-DrugBank.d637.s2.e1,DDI-DrugBank.d637.s2.e6,"Interaction with drug0: drug1 (i.e., drug0, drug0, drug0, or drug0) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug2",True,advise
DDI-DrugBank.d637.s2.e2,DDI-DrugBank.d637.s2.e6,"Interaction with drug0: drug0 (i.e., drug1, drug0, drug0, or drug0) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug2",True,advise
DDI-DrugBank.d637.s2.e3,DDI-DrugBank.d637.s2.e6,"Interaction with drug0: drug0 (i.e., drug0, drug1, drug0, or drug0) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug2",True,advise
DDI-DrugBank.d637.s2.e4,DDI-DrugBank.d637.s2.e6,"Interaction with drug0: drug0 (i.e., drug0, drug0, drug1, or drug0) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug2",True,advise
DDI-DrugBank.d637.s2.e5,DDI-DrugBank.d637.s2.e6,"Interaction with drug0: drug0 (i.e., drug0, drug0, drug0, or drug1) should NOT be administered to patients who have received or are receiving a course of therapy with a proof drug2",True,advise
DDI-DrugBank.d704.s0.e0,DDI-DrugBank.d704.s0.e1,Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between drug1 capsules and other drug2,False, 
DDI-DrugBank.d704.s1.e0,DDI-DrugBank.d704.s1.e1,"However, interactions may be expected and drug1 capsules should NOT be used in combination with other drug2",True,advise
DDI-DrugBank.d704.s2.e0,DDI-DrugBank.d704.s2.e1,The pharmacokinetic interaction between drug1 and drug2,False, 
DDI-DrugBank.d704.s4.e0,DDI-DrugBank.d704.s4.e1,"Therefore, drug1 capsules should be used with caution in combination with drug2",True,advise
DDI-DrugBank.d704.s5.e0,DDI-DrugBank.d704.s5.e1,Results from limited in vitro and in vivo drug-drug interaction studies between drug1 and drug2,False, 
DDI-DrugBank.d704.s6.e0,DDI-DrugBank.d704.s6.e1,"Therefore, caution should be exercised with concomitant administration of drug1 and drug2",True,advise
DDI-DrugBank.d622.s0.e0,DDI-DrugBank.d622.s0.e1,"When drug1 and drug2 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when drug0",True,effect
DDI-DrugBank.d622.s0.e0,DDI-DrugBank.d622.s0.e2,"When drug1 and drug0 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when drug2",False, 
DDI-DrugBank.d622.s0.e1,DDI-DrugBank.d622.s0.e2,"When drug0 and drug1 are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when drug2",False, 
DDI-DrugBank.d622.s1.e0,DDI-DrugBank.d622.s1.e1,This is especially true if the total dose of drug1 has been large and the administration of drug2,False, 
DDI-DrugBank.d622.s2.e0,DDI-DrugBank.d622.s2.e1,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of drug1: since drug2 are potentiated by the drug0",False, 
DDI-DrugBank.d622.s2.e0,DDI-DrugBank.d622.s2.e2,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of drug1: since drug0 are potentiated by the drug2",False, 
DDI-DrugBank.d622.s2.e1,DDI-DrugBank.d622.s2.e2,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of drug0: since drug1 are potentiated by the drug2",True,effect
DDI-DrugBank.d622.s3.e0,DDI-DrugBank.d622.s3.e1,"drug1, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d622.s3.e0,DDI-DrugBank.d622.s3.e2,"drug1, drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d751.s0.e0,DDI-DrugBank.d751.s0.e1,drug1 has been studied on a background of drug2 and drug0,False, 
DDI-DrugBank.d751.s0.e0,DDI-DrugBank.d751.s0.e2,drug1 has been studied on a background of drug0 and drug2,False, 
DDI-DrugBank.d751.s1.e0,DDI-DrugBank.d751.s1.e1,"The use of drug1, in combination with drug2 and drug0, has been associated with an increase in bleeding compared to drug0 and drug0",True,effect
DDI-DrugBank.d751.s1.e0,DDI-DrugBank.d751.s1.e2,"The use of drug1, in combination with drug0 and drug2, has been associated with an increase in bleeding compared to drug0 and drug0",True,effect
DDI-DrugBank.d751.s1.e0,DDI-DrugBank.d751.s1.e3,"The use of drug1, in combination with drug0 and drug0, has been associated with an increase in bleeding compared to drug2 and drug0",False, 
DDI-DrugBank.d751.s1.e0,DDI-DrugBank.d751.s1.e4,"The use of drug1, in combination with drug0 and drug0, has been associated with an increase in bleeding compared to drug0 and drug2",False, 
DDI-MedLine.d209.s1.e0,DDI-MedLine.d209.s1.e1,"drug1, an drug2",False, 
DDI-MedLine.d209.s5.e0,DDI-MedLine.d209.s5.e1,drug1 and drug2 reduce the plasma concentration of drug0,False, 
DDI-MedLine.d209.s5.e0,DDI-MedLine.d209.s5.e2,drug1 and drug0 reduce the plasma concentration of drug2,True,mechanism
DDI-MedLine.d209.s5.e1,DDI-MedLine.d209.s5.e2,drug0 and drug1 reduce the plasma concentration of drug2,True,mechanism
DDI-MedLine.d209.s9.e0,DDI-MedLine.d209.s9.e1,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with drug1 for breast cancer, especially drug2 such as drug0 and drug0",True,advise
DDI-MedLine.d209.s9.e0,DDI-MedLine.d209.s9.e2,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with drug1 for breast cancer, especially drug0 such as drug2 and drug0",True,advise
DDI-MedLine.d209.s9.e0,DDI-MedLine.d209.s9.e3,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with drug1 for breast cancer, especially drug0 such as drug0 and drug2",True,advise
DDI-MedLine.d209.s9.e1,DDI-MedLine.d209.s9.e2,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with drug0 for breast cancer, especially drug1 such as drug2 and drug0",False, 
DDI-MedLine.d209.s9.e1,DDI-MedLine.d209.s9.e3,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with drug0 for breast cancer, especially drug1 such as drug0 and drug2",False, 
DDI-MedLine.d209.s10.e0,DDI-MedLine.d209.s10.e1,"Depression does not always require drug1 therapy, and drug2",False, 
DDI-MedLine.d209.s11.e0,DDI-MedLine.d209.s11.e1,"If in certain cases, an drug1 is considered necessary, it may be advisable to replace drug2 with drug0",True,advise
DDI-MedLine.d209.s11.e0,DDI-MedLine.d209.s11.e2,"If in certain cases, an drug1 is considered necessary, it may be advisable to replace drug0 with drug2",False, 
DDI-MedLine.d209.s11.e1,DDI-MedLine.d209.s11.e2,"If in certain cases, an drug0 is considered necessary, it may be advisable to replace drug1 with drug2",False, 
DDI-MedLine.d204.s0.e0,DDI-MedLine.d204.s0.e1,Distinct synergistic action of drug1 and drug2,False, 
DDI-MedLine.d204.s7.e0,DDI-MedLine.d204.s7.e1,"Results revealed that the strains were resistant to many drugs at high levels, only drug1, drug2, drug0 and drug0",False, 
DDI-MedLine.d204.s7.e0,DDI-MedLine.d204.s7.e2,"Results revealed that the strains were resistant to many drugs at high levels, only drug1, drug0, drug2 and drug0",False, 
DDI-MedLine.d204.s9.e0,DDI-MedLine.d204.s9.e1,Distinct and statistically significant synergism was observed between drug1 and drug2,True,effect
DDI-MedLine.d204.s11.e0,DDI-MedLine.d204.s11.e1,Synergism was also noted when drug1 was combined with drug2 and drug0,True,effect
DDI-MedLine.d204.s11.e0,DDI-MedLine.d204.s11.e2,Synergism was also noted when drug1 was combined with drug0 and drug2,True,effect
DDI-MedLine.d204.s11.e1,DDI-MedLine.d204.s11.e2,Synergism was also noted when drug0 was combined with drug1 and drug2,False, 
DDI-MedLine.d193.s0.e0,DDI-MedLine.d193.s0.e1,drug1 (drug2)--better than drug0 (drug0,False, 
DDI-MedLine.d193.s0.e0,DDI-MedLine.d193.s0.e2,drug1 (drug0)--better than drug2 (drug0,False, 
DDI-MedLine.d193.s1.e0,DDI-MedLine.d193.s1.e1,"The FDA has approved drug1 (drug2-AstraZeneca), an oral drug0, for use with low-dose drug0",False, 
DDI-MedLine.d193.s1.e0,DDI-MedLine.d193.s1.e2,"The FDA has approved drug1 (drug0-AstraZeneca), an oral drug2, for use with low-dose drug0",False, 
DDI-MedLine.d193.s1.e0,DDI-MedLine.d193.s1.e3,"The FDA has approved drug1 (drug0-AstraZeneca), an oral drug0, for use with low-dose drug2",True,effect
DDI-MedLine.d193.s1.e1,DDI-MedLine.d193.s1.e3,"The FDA has approved drug0 (drug1-AstraZeneca), an oral drug0, for use with low-dose drug2",True,effect
DDI-MedLine.d193.s2.e0,DDI-MedLine.d193.s2.e1,It will compete with drug1 (drug2) and drug0 (drug0,False, 
DDI-MedLine.d193.s2.e0,DDI-MedLine.d193.s2.e2,It will compete with drug1 (drug0) and drug2 (drug0,False, 
DDI-MedLine.d184.s0.e0,DDI-MedLine.d184.s0.e1,drug1 locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with drug2,False, 
DDI-MedLine.d184.s2.e0,DDI-MedLine.d184.s2.e1,The objective was to analyze the effects of neonatal drug1 treatment on effects of drug2,False, 
DDI-MedLine.d184.s5.e0,DDI-MedLine.d184.s5.e1,"In female rats, neonatal drug1 treatment enhanced drug2 locomotor sensitization compared with drug0-free controls sensitized to drug0",True,effect
DDI-MedLine.d184.s5.e0,DDI-MedLine.d184.s5.e2,"In female rats, neonatal drug1 treatment enhanced drug0 locomotor sensitization compared with drug2-free controls sensitized to drug0",False, 
DDI-MedLine.d184.s5.e0,DDI-MedLine.d184.s5.e3,"In female rats, neonatal drug1 treatment enhanced drug0 locomotor sensitization compared with drug0-free controls sensitized to drug2",False, 
DDI-MedLine.d184.s6.e0,DDI-MedLine.d184.s6.e1,"Male rats demonstrated sensitization to drug1, although this was muted compared with female rats, and were unaffected by neonatal drug2",False, 
DDI-MedLine.d184.s8.e0,DDI-MedLine.d184.s8.e1,"Rats treated with neonatal drug1 enhanced time spent in the drug2-paired context compared with drug0-free controls conditioned with drug0, but only female controls conditioned with drug0",False, 
DDI-MedLine.d184.s8.e0,DDI-MedLine.d184.s8.e2,"Rats treated with neonatal drug1 enhanced time spent in the drug0-paired context compared with drug2-free controls conditioned with drug0, but only female controls conditioned with drug0",False, 
DDI-MedLine.d179.s0.e0,DDI-MedLine.d179.s0.e1,Synergistic interaction between drug1 and drug2,True,int
DDI-MedLine.d179.s2.e0,DDI-MedLine.d179.s2.e1,This study was aimed to investigate the efficacy of single use of drug1 and that of concurrent or sequential administration of drug2 and drug0,False, 
DDI-MedLine.d179.s2.e0,DDI-MedLine.d179.s2.e2,This study was aimed to investigate the efficacy of single use of drug1 and that of concurrent or sequential administration of drug0 and drug2,False, 
DDI-MedLine.d179.s3.e0,DDI-MedLine.d179.s3.e1,NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either drug1 or drug2,False, 
DDI-MedLine.d179.s5.e0,DDI-MedLine.d179.s5.e1,"drug1 exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas drug2",False, 
DDI-MedLine.d179.s6.e0,DDI-MedLine.d179.s6.e1,Although single or concurrent use of drug1 and drug2,True,effect
DDI-MedLine.d179.s7.e0,DDI-MedLine.d179.s7.e1,When cells were exposed to drug1 followed by drug2,True,effect
DDI-MedLine.d179.s8.e0,DDI-MedLine.d179.s8.e1,The molecular basis of this synergism is that the signaling pathways that were initially activated by drug1 exposure were efficiently suppressed by the subsequent exposure to drug2,True,effect
DDI-MedLine.d179.s10.e0,DDI-MedLine.d179.s10.e1,drug1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of drug2 followed by drug0 is superior to drug0 followed by drug0,False, 
DDI-MedLine.d179.s10.e0,DDI-MedLine.d179.s10.e2,drug1 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of drug0 followed by drug2 is superior to drug0 followed by drug0,False, 
DDI-MedLine.d179.s10.e1,DDI-MedLine.d179.s10.e2,drug0 as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of drug1 followed by drug2 is superior to drug0 followed by drug0,True,effect
DDI-MedLine.d189.s3.e0,DDI-MedLine.d189.s3.e1,"The incubations were performed in the absence and presence of the non-specific CYP inhibitor, drug1 (drug2",False, 
DDI-MedLine.d189.s7.e0,DDI-MedLine.d189.s7.e1,drug1 decreased the toxicity of drug2,True,effect
DDI-MedLine.d189.s8.e0,DDI-MedLine.d189.s8.e1,"Of the isoform-specific CYP inhibitors tested for an effect on the drug1 metabolite profile, only drug2",False, 
DDI-MedLine.d189.s9.e0,DDI-MedLine.d189.s9.e1,"With respect to toxicity, the order of CYP inhibitor effectiveness was drug1>drug2~drug0>drug0",False, 
DDI-MedLine.d189.s9.e0,DDI-MedLine.d189.s9.e2,"With respect to toxicity, the order of CYP inhibitor effectiveness was drug1>drug0~drug2>drug0",False, 
DDI-MedLine.d189.s10.e0,DDI-MedLine.d189.s10.e1,"drug1 and drug2 had no effect, while drug0 appeared to augment drug0",False, 
DDI-MedLine.d189.s10.e0,DDI-MedLine.d189.s10.e2,"drug1 and drug0 had no effect, while drug2 appeared to augment drug0",False, 
DDI-MedLine.d189.s10.e2,DDI-MedLine.d189.s10.e3,"drug0 and drug0 had no effect, while drug1 appeared to augment drug2",True,effect
DDI-MedLine.d189.s11.e0,DDI-MedLine.d189.s11.e1,These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of drug1 and therefore may not be an appropriate model for drug2,False, 
DDI-MedLine.d214.s0.e0,DDI-MedLine.d214.s0.e1,[Influence of drug1 and drug2,False, 
DDI-MedLine.d214.s1.e0,DDI-MedLine.d214.s1.e1,The effects of drug1 drug2 [drug0,False, 
DDI-MedLine.d214.s1.e0,DDI-MedLine.d214.s1.e2,The effects of drug1 drug0 [drug2,False, 
DDI-MedLine.d214.s2.e0,DDI-MedLine.d214.s2.e1,"and/or drug1 drug2 (100 mg/kg, p. o.), as well as that of neurotoxin drug0 (drug0",False, 
DDI-MedLine.d214.s2.e0,DDI-MedLine.d214.s2.e2,"and/or drug1 drug0 (100 mg/kg, p. o.), as well as that of neurotoxin drug2 (drug0",False, 
DDI-MedLine.d214.s5.e0,DDI-MedLine.d214.s5.e1,Acute administration of drug1 or drug2,True,effect
DDI-MedLine.d159.s0.e0,DDI-MedLine.d159.s0.e1,Protective effect of drug1 and  drug2,False, 
DDI-MedLine.d159.s6.e0,DDI-MedLine.d159.s6.e1,"(ii) drug1 elicits a significant protective effect on DEB induced toxicity, which was potentiated by  drug2",True,effect
DDI-MedLine.d147.s0.e0,DDI-MedLine.d147.s0.e1,Interaction of drug1 and drug2,False, 
DDI-MedLine.d147.s1.e0,DDI-MedLine.d147.s1.e1,"We evaluated mechanisms of interaction between the alkyating agent drug1 (drug2) and the pro-oxidant, drug0",False, 
DDI-MedLine.d147.s1.e0,DDI-MedLine.d147.s1.e2,"We evaluated mechanisms of interaction between the alkyating agent drug1 (drug0) and the pro-oxidant, drug2",False, 
DDI-MedLine.d147.s2.e0,DDI-MedLine.d147.s2.e1,The effect of drug1 and drug2,False, 
DDI-MedLine.d147.s6.e0,DDI-MedLine.d147.s6.e1,There was a >75% reduction in cellular glutathione and cysteine with drug1 but not drug2,False, 
DDI-MedLine.d147.s8.e0,DDI-MedLine.d147.s8.e1,drug1 and drug2,True,effect
DDI-MedLine.d217.s0.e0,DDI-MedLine.d217.s0.e1,Interaction of drug1 with different drug2,True,effect
DDI-MedLine.d217.s2.e0,DDI-MedLine.d217.s2.e1,This study investigates the ability of drug1 to sensitize cells from different origins to several drug2,False, 
DDI-MedLine.d217.s4.e0,DDI-MedLine.d217.s4.e1,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to drug1, drug2, drug0 and drug0   drug0",False, 
DDI-MedLine.d217.s4.e0,DDI-MedLine.d217.s4.e2,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to drug1, drug0, drug2 and drug0   drug0",False, 
DDI-MedLine.d217.s5.e0,DDI-MedLine.d217.s5.e1,We found antagonism between drug1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between drug2 and drug0,False, 
DDI-MedLine.d217.s5.e0,DDI-MedLine.d217.s5.e2,We found antagonism between drug1 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between drug0 and drug2,False, 
DDI-MedLine.d217.s5.e1,DDI-MedLine.d217.s5.e2,We found antagonism between drug0 and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between drug1 and drug2,True,effect
DDI-MedLine.d217.s11.e0,DDI-MedLine.d217.s11.e1,"These results, if confirmed in-vivo, indicate that drug1 is not a suitable chemosensitizer for breast cancer or with drug2",False, 
DDI-MedLine.d218.s0.e0,DDI-MedLine.d218.s0.e1,drug1-drug2,False, 
DDI-MedLine.d218.s3.e0,DDI-MedLine.d218.s3.e1,We sought to evaluate whether initiation of an drug1 increases the risk of hospitalization for gastrointestinal bleeding in drug2,False, 
DDI-MedLine.d218.s5.e0,DDI-MedLine.d218.s5.e1,"In total, 430,455 drug1 users contributed 407,370 person-years of drug2",False, 
DDI-MedLine.d218.s8.e0,DDI-MedLine.d218.s8.e1,"drug1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of drug2 (OR   =   1.73 [95% CI, 1.25-2.38]), drug0 (OR   =   1.63 [95% CI, 1.11-2.38]), drug0 (OR   =   1.64 [95% CI, 1.27-2.12]), drug0",True,effect
DDI-MedLine.d218.s8.e0,DDI-MedLine.d218.s8.e2,"drug1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of drug0 (OR   =   1.73 [95% CI, 1.25-2.38]), drug2 (OR   =   1.63 [95% CI, 1.11-2.38]), drug0 (OR   =   1.64 [95% CI, 1.27-2.12]), drug0",True,effect
DDI-MedLine.d218.s8.e0,DDI-MedLine.d218.s8.e3,"drug1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of drug0 (OR   =   1.73 [95% CI, 1.25-2.38]), drug0 (OR   =   1.63 [95% CI, 1.11-2.38]), drug2 (OR   =   1.64 [95% CI, 1.27-2.12]), drug0",True,effect
DDI-MedLine.d218.s8.e0,DDI-MedLine.d218.s8.e4,"drug1 users had an increased odds ratio of gastrointestinal bleeding upon initiation of drug0 (OR   =   1.73 [95% CI, 1.25-2.38]), drug0 (OR   =   1.63 [95% CI, 1.11-2.38]), drug0 (OR   =   1.64 [95% CI, 1.27-2.12]), drug2",True,effect
DDI-MedLine.d218.s8.e1,DDI-MedLine.d218.s8.e2,"drug0 users had an increased odds ratio of gastrointestinal bleeding upon initiation of drug1 (OR   =   1.73 [95% CI, 1.25-2.38]), drug2 (OR   =   1.63 [95% CI, 1.11-2.38]), drug0 (OR   =   1.64 [95% CI, 1.27-2.12]), drug0",False, 
DDI-MedLine.d218.s8.e1,DDI-MedLine.d218.s8.e3,"drug0 users had an increased odds ratio of gastrointestinal bleeding upon initiation of drug1 (OR   =   1.73 [95% CI, 1.25-2.38]), drug0 (OR   =   1.63 [95% CI, 1.11-2.38]), drug2 (OR   =   1.64 [95% CI, 1.27-2.12]), drug0",False, 
DDI-MedLine.d218.s9.e0,DDI-MedLine.d218.s9.e1,"Also drug1, which is not believed to interact with drug2",True,effect
DDI-MedLine.d218.s10.e0,DDI-MedLine.d218.s10.e1,"drug1 users who initiated drug2, drug0, drug0, drug0, or drug0",True,effect
DDI-MedLine.d218.s10.e0,DDI-MedLine.d218.s10.e2,"drug1 users who initiated drug0, drug2, drug0, drug0, or drug0",True,effect
DDI-MedLine.d218.s10.e0,DDI-MedLine.d218.s10.e3,"drug1 users who initiated drug0, drug0, drug2, drug0, or drug0",True,effect
DDI-MedLine.d218.s10.e0,DDI-MedLine.d218.s10.e4,"drug1 users who initiated drug0, drug0, drug0, drug2, or drug0",True,effect
DDI-MedLine.d218.s10.e0,DDI-MedLine.d218.s10.e5,"drug1 users who initiated drug0, drug0, drug0, drug0, or drug2",True,effect
DDI-MedLine.d218.s10.e1,DDI-MedLine.d218.s10.e2,"drug0 users who initiated drug1, drug2, drug0, drug0, or drug0",False, 
DDI-MedLine.d218.s10.e1,DDI-MedLine.d218.s10.e3,"drug0 users who initiated drug1, drug0, drug2, drug0, or drug0",False, 
DDI-MedLine.d166.s0.e0,DDI-MedLine.d166.s0.e1,Improved parathyroid hormone control by drug1 is associated with reduction in drug2,False, 
DDI-MedLine.d166.s1.e0,DDI-MedLine.d166.s1.e1,"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to drug1 (drug2",False, 
DDI-MedLine.d166.s2.e0,DDI-MedLine.d166.s2.e1,"Medical treatment with drug1 is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on drug2",False, 
DDI-MedLine.d166.s6.e0,DDI-MedLine.d166.s6.e1,The primary objective of the study was to ascertain the difference in drug1 responsiveness before and after 12 months of drug2,False, 
DDI-MedLine.d166.s17.e0,DDI-MedLine.d166.s17.e1,Reduction of PTH by drug1 is associated with a decrease in drug2,True,effect
DDI-MedLine.d216.s0.e0,DDI-MedLine.d216.s0.e1,Exposure to oral drug1 is unaffected by drug2 but greatly increased by drug0,False, 
DDI-MedLine.d216.s0.e0,DDI-MedLine.d216.s0.e2,Exposure to oral drug1 is unaffected by drug0 but greatly increased by drug2,True,effect
DDI-MedLine.d216.s0.e1,DDI-MedLine.d216.s0.e2,Exposure to oral drug0 is unaffected by drug1 but greatly increased by drug2,False, 
DDI-MedLine.d216.s1.e0,DDI-MedLine.d216.s1.e1,This study examined drug-drug interactions of oral drug1 with the cytochrome P450 (CYP) 2B6 inhibitor drug2 and the CYP3A inhibitor drug0,False, 
DDI-MedLine.d216.s1.e0,DDI-MedLine.d216.s1.e2,This study examined drug-drug interactions of oral drug1 with the cytochrome P450 (CYP) 2B6 inhibitor drug0 and the CYP3A inhibitor drug2,False, 
DDI-MedLine.d216.s2.e0,DDI-MedLine.d216.s2.e1,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg drug1 after pretreatments with oral drug2 (250 mg twice daily), drug0",False, 
DDI-MedLine.d216.s2.e0,DDI-MedLine.d216.s2.e2,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg drug1 after pretreatments with oral drug0 (250 mg twice daily), drug2",False, 
DDI-MedLine.d216.s3.e0,DDI-MedLine.d216.s3.e1,"drug1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral drug2 by 2.4-fold, whereas drug0 treatment did not increase the exposure to drug0",True,mechanism
DDI-MedLine.d216.s3.e0,DDI-MedLine.d216.s3.e2,"drug1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral drug0 by 2.4-fold, whereas drug2 treatment did not increase the exposure to drug0",False, 
DDI-MedLine.d216.s3.e0,DDI-MedLine.d216.s3.e3,"drug1 treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral drug0 by 2.4-fold, whereas drug0 treatment did not increase the exposure to drug2",False, 
DDI-MedLine.d216.s4.e0,DDI-MedLine.d216.s4.e1,The ratio of drug1 AUC(0-   ) to drug2 AUC(0-   ) was significantly decreased in the drug0 (P &lt; 0.001) and drug0,False, 
DDI-MedLine.d216.s4.e0,DDI-MedLine.d216.s4.e2,The ratio of drug1 AUC(0-   ) to drug0 AUC(0-   ) was significantly decreased in the drug2 (P &lt; 0.001) and drug0,False, 
DDI-MedLine.d216.s5.e0,DDI-MedLine.d216.s5.e1,In the drug1 and drug2,False, 
DDI-MedLine.d216.s6.e0,DDI-MedLine.d216.s6.e1,The findings suggest that the dosage of drug1 should be reduced in patients receiving drug2,True,advise
DDI-MedLine.d231.s0.e0,DDI-MedLine.d231.s0.e1,Interaction study of drug1 and drug2,False, 
DDI-MedLine.d231.s1.e0,DDI-MedLine.d231.s1.e1,drug1 and drug2 are drug0,False, 
DDI-MedLine.d231.s1.e0,DDI-MedLine.d231.s1.e2,drug1 and drug0 are drug2,False, 
DDI-MedLine.d231.s3.e0,DDI-MedLine.d231.s3.e1,"Being drug1 and lomefloxacin drug2 the interaction study of was carried out with drug0, drug0, drug0 and drug0",False, 
DDI-MedLine.d231.s3.e0,DDI-MedLine.d231.s3.e2,"Being drug1 and lomefloxacin drug0 the interaction study of was carried out with drug2, drug0, drug0 and drug0",False, 
DDI-MedLine.d231.s6.e0,DDI-MedLine.d231.s6.e1,The response of drug1 and drug2,False, 
DDI-MedLine.d231.s8.e0,DDI-MedLine.d231.s8.e1,drug1 and drug2 reacts faster with drug0 and drug0 in acidic media whereas with drug0 in basic media and drug0,False, 
DDI-MedLine.d231.s8.e0,DDI-MedLine.d231.s8.e2,drug1 and drug0 reacts faster with drug2 and drug0 in acidic media whereas with drug0 in basic media and drug0,True,mechanism
DDI-MedLine.d231.s8.e0,DDI-MedLine.d231.s8.e3,drug1 and drug0 reacts faster with drug0 and drug2 in acidic media whereas with drug0 in basic media and drug0,True,mechanism
DDI-MedLine.d231.s8.e0,DDI-MedLine.d231.s8.e4,drug1 and drug0 reacts faster with drug0 and drug0 in acidic media whereas with drug2 in basic media and drug0,True,mechanism
DDI-MedLine.d231.s8.e0,DDI-MedLine.d231.s8.e5,drug1 and drug0 reacts faster with drug0 and drug0 in acidic media whereas with drug0 in basic media and drug2,True,mechanism
DDI-MedLine.d231.s8.e1,DDI-MedLine.d231.s8.e2,drug0 and drug1 reacts faster with drug2 and drug0 in acidic media whereas with drug0 in basic media and drug0,True,mechanism
DDI-MedLine.d231.s8.e1,DDI-MedLine.d231.s8.e3,drug0 and drug1 reacts faster with drug0 and drug2 in acidic media whereas with drug0 in basic media and drug0,True,mechanism
DDI-MedLine.d231.s8.e1,DDI-MedLine.d231.s8.e4,drug0 and drug1 reacts faster with drug0 and drug0 in acidic media whereas with drug2 in basic media and drug0,True,mechanism
DDI-MedLine.d231.s8.e1,DDI-MedLine.d231.s8.e5,drug0 and drug1 reacts faster with drug0 and drug0 in acidic media whereas with drug0 in basic media and drug2,True,mechanism
DDI-MedLine.d231.s8.e2,DDI-MedLine.d231.s8.e3,drug0 and drug0 reacts faster with drug1 and drug2 in acidic media whereas with drug0 in basic media and drug0,False, 
DDI-MedLine.d169.s0.e0,DDI-MedLine.d169.s0.e1,drug1 does not inhibit the absorption of 5 milligrams of drug2 or drug0,False, 
DDI-MedLine.d169.s0.e0,DDI-MedLine.d169.s0.e2,drug1 does not inhibit the absorption of 5 milligrams of drug0 or drug2,False, 
DDI-MedLine.d169.s1.e0,DDI-MedLine.d169.s1.e1,drug1 is the only known component in the diet that may affect absorption of both drug2 and drug0,True,mechanism
DDI-MedLine.d169.s1.e0,DDI-MedLine.d169.s1.e2,drug1 is the only known component in the diet that may affect absorption of both drug0 and drug2,True,mechanism
DDI-MedLine.d169.s1.e1,DDI-MedLine.d169.s1.e2,drug0 is the only known component in the diet that may affect absorption of both drug1 and drug2,False, 
DDI-MedLine.d169.s2.e0,DDI-MedLine.d169.s2.e1,"However, the evidence for a drug1 effect on drug2 absorption mainly comes from studies that did not isolate the effect of drug0",True,mechanism
DDI-MedLine.d169.s2.e0,DDI-MedLine.d169.s2.e2,"However, the evidence for a drug1 effect on drug0 absorption mainly comes from studies that did not isolate the effect of drug2",False, 
DDI-MedLine.d169.s2.e1,DDI-MedLine.d169.s2.e2,"However, the evidence for a drug0 effect on drug1 absorption mainly comes from studies that did not isolate the effect of drug2",False, 
DDI-MedLine.d169.s3.e0,DDI-MedLine.d169.s3.e1,Our objective was to establish potential effects of drug1 on absorption of drug2 and drug0,False, 
DDI-MedLine.d169.s3.e0,DDI-MedLine.d169.s3.e2,Our objective was to establish potential effects of drug1 on absorption of drug0 and drug2,False, 
DDI-MedLine.d169.s5.e0,DDI-MedLine.d169.s5.e1,We evaluated the effects of drug1 doses between 200 and 1500 mg on absorption of 5 mg drug2 (as drug0,False, 
DDI-MedLine.d169.s5.e0,DDI-MedLine.d169.s5.e2,We evaluated the effects of drug1 doses between 200 and 1500 mg on absorption of 5 mg drug0 (as drug2,False, 
DDI-MedLine.d169.s6.e0,DDI-MedLine.d169.s6.e1,We also evaluated the effects of drug1 doses between 200 and 800 mg on absorption of 5 mg drug2,False, 
DDI-MedLine.d169.s7.e0,DDI-MedLine.d169.s7.e1,drug1 was administered as drug2 in all studies and drug0,False, 
DDI-MedLine.d169.s7.e0,DDI-MedLine.d169.s7.e2,drug1 was administered as drug0 in all studies and drug2,False, 
DDI-MedLine.d169.s8.e0,DDI-MedLine.d169.s8.e1,drug1 doses   1000 mg diminished drug2,True,mechanism
DDI-MedLine.d169.s9.e0,DDI-MedLine.d169.s9.e1,A drug1 dose of 800 mg diminished absorption of 5 mg drug2,True,mechanism
DDI-MedLine.d169.s10.e0,DDI-MedLine.d169.s10.e1,"In conclusion, we demonstrated an isolated effect of drug1 (as chloride) on absorption of 5 mg of iron provided as drug2 (as sulfate) and drug0 (as CRBC) ",True,mechanism
DDI-MedLine.d169.s10.e0,DDI-MedLine.d169.s10.e2,"In conclusion, we demonstrated an isolated effect of drug1 (as chloride) on absorption of 5 mg of iron provided as drug0 (as sulfate) and drug2 (as CRBC) ",True,mechanism
DDI-MedLine.d169.s10.e1,DDI-MedLine.d169.s10.e2,"In conclusion, we demonstrated an isolated effect of drug0 (as chloride) on absorption of 5 mg of iron provided as drug1 (as sulfate) and drug2 (as CRBC) ",False, 
DDI-MedLine.d143.s0.e0,DDI-MedLine.d143.s0.e1,[Interaction between drug1 and drug2,False, 
DDI-MedLine.d143.s1.e0,DDI-MedLine.d143.s1.e1,The drug interaction between drug1 and drug2,False, 
DDI-MedLine.d143.s2.e0,DDI-MedLine.d143.s2.e1,Contradictory results regarding the effect of drug1 on platelet reactivity and on clinical outcome in drug2,False, 
DDI-MedLine.d143.s3.e0,DDI-MedLine.d143.s3.e1,"Concomitant use of drug1 and drug2 was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by drug0",True,mechanism
DDI-MedLine.d143.s3.e0,DDI-MedLine.d143.s3.e2,"Concomitant use of drug1 and drug0 was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by drug2",False, 
DDI-MedLine.d143.s3.e1,DDI-MedLine.d143.s3.e2,"Concomitant use of drug0 and drug1 was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by drug2",False, 
DDI-MedLine.d143.s4.e0,DDI-MedLine.d143.s4.e1,drug1 has a much weaker effect on drug2,True,mechanism
DDI-MedLine.d143.s5.e0,DDI-MedLine.d143.s5.e1,The influence of the other drug1 when used simultaneously with drug2,False, 
DDI-MedLine.d143.s6.e0,DDI-MedLine.d143.s6.e1,Regulatory agencies state that the combination of drug1 and the CYP2C19 inhibitors drug2 and drug0,True,advise
DDI-MedLine.d143.s6.e0,DDI-MedLine.d143.s6.e2,Regulatory agencies state that the combination of drug1 and the CYP2C19 inhibitors drug0 and drug2,True,advise
DDI-MedLine.d143.s6.e1,DDI-MedLine.d143.s6.e2,Regulatory agencies state that the combination of drug0 and the CYP2C19 inhibitors drug1 and drug2,False, 
DDI-MedLine.d143.s7.e0,DDI-MedLine.d143.s7.e1,"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the drug1 and drug2",False, 
DDI-MedLine.d211.s0.e0,DDI-MedLine.d211.s0.e1,Phase I trial of drug1 and drug2 in patients with relapsed multiple myeloma: evidence for drug0-drug0,False, 
DDI-MedLine.d211.s0.e0,DDI-MedLine.d211.s0.e2,Phase I trial of drug1 and drug0 in patients with relapsed multiple myeloma: evidence for drug2-drug0,False, 
DDI-MedLine.d211.s2.e0,DDI-MedLine.d211.s2.e1,The preclinical combination of drug1 with the mTOR inhibitor drug2,True,effect
DDI-MedLine.d180.s1.e0,DDI-MedLine.d180.s1.e1,The drug1 (drug2,False, 
DDI-MedLine.d180.s10.e0,DDI-MedLine.d180.s10.e1,"We also found that Bcl-2 was overexpressed in drug1 insensitive cells, and cotreatment with drug2 and drug0, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of drug0",False, 
DDI-MedLine.d180.s10.e0,DDI-MedLine.d180.s10.e2,"We also found that Bcl-2 was overexpressed in drug1 insensitive cells, and cotreatment with drug0 and drug2, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of drug0",False, 
DDI-MedLine.d180.s10.e1,DDI-MedLine.d180.s10.e2,"We also found that Bcl-2 was overexpressed in drug0 insensitive cells, and cotreatment with drug1 and drug2, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of drug0",True,effect
DDI-MedLine.d180.s12.e0,DDI-MedLine.d180.s12.e1,"In addition, drug1 insensitivity might be associated with overexpression of Bcl-2, and the combination of drug2 and drug0",False, 
DDI-MedLine.d180.s12.e0,DDI-MedLine.d180.s12.e2,"In addition, drug1 insensitivity might be associated with overexpression of Bcl-2, and the combination of drug0 and drug2",False, 
DDI-MedLine.d180.s12.e1,DDI-MedLine.d180.s12.e2,"In addition, drug0 insensitivity might be associated with overexpression of Bcl-2, and the combination of drug1 and drug2",True,effect
DDI-MedLine.d190.s1.e0,DDI-MedLine.d190.s1.e1,To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of drug1 (drug2,False, 
DDI-MedLine.d190.s2.e0,DDI-MedLine.d190.s2.e1,"drug1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including drug2, drug0, drug0, or drug0",False, 
DDI-MedLine.d190.s2.e0,DDI-MedLine.d190.s2.e2,"drug1 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including drug0, drug2, drug0, or drug0",False, 
DDI-MedLine.d190.s5.e0,DDI-MedLine.d190.s5.e1,The addition of drug1 or drug2,False, 
DDI-MedLine.d190.s6.e0,DDI-MedLine.d190.s6.e1,drug1 had a limited effect and drug2,False, 
DDI-MedLine.d190.s7.e0,DDI-MedLine.d190.s7.e1,Electroretinograms survived with higher concentrations of drug1 and drug2,False, 
DDI-MedLine.d190.s8.e0,DDI-MedLine.d190.s8.e1,drug1-mediated retinal transduction is improved by co-injection of drug2 or drug0,True,effect
DDI-MedLine.d190.s8.e0,DDI-MedLine.d190.s8.e2,drug1-mediated retinal transduction is improved by co-injection of drug0 or drug2,True,effect
DDI-MedLine.d190.s8.e1,DDI-MedLine.d190.s8.e2,drug0-mediated retinal transduction is improved by co-injection of drug1 or drug2,False, 
DDI-MedLine.d227.s0.e0,DDI-MedLine.d227.s0.e1,drug1 enhances the antinociceptive effect of drug2,True,effect
DDI-MedLine.d227.s2.e0,DDI-MedLine.d227.s2.e1,The purpose of this study was to evaluate whether the psychostimulant drug drug1 has any effect on drug2,False, 
DDI-MedLine.d227.s6.e0,DDI-MedLine.d227.s6.e1,"saline + saline, drug1 (10   mg/kg) + saline, saline + drug2 (15     g/kg) and drug0 (10   mg/kg) + drug0",False, 
DDI-MedLine.d227.s6.e0,DDI-MedLine.d227.s6.e2,"saline + saline, drug1 (10   mg/kg) + saline, saline + drug0 (15     g/kg) and drug2 (10   mg/kg) + drug0",False, 
DDI-MedLine.d227.s7.e0,DDI-MedLine.d227.s7.e1,"In the hot plate test in mice, co-administration of 15     g/kg drug1 with 10   mg/kg drug2 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by drug0",True,effect
DDI-MedLine.d227.s7.e0,DDI-MedLine.d227.s7.e2,"In the hot plate test in mice, co-administration of 15     g/kg drug1 with 10   mg/kg drug0 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by drug2",False, 
DDI-MedLine.d227.s7.e1,DDI-MedLine.d227.s7.e2,"In the hot plate test in mice, co-administration of 15     g/kg drug0 with 10   mg/kg drug1 intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by drug2",False, 
DDI-MedLine.d227.s8.e0,DDI-MedLine.d227.s8.e1,"At the same time, the locomotor inhibitory effect of drug1 was counteracted by drug2",True,effect
DDI-MedLine.d227.s9.e0,DDI-MedLine.d227.s9.e1,"We concluded that the combined administration of drug1 with drug2 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of drug0 as an drug0",True,effect
DDI-MedLine.d227.s9.e0,DDI-MedLine.d227.s9.e2,"We concluded that the combined administration of drug1 with drug0 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of drug2 as an drug0",False, 
DDI-MedLine.d227.s9.e0,DDI-MedLine.d227.s9.e3,"We concluded that the combined administration of drug1 with drug0 may have beneficial effects in the treatment of pain without causing sedation, which limits the use of drug0 as an drug2",False, 
DDI-MedLine.d208.s0.e0,DDI-MedLine.d208.s0.e1,drug1   failure in an HIV-positive woman on drug2,True,effect
DDI-MedLine.d208.s3.e0,DDI-MedLine.d208.s3.e1,We present an interesting case of an HIV-positive woman on drug1 therapy having tubal pregnancies on two separate occasions with drug2,True,effect
DDI-MedLine.d200.s0.e0,DDI-MedLine.d200.s0.e1,[Efficacy of fixed combination drug1/drug2,False, 
DDI-MedLine.d200.s1.e0,DDI-MedLine.d200.s1.e1,Efficacy and tolerability of fixed drug1/drug2,False, 
DDI-MedLine.d200.s2.e0,DDI-MedLine.d200.s2.e1,All patients had indications for antihypertensive therapy and were randomized either to fixed combination drug1/drug2,False, 
DDI-MedLine.d200.s7.e0,DDI-MedLine.d200.s7.e1,Rate of achievement of target BP with fixed combination drug1/drug2,False, 
DDI-MedLine.d200.s8.e0,DDI-MedLine.d200.s8.e1,"But the use of fixed combination drug1/drug2 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of drug0",True,effect
DDI-MedLine.d200.s8.e0,DDI-MedLine.d200.s8.e2,"But the use of fixed combination drug1/drug0 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of drug2",False, 
DDI-MedLine.d200.s8.e1,DDI-MedLine.d200.s8.e2,"But the use of fixed combination drug0/drug1 compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of drug2",False, 
DDI-MedLine.d200.s10.e0,DDI-MedLine.d200.s10.e1,"We have demonstrated appropriateness of inhospital administration of fixed drug1/drug2 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer drug0",True,effect
DDI-MedLine.d200.s10.e0,DDI-MedLine.d200.s10.e2,"We have demonstrated appropriateness of inhospital administration of fixed drug1/drug0 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer drug2",False, 
DDI-MedLine.d200.s10.e1,DDI-MedLine.d200.s10.e2,"We have demonstrated appropriateness of inhospital administration of fixed drug0/drug1 combination as an approach allowing to achieve target BP in shorter time, with the use of fewer drug2",False, 
DDI-MedLine.d201.s4.e0,DDI-MedLine.d201.s4.e1,"The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, drug1 (drug2",False, 
DDI-MedLine.d201.s5.e0,DDI-MedLine.d201.s5.e1,"We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of drug1 on these cells alone or in combination with drug2",False, 
DDI-MedLine.d201.s9.e0,DDI-MedLine.d201.s9.e1,"drug1 induced apoptosis, and furthermore, the combination of drug2 plus drug0",False, 
DDI-MedLine.d201.s9.e0,DDI-MedLine.d201.s9.e2,"drug1 induced apoptosis, and furthermore, the combination of drug0 plus drug2",False, 
DDI-MedLine.d201.s9.e1,DDI-MedLine.d201.s9.e2,"drug0 induced apoptosis, and furthermore, the combination of drug1 plus drug2",True,effect
DDI-MedLine.d154.s0.e0,DDI-MedLine.d154.s0.e1,Enhancement of humoral immune responses to inactivated Newcastle disease and drug1 by oral administration of drug2,False, 
DDI-MedLine.d154.s2.e0,DDI-MedLine.d154.s2.e1,The objective of this study was to evaluate the effect of oral administration of drug1 (drug2) on the humoral immune responses of chickens to drug0drug0 ND and  ,False, 
DDI-MedLine.d154.s2.e0,DDI-MedLine.d154.s2.e2,The objective of this study was to evaluate the effect of oral administration of drug1 (drug0) on the humoral immune responses of chickens to drug2drug0 ND and  ,False, 
DDI-MedLine.d154.s3.e0,DDI-MedLine.d154.s3.e1,"In experiment 1, oral administration of drug1 at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with drug2",False, 
DDI-MedLine.d154.s5.e0,DDI-MedLine.d154.s5.e1,"In experiment 2, the same regimen of drug1 was administered to chickens inoculated with drug2",True,effect
DDI-MedLine.d154.s6.e0,DDI-MedLine.d154.s6.e1,"Considering the safety of drug1, because no adverse effect was found throughout the experiments, drug2",False, 
DDI-MedLine.d163.s0.e0,DDI-MedLine.d163.s0.e1,In vitro activity of drug1 combined with drug2 against clinical isolates of drug0,False, 
DDI-MedLine.d163.s0.e0,DDI-MedLine.d163.s0.e2,In vitro activity of drug1 combined with drug0 against clinical isolates of drug2,False, 
DDI-MedLine.d163.s1.e0,DDI-MedLine.d163.s1.e1,This study aimed to evaluate the in vitro activity of drug1 combined with drug2 against isolates of drug0,False, 
DDI-MedLine.d163.s1.e0,DDI-MedLine.d163.s1.e2,This study aimed to evaluate the in vitro activity of drug1 combined with drug0 against isolates of drug2,False, 
DDI-MedLine.d163.s4.e0,DDI-MedLine.d163.s4.e1,The susceptibility results for drug1 and drug2,False, 
DDI-MedLine.d163.s7.e0,DDI-MedLine.d163.s7.e1,The combination of drug1 and drug2,True,effect
DDI-MedLine.d181.s4.e0,DDI-MedLine.d181.s4.e1,The authors report the case of an infant with confirmed congenital hypothyroidism on drug1 who experienced a possible drug interaction with drug2,True,int
DDI-MedLine.d181.s6.e0,DDI-MedLine.d181.s6.e1,Questioning revealed the child was taking drug1 drops before feeds while on drug2,False, 
DDI-MedLine.d181.s8.e0,DDI-MedLine.d181.s8.e1,Drug interaction of drug1 with drug2,False, 
DDI-MedLine.d199.s0.e0,DDI-MedLine.d199.s0.e1,Prevention of emergence agitation in seven children receiving low-dose drug1 and drug2,False, 
DDI-MedLine.d199.s2.e0,DDI-MedLine.d199.s2.e1,We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose drug1 in conjunction with drug2,False, 
DDI-MedLine.d199.s3.e0,DDI-MedLine.d199.s3.e1,EA signs were observed in all 7 patients in association with drug1 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose drug2 was added to drug0,False, 
DDI-MedLine.d199.s3.e0,DDI-MedLine.d199.s3.e2,EA signs were observed in all 7 patients in association with drug1 TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose drug0 was added to drug2,False, 
DDI-MedLine.d199.s4.e0,DDI-MedLine.d199.s4.e1,"Based on this experience, we suggest that low-dose drug1 added to drug2 may be associated with prevention of EA in children with a history of EA with drug0",True,effect
DDI-MedLine.d199.s4.e0,DDI-MedLine.d199.s4.e2,"Based on this experience, we suggest that low-dose drug1 added to drug0 may be associated with prevention of EA in children with a history of EA with drug2",False, 
DDI-MedLine.d199.s4.e1,DDI-MedLine.d199.s4.e2,"Based on this experience, we suggest that low-dose drug0 added to drug1 may be associated with prevention of EA in children with a history of EA with drug2",False, 
DDI-MedLine.d213.s0.e0,DDI-MedLine.d213.s0.e1,In vivo CYP3A activity is significantly lower in drug1-treated as compared with drug2,False, 
DDI-MedLine.d213.s1.e0,DDI-MedLine.d213.s1.e1,In vitro studies have identified drug1 and drug2,False, 
DDI-MedLine.d213.s3.e0,DDI-MedLine.d213.s3.e1,"Systemic and apparent oral drug1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in drug2-treated patients (n = 20) than in matched drug0",True,mechanism
DDI-MedLine.d213.s3.e0,DDI-MedLine.d213.s3.e2,"Systemic and apparent oral drug1 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in drug0-treated patients (n = 20) than in matched drug2",False, 
DDI-MedLine.d213.s3.e1,DDI-MedLine.d213.s3.e2,"Systemic and apparent oral drug0 clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in drug1-treated patients (n = 20) than in matched drug2",False, 
DDI-MedLine.d213.s4.e0,DDI-MedLine.d213.s4.e1,The latter displayed drug1 clearances similar to those in two larger cohorts of nonmatched drug2-treated patients (n = 58 and n = 80) and to those receiving a drug0,False, 
DDI-MedLine.d213.s4.e0,DDI-MedLine.d213.s4.e2,The latter displayed drug1 clearances similar to those in two larger cohorts of nonmatched drug0-treated patients (n = 58 and n = 80) and to those receiving a drug2,False, 
DDI-MedLine.d213.s5.e0,DDI-MedLine.d213.s5.e1,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving drug1 than in those receiving drug2, indicating that, at the doses generally used in clinical practice, drug0",False, 
DDI-MedLine.d213.s5.e0,DDI-MedLine.d213.s5.e2,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving drug1 than in those receiving drug0, indicating that, at the doses generally used in clinical practice, drug2",False, 
DDI-MedLine.d194.s0.e0,DDI-MedLine.d194.s0.e1,The role of p27(Kip1) in drug1-enhanced drug2,True,effect
DDI-MedLine.d194.s4.e0,DDI-MedLine.d194.s4.e1,"The effect of drug1, an inhibitor of Src and Abl kinases, on drug2",False, 
DDI-MedLine.d194.s5.e0,DDI-MedLine.d194.s5.e1,"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by drug1 and drug2",False, 
DDI-MedLine.d194.s9.e0,DDI-MedLine.d194.s9.e1,HEY cells treated with drug1 plus drug2,True,effect
DDI-MedLine.d194.s10.e0,DDI-MedLine.d194.s10.e1,"Treatment of HEY xenograft-bearing mice with drug1 plus drug2 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, drug0 + drug0 vs drug0",True,effect
DDI-MedLine.d194.s10.e0,DDI-MedLine.d194.s10.e2,"Treatment of HEY xenograft-bearing mice with drug1 plus drug0 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, drug2 + drug0 vs drug0",False, 
DDI-MedLine.d194.s10.e0,DDI-MedLine.d194.s10.e3,"Treatment of HEY xenograft-bearing mice with drug1 plus drug0 inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, drug0 + drug2 vs drug0",False, 
DDI-MedLine.d194.s11.e0,DDI-MedLine.d194.s11.e1,drug1 + drug2,False, 
DDI-MedLine.d194.s15.e0,DDI-MedLine.d194.s15.e1,The siRNA knockdown of p27(Kip1) decreased drug1- and drug2,False, 
DDI-MedLine.d194.s16.e0,DDI-MedLine.d194.s16.e1,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that drug1-mediated induction of p27(Kip1) enhanced drug2,True,effect
DDI-MedLine.d194.s17.e0,DDI-MedLine.d194.s17.e1,Inhibition of Src family and Abl kinases with either siRNAs or drug1 enhances drug2,True,effect
